


**CUMULATIVE
SUPPLEMENT 06
June 2006**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

Cumulative Supplement 06

June 2006

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Availability of the Edition	vi
1.4 Report of Counts for the Prescription Drug Product List	vi
1.5 Zocor (simvastatin) Patent Relisting.....	viii
1.6 Cumulative Supplement Legend	vi

DRUG PRODUCT LISTS

Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

Note:

Historically, the Electronic Orange Book (EOB) and Cumulative Supplement (CS) have been updated monthly, each month updated by the end of the second full working week of the following month.

As of February 2005, we are also providing daily EOB product information for new generic drug approvals. Daily generic updates will provide the consumer with the most current listing of approved generic products. Previously, a first-time-generic approved early in the month would not be published in the CS for several weeks. Daily generic updates are especially important since the Orange Book listing may be relevant for substitution.

As a result, the monthly CS will include generic approvals and related product changes current to the day of publication (e.g., the June CS will include generic approvals up to the second week of July). Patent information is also current to the day of publication.

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

**CUMULATIVE SUPPLEMENT 06
June 2006**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

AMERICAN PHARMACEUTICAL PARTNERS INC
(AM PHARM PARTNERS)
AMERICAN PHARMACEUTICAL CO INC SUB
BURR CORP

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

ABRAXIS PHARMACEUTICAL PRODUCTS
(ABRAXIS PHARM)
ABRAXIS PHARMACEUTICAL PRODUCTS

(AM PHARM)	(ABRAXIS PHARM)
AMIDE PHARMACEUTICAL INC	ACTAVIS TOTOWA LLC
(AMIDE PHARM)	(ACTAVIS TOTOWA)
APOTEX CORP	APOTEX INC ETOBICOKE SITE
(APOTEX)	(APOTEX INC)
APOTEX CORP	APOTEX INC RICHMOND HILL
(APOTEX)	(APOTEX INC)
APOTEX INC	APOTEX INC ETOBICOKE SITE
(APOTEX)	(APOTEX INC)
APOTEX INC	APOTEX INC RICHMOND HILL
(APOTEX)	(APOTEX INC)
APOTEX INC	APOTEX INC ETOBICOKE SITE
(APOTEX INC)	(APOTEX INC)
APOTEX INC	APOTEX INC RICHMOND HILL
(APOTEX INC)	(APOTEX INC)
AVENTIS PHARMACEUTICALS INC	SANOFI AVENTIS US LLC
(AVENTIS)	(SANOFI AVENTIS US)
AVENTIS PHARMACEUTICAL PRODUCTS INC	SANOFI AVENTIS US LLC
(AVENTIS PHARMS)	(SANOFI AVENTIS US)
DERMIK LABORATORIES DIV AVENTIS	SANOFI AVENTIS US LLC
PHARMACEUTICALS INC	
(DERMIK LABS)	(SANOFI AVENTIS US)
DERMIK LABORATORIES INC	SANOFI AVENTIS US LLC
(DERMIK LABS)	(SANOFI AVENTIS US)
DERMIK LABORATORIES INC SUB RORER	SANOFI AVENTIS US LLC
(DERMIK LABS)	(SANOFI AVENTIS US)
CLAY PARK LABORATORIES INC	PERRIGO NEW YORK INC
(CLAY PARK)	(PERRIGO NEW YORK)
CLAY PARK LABS INC	PERRIGO NEW YORK INC
(CLAY PARK)	(PERRIGO NEW YORK)
LOREX PHARMACEUTICALS	SANOFI AVENTIS US LLC
(LOREX)	(SANOFI AVENTIS US)
MARTEC PHARMACEUTICALS	MARTEC USA LLC
(MARTEC)	(MARTEC USA LLC)
MARTEC SCIENTIFIC INC	MARTEC USA LLC
(MARTEC)	(MARTEC USA LLC)
ORPHAN MEDICAL INC	JAZZ PHARMACEUTICALS
(ORPHAN MEDCL)	(JAZZ)
PRIVATE FORMULATIONS INC	LEINER HEALTH PRODUCTS INC
(PRIVATE FMLTNS)	(LEINER HLTH PRODS)
PHARMACEUTICAL FORMULATIONS INC	LEINER HEALTH PRODUCTS INC
(PHARM FORM)	(LEINER HLTH PRODS)
PHARMA TEK INC	X GEN PHARMACEUTICALS INC
(PHARMA TEK)	(X GEN)
SANKYO PHARMA INC	DAIICHI SANKYO INC
(SANKYO)	(DAIICHI SANKYO)
SANOFI AVENTIS US INC	SANOFI AVENTIS US LLC
(SANOFI AVENTIS US)	(SANOFI AVENTIS US)
SANOFI-AVENTIS US INC	SANOFI AVENTIS US LLC
(SANOFI AVENTIS)	(SANOFI AVENTIS US)
SANOFI INC	SANOFI AVENTIS US LLC
(SANOFI)	(SANOFI AVENTIS US)
SANOFI SYNTHELABO INC	SANOFI AVENTIS US LLC
(SANOFI SYNTHELABO)	(SANOFI AVENTIS US)
SANOFI SYNTHELABO RESEARCH DIV SANOFI	SANOFI AVENTIS US LLC
SYNTHELABO INC	
(SANOFI SYN RES)	(SANOFI AVENTIS US)
STERIS LABORATORIES INC	WATSON LABORATORIES INC
(STERIS)	(WATSON)
TRIGEN LABORATORIES INC	JUBILANT PHARMACEUTICALS INC
(TRIGEN)	(JUBILANT PHARMS)
UCB PHARMA INC	UCB INC
(UCB PHARMA)	(UCB INC)

1.3 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB) <http://www.fda.gov/cder/ob/default.htm>, has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob/default.htm>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm>

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline

count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2005	MAR 2006	JUN 2006	SEPT 2006
DRUG PRODUCTS LISTED	11368	11487	11549	
SINGLE SOURCE	2428	2461	2447	
	(21.4%)	(21.4%)	(1.2%)	
MULTISOURCE	8851	8937	9013	
	(77.9%)	(77.8%)	(8.0%)	
THERAPEUTICALLY EQUIVALENT	8642	8730	8813	
	(76.04%)	(76.0%)	(6.3%)	
NOT THERAPEUTICALLY EQUIVALENT EXCEPTIONS ¹	209 (1.8%)	207	200	
		(1.8%)	(1.7%)	
NEW MOLECULAR ENTITIES APPROVED	89	89	89	
NUMBER OF APPLICANTS	(0.8%)	(0.8%)	(0.8%)	
	11	6	3	
	628	629	634	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 ZOCOR (SIMVASTATIN) PATENT RELISTING

U.S. Patent Nos. RE 36481 and RE 36520 are being relisted for Zocor (NDA 19-766) pursuant to the decision and related order in *Ranbaxy Labs. v. Leavitt*, No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents will remain listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* until any applicable periods of exclusivity pursuant to section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act have been triggered and run, unless the agency's appeal of the decision to the U.S. Court of Appeals for the District of Columbia is decided in the agency's favor before the exclusivity periods have expired. While the patents remain listed, any new or pending ANDA referencing Zocor must contain patent certifications to these patents. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046.

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition

PRESCRIPTION DRUG PRODUCT LIST - 26TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLMENT 6 - June 2006

1-1

ACEBUTOLOL HYDROCHLORIDECAPSULE; ORAL
SECTRAL

AB	DR REDDYS LABS INC	EQ 200MG BASE	N18917 001 Dec 28, 1984 May CAHN
AB	+	EQ 400MG BASE	N18917 003 Dec 28, 1984 May CAHN

ACETAMINOPHEN; BUTALBITALTABLET; ORAL
BUTAPAP
SEDAPAP

AB	+	MIKART	650MG;50MG	N89988 001 Oct 26, 1992 Jan CRLD
		@ MAYRAND	650MG;50MG	N88944 001 Oct 17, 1985 Jan DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE
@ CLONMEL 120MG/5ML;12MG/5ML

N40098 001 Sep 20, 1996 Jan DISC

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+	TEVA	300MG;60MG	N88629 001 Mar 06, 1985 Apr CRLD
----	---	------	------------	----------------------------------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@ ENDO PHARMS	500MG;7.5MG	N40280 001 Sep 30, 1998 Feb DISC
	@	650MG;7.5MG	N40280 002 Sep 30, 1998 Feb DISC
	@	650MG;10MG	N40280 003 Sep 30, 1998 Feb DISC
	@	750MG;7.5MG	N40281 002 Sep 30, 1998 Feb DISC
	MIKART	300MG;5MG	N40658 001 Jan 19, 2006 Jan NEWA
+		300MG;7.5MG	N40556 002 Mar 24, 2006 Mar NEWA
AA	VINTAGE PHARMS	325MG;5MG	N40655 001 Jan 19, 2006 Jan NEWA
AA		325MG;7.5MG	N40656 001 Jan 19, 2006 Jan NEWA
	HY-PHEN		
	@ ASCHER	500MG;5MG	N87677 001 May 03, 1982 Mar DISC
	ZYDONE		
+	ENDO PHARMS	400MG;5MG	N40288 001 Nov 27, 1998 May CTNA
+		400MG;7.5MG	N40288 002 Nov 27, 1998 May CTNA
+		400MG;10MG	N40288 003 Nov 27, 1998 May CTNA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

+	MIKART	400MG;2.5MG	N40679 001 May 16, 2006 May NEWA
+		400MG;5MG	N40687 001 Apr 27, 2006 Apr NEWA
+		400MG;7.5MG	N40698 001 Apr 27, 2006 Apr NEWA
+		400MG;10MG	N40692 001 Apr 27, 2006 Apr NEWA
		500MG;10MG	N40676 001 Apr 19, 2006 Apr NEWA

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>A>	AB	ACTAVIS ELIZABETH	650MG;100MG	N70910 001 Jan 02, 1987 Jun CAHN
>D>	AB	PUREPAC PHARM	650MG;100MG	N70910 001 Jan 02, 1987 Jun CAHN

ACETAZOLAMIDE

TABLET; ORAL
ACETAZOLAMIDE

AB	+	TARO	250MG	N40195 002 May 28, 1997 Mar CRLD
DIAMOX				
@ DURAMED PHARMS BARR 125MG				N08943 001 Mar DISC
@ 250MG				N08943 002 Mar DISC

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC
HYDROCORTISONE AND ACETIC ACID

AT	VINTAGE	2%:1%	N40609 001 Feb 06, 2006 Jan NEWA
----	---------	-------	----------------------------------

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

>A>	AB	ACTAVIS ELIZABETH	200MG	N74906 001 Aug 26, 1997 Jun CAHN
	AB	CLONMEL HLTHCARE	200MG	N74833 001 Apr 22, 1997 May CAHN
>D>	AB	PUREPAC PHARM	200MG	N74906 001 Aug 26, 1997 Jun CAHN
TABLET; ORAL				
ACYCLOVIR				
>A>	AB	ACTAVIS ELIZABETH	400MG	N74870 001 Jun 05, 1997 Jun CAHN
>A>	AB		800MG	N74870 002 Jun 05, 1997 Jun CAHN
	AB	CLONMEL HLTHCARE	400MG	N74946 001 Nov 19, 1997 May CAHN
	AB		800MG	N74946 002 Nov 19, 1997 May CAHN
>D>	AB	PUREPAC PHARM	400MG	N74870 001 Jun 05, 1997 Jun CAHN
>D>	AB		800MG	N74870 002 Jun 05, 1997 Jun CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

>D>	AP	HOSPIRA	EQ 500MG BASE/VIAL	N74663 001 Apr 22, 1997 Jun DISC
>A>		@	EQ 500MG BASE/VIAL	N74663 001 Apr 22, 1997 Jun DISC
>D>	AP		EQ 1GM BASE/VIAL	N74663 002 Apr 22, 1997 Jun DISC
>A>		@	EQ 1GM BASE/VIAL	N74663 002 Apr 22, 1997 Jun DISC

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL

@ GENPHARM	0.09MG/INH	N73045 001 Aug 19, 1997 Feb DISC
@ PLIVA	0.09MG/INH	N74072 001 Aug 01, 1996 Feb DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	RXELITE	EQ 0.083% BASE	N77569 001 Apr 04, 2006 Mar NEWA
----	---------	----------------	----------------------------------

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION
INFUVITE ADULT

+ SANDOZ	2 IU/ML; 40MG/ML; 12UGM/ML; 40 IU/ML; 1UGM/ML; 3MG/ML; 120UGM/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N21163 001 May 18, 2000 Jan CAHN
----------	---	----------------------------------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+ SANDOZ 2 IU/ML;40MG/ML;12UGM/ML;40
IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8M
G/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;
660 IU/ML;30UGM/ML

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

>A>	AB	ACTAVIS ELIZABETH	0.25MG	N74342 001	Oct 31, 1993	Jun	CAHN
>A>	AB		0.5MG	N74342 002	Oct 31, 1993	Jun	CAHN
>A>	AB		1MG	N74342 003	Oct 31, 1993	Jun	CAHN
>A>	AB		2MG	N74342 004	Oct 31, 1993	Jun	CAHN
>D>	AB	PUREPAC PHARM	0.25MG	N74342 001	Oct 31, 1993	Jun	CAHN
>D>	AB		0.5MG	N74342 002	Oct 31, 1993	Jun	CAHN
>D>	AB		1MG	N74342 003	Oct 31, 1993	Jun	CAHN
>D>	AB		2MG	N74342 004	Oct 31, 1993	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	MYLAN	0.5MG	N77391 002	Jan 26, 2006	Jan	NEWA	
AB		1MG	N77391 003	Jan 26, 2006	Jan	NEWA	
AB		2MG	N77391 004	Jan 26, 2006	Jan	NEWA	
AB		3MG	N77391 001	Jan 26, 2006	Jan	NEWA	
>A>	AB	SANDOZ	0.5MG	N77777 001	Jun 30, 2006	Jun	NEWA
>A>	AB		1MG	N77777 002	Jun 30, 2006	Jun	NEWA
>A>	AB		2MG	N77777 003	Jun 30, 2006	Jun	NEWA
>A>	AB		3MG	N77777 004	Jun 30, 2006	Jun	NEWA
XANAX XR							
AB	PHARMACIA AND UPJOHN	0.5MG	N21434 001	Jan 17, 2003	Jan	CFTG	
AB		1MG	N21434 002	Jan 17, 2003	Jan	CFTG	
AB		2MG	N21434 003	Jan 17, 2003	Jan	CFTG	
AB	+	3MG	N21434 004	Jan 17, 2003	Jan	CFTG	

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	AMIDE PHARM	100MG	N77659 001	Feb 23, 2006	Feb	NEWA
----	-------------	-------	------------	--------------	-----	------

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

>D>	AB	PAR PHARM	5MG	N70346 001	Jan 22, 1986	Jun	CRLD
>A>	+		5MG	N70346 001	Jan 22, 1986	Jun	CRLD
>D>		MIDAMOR					
>D>	AB	+	MERCK	5MG	N18200 001		DISC
>A>		@		5MG	N18200 001		DISC

AMILORIDE HYDROCHLORIDE; HYDROCHLORTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLORTHIAZIDE

>D>	AB	MYLAN	EQ 5MG ANHYDROUS;50MG	N73209 001	Oct 31, 1991	Jun	CRLD
>A>	AB	+	EQ 5MG ANHYDROUS;50MG	N73209 001	Oct 31, 1991	Jun	CRLD
>D>		MODURETIC 5-50					
>D>	AB	+	MERCK	EQ 5MG ANHYDROUS;50MG	N18201 001		DISC
>A>		@		EQ 5MG ANHYDROUS;50MG	N18201 001		DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

>A> AP + AKORN 50MG/ML N76232 001 Jul 05, 2006 Jun NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

NOVARTIS

EQ 5MG BASE;40MG

N20364 007 Apr 11, 2006 Apr NEWA

EQ 10MG BASE;20MG

N20364 005 Jun 20, 2002 Apr CRLD

+

EQ 10MG BASE;40MG

N20364 006 Apr 11, 2006 Apr NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB PADDOCK EQ 12% BASE N76829 001 Feb 07, 2006 Jan NEWA

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB AM ANTIBIOTICS 250MG N62058 001 Jan CAHN

AB 500MG N62058 002 Jan CAHN

FOR SUSPENSION; ORAL

AMOXICILLIN

AB AM ANTIBIOTICS 125MG/5ML N62059 001 Jan CAHN

AB 250MG/5ML N62059 002 Jan CAHN

>A> AB HIKMA 125MG/5ML N65322 002 Jun 19, 2006 Jun NEWA

>A> AB 200MG/5ML N65325 002 Jun 19, 2006 Jun NEWA

>A> AB 250MG/5ML N65322 001 Jun 19, 2006 Jun NEWA

>A> AB 400MG/5ML N65325 001 Jun 19, 2006 Jun NEWA

TABLET; ORAL

AMOXICILLIN

AB HIKMA 875MG N65255 001 Mar 29, 2006 Mar NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB TEVA PHARMS 1.25MG;1.25MG;1.25MG;1.25MG N40472 001 Sep 30, 2003 May CAHN

AB 2.5MG;2.5MG;2.5MG;2.5MG N40472 002 Sep 30, 2003 May CAHN

AB 5MG;5MG;5MG;5MG N40472 003 Sep 30, 2003 May CAHN

AB 7.5MG;7.5MG;7.5MG;7.5MG N40472 004 Sep 30, 2003 May CAHN

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

>D> AP PHARMA TEK 50MG/VIAL N63206 001 Apr 29, 1992 Jun CAHN

>A> AP X GEN PHARMS 50MG/VIAL N63206 001 Apr 29, 1992 Jun CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@ AM ANTIBIOTICS EQ 250MG BASE N61602 001 Jan CAHN

@ EQ 500MG BASE N61602 002 Jan CAHN

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

@ AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61601 001	Jan CAHN
@	EQ 250MG BASE/5ML	N61601 002	Jan CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

>A> AB	ALPHAPHARM	EQ 0.5MG BASE	N77613 001 Jun 27, 2006 Jun NEWA
>A> AB		EQ 1MG BASE	N77613 002 Jun 27, 2006 Jun NEWA

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+ VICURON	50MG/VIAL	N21632 001 Feb 17, 2006 Feb NEWA
-----------	-----------	----------------------------------

ANISINDIONE

TABLET; ORAL

MIRADON

@ SCHERING	50MG	N10909 003	Jan DISC
------------	------	------------	----------

APREPITANT

CAPSULE; ORAL

EMEND

>A>	MERCK	40MG	N21549 003 Jun 30, 2006 Jun NEWA
-----	-------	------	----------------------------------

ARIPIPRAZOLE

>A>	TABLET, ORALLY DISINTEGRATING; ORAL		
>A>	ABILIFY		
>A>	OTSUKA	10MG	N21729 002 Jun 07, 2006 Jun NEWA
>A>		15MG	N21729 003 Jun 07, 2006 Jun NEWA
>A>		20MG	N21729 004 Jun 07, 2006 Jun NEWA
>A>	+	30MG	N21729 005 Jun 07, 2006 Jun NEWA

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

SEPTOCAIN

DEPROCO	4%;EQ 0.005MG BASE/ML	N22010 001 Mar 30, 2006 Mar NEWA
+	4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971 001 Apr 03, 2000 Mar CPOT

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCAIN

+ DEPROCO	4%;EQ 0.0085MG BASE/1.7ML(4%; EQ 0.005MG BASE/ML)	N22010 001 Mar 30, 2006 Apr CAIN
+	4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971 001 Apr 03, 2000 Apr CAIN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SANDOZ	80MG/VIAL;0.02MG/VIAL;400IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300IU/VIAL;0.2MG/VIAL	N21265 001 Feb 21, 2001 Jan CAHN
----------	---	----------------------------------

INJECTABLE; IV (INFUSION)INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1 4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG /VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646 001 Jan 29, 2004 Jan CAHN
----------	---	----------------------------------

ASPIRIN; BUTALBITAL; CAFFEINETABLET; ORALASPIRIN AND CAFFEINE W/ BUTALBITAL

>A> AB	ACTAVIS ELIZABETH	325MG;50MG;40MG	N86710 002 Aug 23, 1983 Jun CAHN
>D> AB	PUREPAC PHARM	325MG;50MG;40MG	N86710 002 Aug 23, 1983 Jun CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATECAPSULE; ORALBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@ ENDO PHARMS 325MG;50MG;40MG;30MG

N75351 001 Mar 05, 1999 Feb DISC

FIORINAL W/CODEINE

AB + WATSON PHARMS 325MG;50MG;40MG;30MG

N19429 003 Oct 26, 1990 Apr CTNA

>A> ASPIRIN; OXYCODONE HYDROCHLORIDE>A> TABLET; ORAL>A> ASPIRIN AND OXYCODONE

>A> + ENDO PHARMS 325MG;4.8355MG

N07337 007 Aug 05, 2005 Jun NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATETABLET; ORALPERCODAN-DEMI

@ ENDO PHARMS 325MG;2.25MG;0.19MG

N07337 005

Feb DISC

ATOVAQUONETABLET; ORALMEPRON

@ GLAXOSMITHKLINE 250MG

N20259 001 Nov 25, 1992 May DISC

AZITHROMYCINFOR SUSPENSION; ORAL>A> AZITHROMYCIN

>A> AB PLIVA EQ 100MG BASE/5ML

N65246 002 Jul 05, 2006 Jun NEWA

>A> AB EQ 200MG BASE/5ML

N65246 001 Jul 05, 2006 Jun NEWA

ZITHROMAX>D> PFIZER

EQ 100MG BASE/5ML

N50710 001 Oct 19, 1995 Jun CFTG

>A> AB EQ 100MG BASE/5ML

N50710 001 Oct 19, 1995 Jun CFTG

>D> + EQ 200MG BASE/5ML

N50710 002 Oct 19, 1995 Jun CFTG

>A> AB + EQ 200MG BASE/5ML

N50710 002 Oct 19, 1995 Jun CFTG

BACAMPICILLIN HYDROCHLORIDEFOR SUSPENSION; ORALSPECTROBID

@ PFIZER 125MG/5ML

N50556 001 Mar 23, 1982 Feb DISC

TABLET; ORALSPECTROBID

@ PFIZER 400MG

N50520 001

Feb DISC

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	APOTEX INC	5MG	N77128 001 Mar 08, 2006 Feb NEWA
AB		10MG	N77128 002 Mar 08, 2006 Feb NEWA
AB		20MG	N77128 003 Mar 08, 2006 Feb NEWA
AB		40MG	N77128 004 Mar 08, 2006 Feb NEWA
AB	BIOKEY	5MG	N76820 001 Feb 03, 2006 Jan NEWA
AB		10MG	N76820 002 Feb 03, 2006 Jan NEWA
AB		20MG	N76820 003 Feb 03, 2006 Jan NEWA
AB		40MG	N76820 004 Feb 03, 2006 Jan NEWA

>D> BENDROFLUMETHIAZIDE

>D> TABLET; ORAL

>D> NATURETIN-5

>D> +	APOTHECON	5MG	N12164 002 Jun DISC
>A>	@	5MG	N12164 002 Jun DISC

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA	PADDOCK	50MG	N40578 001 Apr 17, 2006 Apr NEWA
AA	DIDREX		

AA	+ PHARMACIA AND UPJOHN	50MG	N12427 002 Apr CFTG
----	------------------------	------	---------------------

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

>D> @	PFIZER	EQ 50MG BASE/VIAL	N16820 001 Mar DISC
-------	--------	-------------------	---------------------

BETAINE, ANHYDROUS

FOR SOLUTION; ORAL

CYSTADANE

>D> +	JAZZ	1GM/SCOOPFUL
-------	------	--------------

N20576 001 Oct 25, 1996 Feb CAHN

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

>D> AB	+ SAVAGE LABS	EQ 0.05% BASE	N19138 001 Jun 26, 1984 Jun DISC
>A>	@	EQ 0.05% BASE	N19138 001 Jun 26, 1984 Jun DISC

BETAMETHASONE DIPROPIONATE

>A> AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	N70885 001 Feb 03, 1987 Jun CAHN
>D> AB	ALPHARMA US PHARMS	EQ 0.05% BASE	N70885 001 Feb 03, 1987 Jun CAHN

>D> AB	FOUGERA	EQ 0.05% BASE	N19137 001 Jun 26, 1984 Jun CRLD
>A> AB	+	EQ 0.05% BASE	N19137 001 Jun 26, 1984 Jun CRLD

LOTION; TOPICAL

ALPHATREX

>D> AB	SAVAGE LABS	EQ 0.05% BASE	N70273 001 Aug 12, 1985 Jun DISC
>A>	@	EQ 0.05% BASE	N70273 001 Aug 12, 1985 Jun DISC

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

>A> AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	N71012 001 Feb 03, 1987 Jun CAHN
>D> AB	ALPHARMA US PHARMS	EQ 0.05% BASE	N71012 001 Feb 03, 1987 Jun CAHN

OINTMENT, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

>A>	AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	N74304 001 Aug 31, 1995 Jun CAHN
>D>	AB	ALPHARMA US PHARMS	EQ 0.05% BASE	N74304 001 Aug 31, 1995 Jun CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL
TACLONEX
+ LEO PHARM PRODS 0.064%;0.005%

N21852 001 Jan 09, 2006 Jan NEWA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

>A>	AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE;1%	N76002 001 Aug 02, 2002 Jun CAHN
>D>	AB	ALPHARMA US PHARMS	EQ 0.05% BASE;1%	N76002 001 Aug 02, 2002 Jun CAHN

BETAMETHASONE VALERATE

CREAM; TOPICAL
VALNAC

>A>	AB	ACTAVIS MID ATLANTIC	EQ 0.1% BASE	N70050 001 Oct 10, 1984 Jun CAHN
>D>	AB	ALPHARMA US PHARMS	EQ 0.1% BASE	N70050 001 Oct 10, 1984 Jun CAHN

OINTMENT; TOPICAL
BETAMETHASONE VALERATE

>A>	AB	ACTAVIS MID ATLANTIC	EQ 0.1% BASE	N70051 001 Oct 10, 1984 Jun CAHN
>D>	AB	ALPHARMA US PHARMS	EQ 0.1% BASE	N70051 001 Oct 10, 1984 Jun CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

>A>	AB	ACTAVIS ELIZABETH	2.5MG;6.25MG	N75672 001 Sep 25, 2000 Jun CAHN
>A>	AB		5MG;6.25MG	N75672 002 Sep 25, 2000 Jun CAHN
>A>	AB		10MG;6.25MG	N75672 003 Sep 25, 2000 Jun CAHN
>D>	AB	PUREPAC PHARM	2.5MG;6.25MG	N75672 001 Sep 25, 2000 Jun CAHN
>D>	AB		5MG;6.25MG	N75672 002 Sep 25, 2000 Jun CAHN
>D>	AB		10MG;6.25MG	N75672 003 Sep 25, 2000 Jun CAHN

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLEOMYCIN SULFATE

>D>	AP	SICOR PHARMS	EQ 15 UNITS BASE/VIAL	N64084 001 Jun 01, 1996 Jun DISC
>A>		@	EQ 15 UNITS BASE/VIAL	N64084 001 Jun 01, 1996 Jun DISC
>D>	AP		EQ 30 UNITS BASE/VIAL	N64084 002 Jun 01, 1996 Jun DISC
>A>		@	EQ 30 UNITS BASE/VIAL	N64084 002 Jun 01, 1996 Jun DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN P

AT	+	ALLERGAN	0.15%	N21262 001 Mar 16, 2001 May CTEC
		BRIMONIDINE TARTRATE		
AT		AKORN	0.2%	N76439 001 Mar 14, 2006 Feb NEWA
AT		ALCON RES	0.15%	N21764 001 May 22, 2006 May NEWA

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

+ ALCON 1%

N20816 001 Apr 01, 1998 Feb CAHN

BUDESONIDE

SPRAY, METERED; NASAL

RHINOCORT

+ ASTRazeneca 0.032MG/INH
@ 0.064MG/INHN20746 001 Oct 01, 1999 Mar CRLD
N20746 002 Oct 01, 1999 Mar DISCBUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP + BEDFORD 0.25MG/ML
BUMEX
@ ROCHE 0.25MG/MLN74441 001 Jan 27, 1995 Feb CRLD
N18226 001 Feb 28, 1983 Feb DISCBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

+ HOSPIRA 0.5%

N22046 002 Jul 13, 1983 Apr NEWA

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE

+ HOSPIRA 0.5%;EQ 0.009MG BASE/ML

N22046 001 Jul 13, 1983 Apr NEWA

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB APOTEX INC 75MG
AB 100MGN76143 001 Jan 17, 2006 Jan NEWA
N76143 002 Jan 17, 2006 Jan NEWABUSULFAN

INJECTABLE; INJECTION

BUSULFEX

+ PDL BIOPHARMA INC 6MG/ML

N20954 001 Feb 04, 1999 Jan CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

@ NOVARTIS 100MG;2MG

N09000 002 Feb DISC

MIGERGOT

+ G AND W LABS 100MG;2MG

N86557 001 Oct 04, 1983 Feb CRLD

CALCIPOTRIENE

CREAM; TOPICAL

DOVONEX

+ LEO PHARM 0.005%

N20554 001 Jul 22, 1996 Feb CAHN

OINTMENT; TOPICAL

DOVONEX

+ LEO PHARM 0.005%

N20273 001 Dec 29, 1993 Feb CAHN

SOLUTION; TOPICAL

DOVONEX

+ LEO PHARM 0.005%

N20611 001 Mar 03, 1997 Feb CAHN

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL

FORTICAL

>D> + UNIGENE 200 IU/SPRAY
>A> + UPSHER SMITH 200 IU/SPRAYN21406 001 Aug 12, 2005 Jun CAHN
N21406 001 Aug 12, 2005 Jun CAHNCALCITONIN, SALMON

INJECTABLE; INJECTION

MIACALCIN

+ NOVARTIS 200 IU/ML

N17808 002 Mar 29, 1991 Jan CTEC

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB ROXANE 0.25UGM
INJECTABLE; INJECTION
CALCITRIOL
AP GENIX THERAP 0.001MG/MLN76917 001 Mar 27, 2006 Mar NEWA
N77102 001 Feb 08, 2006 Jan NEWACALCIUM ACETATE>D> TABLET; ORAL
>D> PHOSLO
>D> + NABI EQ 169MG CALCIUM
>A> @ EQ 169MG CALCIUMN19976 001 Dec 10, 1990 Jun DISC
N19976 001 Dec 10, 1990 Jun DISCCANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

ASTRAZENECA 8MG

N20838 002 Jun 04, 1998 May CRLD

CAPTOPRIL

TABLET; ORAL

Captopril

@ CLONMEL HLTHCARE 12.5MG
@ 25MG
@ 50MG
@ 100MG
@ ENDO LABS 12.5MG
@ 25MG
@ 50MG
@ 100MGN74423 001 Feb 13, 1996 Jan DISC
N74423 002 Feb 13, 1996 Jan DISC
N74423 003 Feb 13, 1996 Jan DISC
N74423 004 Feb 13, 1996 Jan DISC
N74418 001 Feb 13, 1996 Feb DISC
N74418 002 Feb 13, 1996 Feb DISC
N74418 003 Feb 13, 1996 Feb DISC
N74418 004 Feb 13, 1996 Feb DISCCAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

Captopril AND Hydrochlorothiazide

@ ENDO LABS 25MG;15MG
@ 25MG;25MG
@ 50MG;15MG
@ 50MG;25MGN74788 001 Dec 29, 1997 Feb DISC
N74788 002 Dec 29, 1997 Feb DISC
N74788 004 Dec 29, 1997 Feb DISC
N74788 003 Dec 29, 1997 Feb DISC

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

>A>	AB	ACTAVIS ELIZABETH	10MG;100MG	N74260 001	Sep 03, 1993	Jun	CAHN
>A>	AB		25MG;100MG	N74260 002	Sep 03, 1993	Jun	CAHN
>A>	AB		25MG;250MG	N74260 003	Sep 03, 1993	Jun	CAHN
>D>	AB	PUREPAC PHARM	10MG;100MG	N74260 001	Sep 03, 1993	Jun	CAHN
>D>	AB		25MG;100MG	N74260 002	Sep 03, 1993	Jun	CAHN
>D>	AB		25MG;250MG	N74260 003	Sep 03, 1993	Jun	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	WATSON LABS	50MG/VIAL	N77383 001	Jan 27, 2006	Jan	NEWA
AP		150MG/VIAL	N77383 002	Jan 27, 2006	Jan	NEWA
AP		450MG/VIAL	N77383 003	Jan 27, 2006	Jan	NEWA

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	@ AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247 001	Oct 21, 2004	Feb	DISC
AP	@	EQ 150MG/15ML (10MG/ML)	N77247 002	Oct 21, 2004	Feb	DISC
AP		EQ 150MG/15ML (10MG/ML)	N77266 002	Feb 15, 2006	Jan	NEWA
AP		EQ 450MG/45ML (10MG/ML)	N77266 003	Feb 15, 2006	Jan	NEWA
AP		EQ 600MG/60ML (10MG/ML)	N77266 004	Feb 15, 2006	Jan	NEWA
AP	BEDFORD LABS	EQ 600MG/60ML (10MG/ML)	N77244 004	Jan 20, 2006	Jan	NEWA

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

CANCIDAS

+	MERCK	50MG/VIAL	N21227 001	Jan 26, 2001	May	CAHN
+		70MG/VIAL	N21227 002	Jan 26, 2001	May	CAHN

CEFACLOR

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

AB	+	PAR PHARM	EQ 500MG BASE	N65057 001	Jan 05, 2001	May	CAHN
----	---	-----------	---------------	------------	--------------	-----	------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

AB	+	IVAX PHARMS	EQ 500MG BASE	N62766 001	Mar 03, 1987	Mar	CRLD
AB		TEVA PHARMS	EQ 500MG BASE	N65282 001	Jan 20, 2006	Jan	NEWA
AB		WESTWARD	EQ 500MG BASE	N65311 001	Feb 07, 2006	Jan	NEWA

DURICEF

@ WARNER CHILCOTT

N50512 001 Jan DISC

FOR SUSPENSION; ORAL

CEFADROXIL

RANBAXY

N65115 001 Mar 26, 2003 Feb CTEC

AB	TEVA PHARMS	EQ 250MG BASE/5ML	N65278 001	Jan 20, 2006	Jan	NEWA
AB		EQ 500MG BASE/5ML	N65278 002	Jan 20, 2006	Jan	NEWA

DURICEF

@ WARNER CHILCOTT

N50527 002 Feb DISC

TABLET; ORALCEFADROXIL

AB	HIKMA	EQ 1GM BASE	N65260 001 Mar 30, 2006 Mar NEWA
AB	+ IVAX PHARMS	EQ 1GM BASE	N62774 001 Apr 08, 1987 Feb CRLD
	DURICEF		
	@ WARNER CHILCOTT	EQ 1GM BASE	N50528 001 Jan DISC

CEFAZOLIN SODIUMINJECTABLE; INJECTIONCEFAZOLIN AND DEXTROSE

@ B BRAUN	EQ 500MG BASE/VIAL	N50779 001 Jul 27, 2000 May DISC
-----------	--------------------	----------------------------------

CEFDINIRCAPSULE; ORALCEFDINIR

AB	LUPIN	300MG	N65264 001 May 19, 2006 May NEWA
	OMNICEF		
AB	+ ABBOTT	300MG	N50739 001 Dec 04, 1997 May CFTG
	FOR SUSPENSION; ORAL		
	CEFDINIR		
AB	LUPIN (USA)	125MG/5ML	N65259 001 May 31, 2006 May NEWA
	OMNICEF		
AB	ABBOTT	125MG/5ML	N50749 001 Dec 04, 1997 May CFTG

CEFOTAXIME SODIUMINJECTABLE; INJECTIONCEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

@ B BRAUN	EQ 2GM BASE	N50792 001 Jul 29, 2004 May DISC
-----------	-------------	----------------------------------

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

@ B BRAUN	EQ 1GM BASE	N50792 002 Jul 29, 2004 May DISC
-----------	-------------	----------------------------------

CEFOTETAN DISODIUMINJECTABLE; INJECTIONCEFOTAN

>D>	ASTRAZENECA	EQ 1GM BASE/VIAL	N63293 001 Apr 29, 1993 Jun DISC
>A>	@	EQ 1GM BASE/VIAL	N63293 001 Apr 29, 1993 Jun DISC
>D>		EQ 2GM BASE/VIAL	N63293 002 Apr 29, 1993 Jun DISC
>A>	@	EQ 2GM BASE/VIAL	N63293 002 Apr 29, 1993 Jun DISC

CEFOXITIN SODIUMINJECTABLE; INJECTIONCEFOXITIN

AP	ORCHID HLTHCARE	EQ 1GM BASE/VIAL	N65313 001 Jan 23, 2006 Jan NEWA
AP		EQ 2GM BASE/VIAL	N65313 002 Jan 23, 2006 Jan NEWA
AP		EQ 10GM BASE/VIAL	N65312 001 Feb 13, 2006 Jan NEWA
	CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER		
AP	B BRAUN	EQ 1GM BASE/VIAL	N65214 001 Mar 10, 2006 Feb NEWA
AP		EQ 2GM BASE/VIAL	N65214 002 Mar 10, 2006 Feb NEWA

CEFPROZILFOR SUSPENSION; ORALCEFPROZIL

>A> AB	RANBAXY	125MG/5ML	N65202 001 Jun 30, 2006 Jun NEWA
>A> AB		250MG/5ML	N65202 002 Jun 30, 2006 Jun NEWA

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

CEPTAZ

@ GLAXOSMITHKLINE

1GM/VIAL

N50646 002 Sep 27, 1990 May DISC

@

2GM/VIAL

N50646 003 Sep 27, 1990 May DISC

@

10GM/VIAL

N50646 004 Sep 27, 1990 May DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

AP AM PHARM PARTNERS

EQ 250MG BASE/VIAL

N65245 001 Feb 15, 2006 Jan NEWA

AP

EQ 500MG BASE/VIAL

N65245 002 Feb 15, 2006 Jan NEWA

AP

EQ 1GM BASE/VIAL

N65245 003 Feb 15, 2006 Jan NEWA

AP

EQ 2GM BASE/VIAL

N65245 004 Feb 15, 2006 Jan NEWA

CEFTRIAXONE SODIUM

>A> AP TEVA

EQ 1GM BASE/VIAL

N65262 001 Jun 29, 2006 Jun NEWA

>A> AP

EQ 2GM BASE/VIAL

N65262 002 Jun 29, 2006 Jun NEWA

INJECTABLE; INJECTION

CEFTRIAXONE

AP AM PHARM

EQ 10GM BASE/VIAL

N65252 001 Feb 15, 2006 Jan NEWA

AP WOCKHARDT

EQ 1GM BASE/VIAL

N65180 001 May 12, 2006 May NEWA

CEFTRIAXONE SODIUM

AP TEVA

EQ 10GM BASE/VIAL

N65274 001 May 01, 2006 Apr NEWA

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB AUROBINDO PHARMA LTD

EQ 125MG BASE

N65308 001 Mar 29, 2006 Mar NEWA

AB

EQ 250MG BASE

N65308 002 Mar 29, 2006 Mar NEWA

AB

EQ 500MG BASE

N65308 003 Mar 29, 2006 Mar NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB HIKMA

EQ 250MG BASE

N65215 001 Jan 24, 2006 Jan NEWA

AB

EQ 500MG BASE

N65215 002 Jan 24, 2006 Jan NEWA

KEFLEX

ADVANCIS PHARM

EQ 333MG BASE

N50405 004 May 12, 2006 May NEWA

AB

EQ 500MG BASE

N50405 003 May CRLD

+

EQ 750MG BASE

N50405 005 May 12, 2006 May NEWA

FOR SUSPENSION; ORAL

CEPHALEXIN

>A> AB ORCHID HLTHCARE

EQ 125MG BASE/5ML

N65326 001 Jul 10, 2006 Jun NEWA

>A> AB

EQ 250MG BASE/5ML

N65326 002 Jul 10, 2006 Jun NEWA

CEPHRADINE

CAPSULE; ORAL

ANSPOR

@ GLAXOSMITHKLINE

250MG

N61859 001

Mar DISC

@

500MG

N61859 002

Mar DISC

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL
 EXOSURF NEONATAL
 @ GLAXOSMITHKLINE 12MG/VIAL;108MG/VIAL;8MG/VIAL N20044 001 Aug 02, 1990 May DISC

>D> CHLOROTHIAZIDE; RESERPINE

>D> TABLET; ORAL
 >D> DIUPRES-250
 >D> BP MERCK 250MG;0.125MG N11635 003 Aug 26, 1987 Jun DISC
 >A> @ 250MG;0.125MG N11635 003 Aug 26, 1987 Jun DISC
 >D> DIUPRES-500
 >D> BP + MERCK 500MG;0.125MG N11635 006 Aug 26, 1987 Jun DISC
 >A> @ 500MG;0.125MG N11635 006 Aug 26, 1987 Jun DISC

CHLORPROMAZINE

SUPPOSITORY; RECTAL
 THORAZINE
 @ GLAXOSMITHKLINE 25MG N09149 024 May DISC
 @ 100MG N09149 033 May DISC

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
 THORAZINE
 @ GLAXOSMITHKLINE 200MG N11120 019 May DISC
 @ 300MG N11120 020 May DISC

CICLOPIROX

CREAM; TOPICAL
 CICLOPIROX
 AB PERRIGO 0.77% N77364 001 Mar 03, 2006 Mar CAHN
 AB PERRIGO NEW YORK 0.77% N77364 001 Mar 03, 2006 Feb NEWA

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION
 PRIMAXIN
 >D> + MERCK EQ 750MG BASE/VIAL;750MG/VIAL N50630 002 Dec 14, 1990 Jun DISC
 >A> @ EQ 750MG BASE/VIAL;750MG/VIAL N50630 002 Dec 14, 1990 Jun DISC

CILOSTAZOL

TABLET; ORAL
 CILOSTAZOL
 AB MUTUAL PHARM 50MG N77208 002 Mar 29, 2006 Mar NEWA
 AB 100MG N77208 001 Mar 29, 2006 Mar NEWA
 AB MYLAN 50MG N77323 002 Apr 20, 2006 Apr NEWA
 AB 100MG N77323 001 Apr 20, 2006 Apr NEWA

CIMETIDINE

TABLET; ORAL
 CIMETIDINE
 @ ENDO PHARMS 200MG N74281 001 May 17, 1994 Feb DISC
 @ 300MG N74281 002 May 17, 1994 Feb DISC
 @ 400MG N74281 003 May 17, 1994 Feb DISC
 @ 800MG N74329 001 May 17, 1994 Feb DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@ ENDO PHARMS EQ 300MG BASE/2ML N74005 001 Aug 31, 1994 Feb DISC

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ ENDO PHARMS EQ 300MG BASE/5ML N74251 001 Dec 22, 1994 Feb DISC

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

AA SILARX EQ 10MG BASE/5ML N77629 001 Jun 15, 2006 May NEWA

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>A>	AB	ACTAVIS ELIZABETH	EQ 10MG BASE	N77033 001 Oct 28, 2004 Jun CAHN
>A>	AB		EQ 20MG BASE	N77033 002 Oct 28, 2004 Jun CAHN
>A>	AB		EQ 40MG BASE	N77033 003 Oct 28, 2004 Jun CAHN
>A>	AB	MUTUAL PHARM	EQ 10MG BASE	N77052 001 Jul 03, 2006 Jun NEWA
>A>	AB		EQ 20MG BASE	N77052 002 Jul 03, 2006 Jun NEWA
>A>	AB		EQ 40MG BASE	N77052 003 Jul 03, 2006 Jun NEWA
>D>	AB	PUREPAC PHARM	EQ 10MG BASE	N77033 001 Oct 28, 2004 Jun CAHN
>D>	AB		EQ 20MG BASE	N77033 002 Oct 28, 2004 Jun CAHN
>D>	AB		EQ 40MG BASE	N77033 003 Oct 28, 2004 Jun CAHN
	AB	TARO	EQ 10MG BASE	N77278 001 Mar 22, 2006 Mar NEWA
	AB		EQ 20MG BASE	N77278 002 Mar 22, 2006 Mar NEWA
	AB		EQ 40MG BASE	N77278 003 Mar 22, 2006 Mar NEWA
	AB	TEVA PHARMS	EQ 10MG BASE	N77213 001 Mar 31, 2006 Mar NEWA
	AB		EQ 20MG BASE	N77213 002 Mar 31, 2006 Mar NEWA
	AB		EQ 40MG BASE	N77213 003 Mar 31, 2006 Mar NEWA

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

>D>		IRRIGATING SOLUTION G IN PLASTIC CONTAINER		
>D>	AT	+ BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/10 OML	N18519 001 Jun 22, 1982 Jun DISC
>A>		@	3.24GM/100ML;380MG/100ML;430MG/10 OML	N18519 001 Jun 22, 1982 Jun DISC
		UROLOGIC G IN PLASTIC CONTAINER		
>D>	AT	+ HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/10 OML	N18904 001 May 27, 1983 Jun CTEC
>A>		+	3.24GM/100ML;380MG/100ML;430MG/10 OML	N18904 001 May 27, 1983 Jun CTEC

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB WOCKHARDT 250MG N65266 001 May 31, 2006 May NEWA
AB 500MG N65266 002 May 31, 2006 May NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

+ RANBAXY 1GM N65210 001 Jan 26, 2005 Apr CRLD

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT ALTANA EQ 1% BASE N65254 001 Feb 14, 2006 Jan NEWA

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE

>A>	AB1	ACTAVIS MID ATLANTIC	0.05%	N74139	001	Aug 03, 1994	Jun	CAHN
>D>	AB1	ALPHARMA US PHARMS	0.05%	N74139	001	Aug 03, 1994	Jun	CAHN

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

>A>	AB	ACTAVIS MID ATLANTIC	0.05%	N74128	001	Aug 03, 1994	Jun	CAHN
>D>	AB	ALPHARMA US PHARMS	0.05%	N74128	001	Aug 03, 1994	Jun	CAHN

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE
@ ALTANA 0.05% N75391 001 Feb 08, 1999 May DISC

SPRAY; TOPICAL
CLOBEX
+ GALDERMA LABS LP 0.05% N21835 001 Oct 27, 2005 Feb CAHN

CLOFAZIMINE

CAPSULE; ORAL
LAMPRENE

>D>		@ NOVARTIS	50MG	N19500	002	Dec 15, 1986	Jun	CMFD
>A>	+		50MG	N19500	002	Dec 15, 1986	Jun	CMFD

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM

>A>	AB	ACTAVIS ELIZABETH	0.5MG	N74869	001	Oct 31, 1996	Jun	CAHN
>A>	AB		1MG	N74869	002	Oct 31, 1996	Jun	CAHN
>A>	AB		2MG	N74869	003	Oct 31, 1996	Jun	CAHN
>D>	AB	PUREPAC PHARM	0.5MG	N74869	001	Oct 31, 1996	Jun	CAHN
>D>	AB		1MG	N74869	002	Oct 31, 1996	Jun	CAHN
>D>	AB		2MG	N74869	003	Oct 31, 1996	Jun	CAHN
>A>	AB	VINTAGE PHARMS	0.5MG	N77856	001	Jun 28, 2006	Jun	NEWA
>A>	AB		1MG	N77856	002	Jun 28, 2006	Jun	NEWA
>A>	AB		2MG	N77856	003	Jun 28, 2006	Jun	NEWA

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	0.1MG	N70974	001	Dec 16, 1986	Jun	CAHN
>A>	AB		0.2MG	N70975	001	Dec 16, 1986	Jun	CAHN
>A>	AB		0.3MG	N70976	001	Dec 16, 1986	Jun	CAHN
>D>	AB	PUREPAC PHARM	0.1MG	N70974	001	Dec 16, 1986	Jun	CAHN
>D>	AB		0.2MG	N70975	001	Dec 16, 1986	Jun	CAHN
>D>	AB		0.3MG	N70976	001	Dec 16, 1986	Jun	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL
CLOPIDOGREL BISULFATE

AB		APOTEX	EQ 75MG BASE	N76274	001	Jan 20, 2006	Jan	NEWA
		PLAVIX						
AB	+	SANOFI SYNTHELABO	EQ 75MG BASE	N20839	001	Nov 17, 1997	Jan	CFTG

>D>	<u>COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR</u>													
>D>	N/A; N/A													
>D>	RUBRATOPE-57 KIT													
>D>	BRACCO N/A;N/A;N/A;N/A N16089 001 Jun DISC													
>A>	@ N/A;N/A;N/A;N/A N16089 001 Jun DISC													
<u>CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>														
SYRUP; ORAL														
PROMETH VC W/ CODEINE														
+ ALPHARMA US PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML				N88764 001 Oct 31, 1984	Jan CTEC								
PROMETHAZINE VC W/ CODEINE														
@ MORTON GROVE	10MG/5ML;5MG/5ML;6.25MG/5ML				N88896 001 Jan 04, 1985	Jan DISC								
<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>														
SYRUP; ORAL														
PROMETHAZINE WITH CODEINE SYRUP														
AA VINTAGE	10MG/5ML;6.25MG/5ML				N40650 001 Jan 31, 2006	Jan NEWA								
<u>COLESTIPOL HYDROCHLORIDE</u>														
GRANULE; ORAL														
COlestid														
AB PHARMACIA AND UPJOHN	5GM/SCOOPFUL				N17563 003 Sep 22, 1995	Apr CFTG								
AB +	5GM/PACKET				N17563 004 Sep 22, 1995	Apr CFTG								
COLESTIPOL HYDROCHLORIDE														
AB IMPAX LABS	5GM/PACKET				N77277 002 May 02, 2006	Apr NEWA								
AB	5GM/SCOOPFUL				N77277 001 May 02, 2006	Apr NEWA								
FLAVORED COlestid														
PHARMACIA AND UPJOHN 5GM/PACKET														
					N17563 001		Apr CFTG							
<u>CROMOLYN SODIUM</u>														
CONCENTRATE; ORAL														
GASTROCROM														
+ AZUR PHARMA	100MG/5ML				N20479 001 Feb 29, 1996	May CDFR								
SOLUTION, CONCENTRATE; ORAL														
GASTROCROM														
+ AZUR PHARMA	100MG/5ML				N20479 001 Feb 29, 1996	Feb CAHN								
<u>CYANOCOBALAMIN</u>														
GEL, METERED; NASAL														
NASCOBAL														
@ QOL MEDCL	0.5MG/INH				N19722 001 Nov 05, 1996	Mar DISC								
<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>														
TABLET; ORAL														
CYCLOBENZAPRINE HYDROCHLORIDE														
AB JUBILANT PHARMS	5MG				N77563 001 Apr 19, 2006	Apr NEWA								
AB	10MG				N77563 002 Apr 19, 2006	Apr NEWA								
CYCLOBENZAPRINE HYDROCHLORIDE														
AB AMIDE PHARM	5MG				N77291 001 Feb 03, 2006	Jan NEWA								
AB MUTUAL PHARM	5MG				N73541 002 Apr 06, 2006	Mar NEWA								
AB MYLAN	5MG				N73144 002 Feb 03, 2006	Jan NEWA								
AB SANDOZ	5MG				N72854 002 Feb 03, 2006	Jan NEWA								
AB WATSON LABS	5MG				N71611 002 Feb 03, 2006	Jan NEWA								
	7.5MG				N71611 003 Feb 03, 2006	Jan NEWA								

TABLET; ORAL

FLEXERIL

AB	MCNEIL CONS SPECLT	5MG	N17821 001	Jan	CFTG
----	--------------------	-----	------------	-----	------

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>D>	+	ALPHARMA US PHARMS	2MG/5ML	N86833 001	Jun	CTEC
>A>	AA	+	2MG/5ML	N86833 001	Jun	CTEC
>A>	AA	LYNE	2MG/5ML	N40668 001	Jun 28, 2006	Jun NEWA

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

@	TG UNITED LABS	4MG	N88212 001	May 26, 1983	May CAHN
CYPROHEPTADINE HYDROCLORIDE					
AA	STASON PHARMS	4MG	N40644 001	May 30, 2006	May NEWA

DAPTOMYCIN

INJECTABLE; IV (INFUSION)

CUBICIN

>D>		CUBIST	250MG/VIAL	N21572 001	Sep 12, 2003	Jun DISC
>A>	@		250MG/VIAL	N21572 001	Sep 12, 2003	Jun DISC

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

>A>	+	TIBOTEC	EQ 300MG BASE	N21976 001	Jun 23, 2006	Jun NEWA
-----	---	---------	---------------	------------	--------------	----------

DASATINIB

TABLET; ORAL

SPRYCEL

>A>		BRISTOL MYERS SQUIBB	20MG	N21986 001	Jun 28, 2006	Jun NEWA
>A>			50MG	N21986 002	Jun 28, 2006	Jun NEWA
>A>	+		70MG	N21986 003	Jun 28, 2006	Jun NEWA

DECITABINE

INJECTABLE; INTRAVENOUS

DACOGEN

+	MGI PHARMA INC	50MG/VIAL	N21790 001	May 02, 2006	May NEWA
---	----------------	-----------	------------	--------------	----------

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP	SICOR PHARMS	500MG/VIAL	N76806 001	Mar 31, 2006	Mar NEWA
AP		2GM/VIAL	N76806 002	Mar 31, 2006	Mar NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

AB	@ GLADES PHARMS LLC	75MG	N50261 001	Mar	CAHN
AB		150MG	N50261 002	Mar	CAHN
AB	+	300MG	N50261 003	Mar	CAHN
	@ PROTEIN DESIGN LABS	75MG	N50261 001	Feb	CAHN
AB		150MG	N50261 002	Feb	CAHN
AB	+	300MG	N50261 003	Feb	CAHN

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARINEX-D 12 HOUR
+ SCHERING 2.5MG;120MG

N21313 001 Feb 01, 2006 Feb NEWA

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE
@ BEDFORD 0.004MG/ML
DESMOPRESSIN ACETATE PRESERVATIVE FREE
@ BEDFORD 0.004MG/ML
TABLET; ORAL
DESMOPRESSIN ACETATE
AB APOTEX 0.1MG
AB 0.2MG
AB TEVA PHARMS 0.1MG
AB 0.2MG

N74575 001 Feb 18, 2000 Jan DISC
N74574 001 Feb 18, 2000 Jan DISC
N77414 001 Mar 07, 2006 Feb NEWA
N77414 002 Mar 07, 2006 Feb NEWA
N77122 001 Jan 25, 2006 Jan NEWA
N77122 002 Jan 25, 2006 Jan NEWA

DESOGESTREL; ETHINYLN STRADIOL

TABLET; ORAL-28
MIRCETTE
AB + DURAMED 0.15MG,N/A;0.02MG,0.01MG
AB + 0.15MG,N/A;0.02MG,0.01MG

N20713 001 Apr 22, 1998 Feb CAHN
N20713 001 Apr 22, 1998 Feb CAHN

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE
>D> AA ALPHARMA US PHARMS 0.5MG/5ML N84754 001 Jun CRLD
>A> AA + 0.5MG/5ML N84754 001 Jun CRLD
>D> HEXADROL
>D> AA + ORGANON USA INC 0.5MG/5ML N12674 001 Jun DISC
>A> @ 0.5MG/5ML N12674 001 Jun DISC
MYMETHASONE
>D> AA MORTON GROVE 0.5MG/5ML N88254 001 Jul 27, 1983 Jun CRLD
>A> AA + 0.5MG/5ML N88254 001 Jul 27, 1983 Jun CRLD
TABLET; ORAL
>D> HEXADROL
>D> BP ORGANON USA INC 4MG N12675 010 Jun DISC
>A> @ 4MG N12675 010 Jun DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE
AP BAXTER HLTHCARE EQ 10MG PHOSPHATE/ML N87702 001 Sep 07, 1982 Mar CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE
@ ENDO PHARMS 5MG N40299 001 May 13, 1999 Feb DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE DM
AA VINTAGE 15MG/5ML;6.25MG/5ML N40649 001 Feb 14, 2006 Jan NEWA

DIAZEPAM

TABLET; ORAL

DIAZEPAM

>A>	AB	ACTAVIS ELIZABETH	2MG	N70781	001	Mar 19,	1986	Jun	CAHN
>A>	AB		5MG	N70706	001	Mar 19,	1986	Jun	CAHN
>A>	AB		10MG	N70707	001	Mar 19,	1986	Jun	CAHN
>D>	AB	PUREPAC PHARM	2MG	N70781	001	Mar 19,	1986	Jun	CAHN
>D>	AB		5MG	N70706	001	Mar 19,	1986	Jun	CAHN
>D>	AB		10MG	N70707	001	Mar 19,	1986	Jun	CAHN
	AB	VINTAGE PHARMS	2MG	N77749	001	Mar 31,	2006	Mar	NEWA
	AB		5MG	N77749	002	Mar 31,	2006	Mar	NEWA
	AB		10MG	N77749	003	Mar 31,	2006	Mar	NEWA

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

>A>	AB	ACTAVIS ELIZABETH	50MG	N74514	001	Mar 26,	1996	Jun	CAHN
>A>	AB		75MG	N74514	002	Mar 26,	1996	Jun	CAHN
>D>	AB	PUREPAC PHARM	50MG	N74514	001	Mar 26,	1996	Jun	CAHN
>D>	AB		75MG	N74514	002	Mar 26,	1996	Jun	CAHN
	AB	SANDOZ	75MG	N74394	001	Nov 30,	1995	May	CRLD
		VOLTAREN							
	AB	+ NOVARTIS	75MG	N19201	003	Jul 28,	1988	May	CMFD
		TABLET, EXTENDED RELEASE; ORAL							
		DICLOFENAC SODIUM							
>A>	AB	ACTAVIS ELIZABETH	100MG	N75910	001	Jan 07,	2002	Jun	CAHN
>D>	AB	PUREPAC PHARM	100MG	N75910	001	Jan 07,	2002	Jun	CAHN

DIETHYLPROMION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROMION HYDROCHLORIDE

@	TG UNITED LABS	25MG	N88267	001	Aug 25,	1983	May	CAHN
@		25MG	N88268	001	Aug 25,	1983	May	CAHN

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	ALTANA	0.05%	N76263	001	Dec 20,	2002	Jan	CRLD
		FLORONE							
	@	PHARMACIA AND UPJOHN	0.05%	N17741	001			Jan	DISC
		FLORONE E							
	@	PHARMACIA AND UPJOHN	0.05%	N19259	001	Aug 28,	1985	Jan	DISC
		OINTMENT; TOPICAL							
		DIFLORASONE DIACETATE							
AB	+	TARO	0.05%	N75331	001	May 14,	1999	Jan	CRLD
		FLORONE							
	@	PHARMACIA AND UPJOHN	0.05%	N17994	001			Jan	DISC
		PSORCON							
	@	PHARMACIA AND UPJOHN	0.05%	N19260	001	Aug 28,	1985	Jan	DISC

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

>D>	AB	TEVA	500MG	N73673	001	Jul 31,	1992	Jun	CRLD
-----	----	------	-------	--------	-----	---------	------	-----	------

TABLET; ORALDIFLUNISAL

>A>	AB	+	TEVA	500MG	N73673	001	Jul 31,	1992	Jun	CRLD
>D>			DOLOBID							
>D>	AB		MERCK	250MG	N18445	001	Apr 19,	1982	Jun	DISC
>A>		@		250MG	N18445	001	Apr 19,	1982	Jun	DISC
>D>	AB	+		500MG	N18445	002	Apr 19,	1982	Jun	DISC
>A>		@		500MG	N18445	002	Apr 19,	1982	Jun	DISC

DIGOXININJECTABLE; INJECTIONDIGOXIN

AP		SANDOZ	0.25MG/ML	N40481	001	Aug 21,	2003	Jan	CAHN
----	--	--------	-----------	--------	-----	---------	------	-----	------

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORALDILTIAZEM HYDROCHLORIDE

>A>	AB3		ACTAVIS ELIZABETH	120MG	N74984	001	Dec 20,	1999	Jun	CAHN
>A>	AB3			180MG	N74984	002	Dec 20,	1999	Jun	CAHN
>A>	AB3			240MG	N74984	003	Dec 20,	1999	Jun	CAHN
>A>	AB3			300MG	N74984	004	Dec 20,	1999	Jun	CAHN
>D>	AB3		PUREPAC PHARM	120MG	N74984	001	Dec 20,	1999	Jun	CAHN
>D>	AB3			180MG	N74984	002	Dec 20,	1999	Jun	CAHN
>D>	AB3			240MG	N74984	003	Dec 20,	1999	Jun	CAHN
>D>	AB3			300MG	N74984	004	Dec 20,	1999	Jun	CAHN
			DILTZAC							
AB4			APOTEX INC	120MG	N76395	001	Feb 01,	2006	Jan	NEWA
AB4				180MG	N76395	002	Feb 01,	2006	Jan	NEWA
AB4				240MG	N76395	003	Feb 01,	2006	Jan	NEWA
AB4				300MG	N76395	004	Feb 01,	2006	Jan	NEWA
AB4				360MG	N76395	005	Feb 01,	2006	Jan	NEWA

DIPYRIDAMOLETABLET; ORALDIPYRIDAMOLE

AB		AMIDE PHARM	25MG	N40542	001	Apr 21,	2006	Apr	NEWA
AB			50MG	N40542	002	Apr 21,	2006	Apr	NEWA
AB			75MG	N40542	003	Apr 21,	2006	Apr	NEWA

DISOPYRAMIDE PHOSPHATECAPSULE; ORALDISOPYRAMIDE PHOSPHATE

@	IVAX PHARMS	EQ 100MG BASE	N70186	001	Nov 18,	1985	Jan	DISC
@		EQ 150MG BASE	N70187	001	Nov 18,	1985	Jan	DISC
@	SANDOZ	EQ 100MG BASE	N70470	001	Dec 10,	1985	Jan	DISC
@		EQ 150MG BASE	N70471	001	Dec 10,	1985	Jan	DISC

DOLASETRON MESYLATEINJECTABLE; INJECTIONANZEMET

+	SANOFI AVENTIS US	EQ 12.5MG BASE/0.625ML (EQ 20MG BASE/ML)	N20624	002	Sep 11,	1997	Mar	CAIN
+		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N20624	001	Sep 11,	1997	Mar	CAIN
+		EQ 500MG BASE/25ML (EQ 20MG BASE/ML)	N20624	003	Dec 11,	2001	Mar	CAIN

TABLET; ORAL

ANZEMET

SANOFI AVENTIS US	EQ 50MG BASE	N20623 001 Sep 11, 1997 Mar CAIN
+	EQ 100MG BASE	N20623 002 Sep 11, 1997 Mar CAIN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

@ HOSPIRA	40MG/ML	N74403 001 May 23, 1996 Apr DISC
@ INTL MEDICATION	40MG/ML	N18014 001 Apr DISC
@ SICOR PHARMS	40MG/ML	N72999 001 Oct 23, 1991 Apr DISC
@	80MG/ML	N73000 001 Oct 23, 1991 Apr DISC

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

>A> AB	ACTAVIS ELIZABETH	EQ 1MG BASE	N75574 001 Oct 18, 2000 Jun CAHN
>A> AB		EQ 2MG BASE	N75574 002 Oct 18, 2000 Jun CAHN
>A> AB		EQ 4MG BASE	N75574 003 Oct 18, 2000 Jun CAHN
>A> AB		EQ 8MG BASE	N75574 004 Oct 18, 2000 Jun CAHN
>D> AB	PUREPAC PHARM	EQ 1MG BASE	N75574 001 Oct 18, 2000 Jun CAHN
>D> AB		EQ 2MG BASE	N75574 002 Oct 18, 2000 Jun CAHN
>D> AB		EQ 4MG BASE	N75574 003 Oct 18, 2000 Jun CAHN
>D> AB		EQ 8MG BASE	N75574 004 Oct 18, 2000 Jun CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

@ PAR PHARM	EQ 75MG BASE	N65055 004 Apr 18, 2005 Mar DISC
@	EQ 150MG BASE	N65055 003 Jul 15, 2005 Mar DISC
RANBAXY	EQ 75MG BASE	N65053 003 Sep 10, 2003 Mar CTEC

CAPSULE, DELAYED RELEASE; ORAL

ORACEA

+ COLLAGENEX PHARMS	40MG	N50805 001 May 26, 2006 May NEWA
---------------------	------	----------------------------------

TABLET; ORAL

DOXYCYCLINE

AB	PAR PHARM	EQ 75MG BASE	N65070 003 Dec 30, 2002 May CFTG
		EQ 75MG BASE	N65070 003 Dec 30, 2002 Mar CMFD
AB	RANBAXY	EQ 50MG BASE	N65356 001 May 31, 2006 May NEWA
AB		EQ 75MG BASE	N65356 002 May 31, 2006 May NEWA
AB		EQ 100MG BASE	N65356 003 May 31, 2006 May NEWA

DOXYCYCLINE HYCLATE

CAPSULE, DELAYED RELEASE; ORAL

DORYX

@ FH FAULDING CO LTD	EQ 75MG BASE	N50582 002 Aug 13, 2001 Apr DISC
@	EQ 100MG BASE	N50582 001 Jul 22, 1985 Apr DISC
@ WARNER CHILCOTT	EQ 100MG BASE	N62653 001 Oct 30, 1985 Apr DISC

DOXYCYCLINE HYCLATE

SANDOZ	EQ 75MG BASE	N65281 001 Dec 21, 2005 Apr CTEC
+	EQ 100MG BASE	N65281 002 Dec 21, 2005 Apr CRLD

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	PAR PHARM	EQ 20MG BASE	N65287 001 Feb 28, 2006 Feb NEWA
----	-----------	--------------	----------------------------------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

YAZ

>A>	+	BERLEX	3MG;0.02MG	N21676 001	Mar 16, 2006	Jun	CAHN
>D>	+	BERLEX LABS	3MG;0.02MG	N21676 001	Mar 16, 2006	Jun	CAHN
	+		3MG;0.02MG	N21676 001	Mar 16, 2006	Mar	NEWA

DYPHYLLINE

TABLET; ORAL

DILOR

>D>	BP	SAVAGE LABS	200MG	N84514 001	Jun	DISC
>A>		@	200MG	N84514 001	Jun	DISC
>D>		DILOR-400				
>D>	BP	+ SAVAGE LABS	400MG	N84751 001	Jun	DISC
>A>		@	400MG	N84751 001	Jun	DISC
		LUFYLLIN				
>D>	BP	MEDPOINTE PHARM HLC	200MG	N84566 001	Jun	CTEC
>A>			200MG	N84566 001	Jun	CTEC
>D>	BP		400MG	N84566 002	Jun	CRLD
>A>		+	400MG	N84566 002	Jun	CRLD

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE W/ EPINEPHRINE

+ DENTSPLY PHARM 0.02MG/ML;2%

N21381 002 Mar CRLD

PATCH; IONTOPHORESIS, TOPICAL

LIDOSITE TOPICAL SYSTEM KIT

+ VYTERIS 1.05MG/PATCH;100MG/PATCH

N21504 001 May 06, 2004 May CDFR

SOLUTION; IONTOPHORESIS, TOPICAL

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

+ EMPI 0.01MG/ML;2%

N21486 001 Oct 26, 2004 May CDFR

ERYTHROMYCIN

SOLUTION; TOPICAL

A/T/S

AT TARO PHARMS NORTH 2% N62405 001 Nov 18, 1982 Feb CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	IVAX PHARMS	5MG	N76765 001	May 22, 2006	May	NEWA
AB		10MG	N76765 002	May 22, 2006	May	NEWA
AB		20MG	N76765 003	May 22, 2006	May	NEWA
	LEXAPRO					
AB	FOREST LABS	5MG	N21323 001	Aug 14, 2002	May	CFTG
AB		10MG	N21323 002	Aug 14, 2002	May	CFTG
AB	+	20MG	N21323 003	Aug 14, 2002	May	CFTG

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

AB PAR PHARM 1MG N74826 001 Jul 03, 1997 Apr CAHN

AB 2MG N74826 002 Jul 03, 1997 Apr CAHN

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
MENOSTAR

>A>	+ BERLEX	0.014MG/24HR	N21674 001 Jun 08, 2004 Jun CAHN
>D>	+ BERLEX LABS	0.014MG/24HR	N21674 001 Jun 08, 2004 Jun CAHN
GEL; TOPICAL			
ESTROGEL			
@ ASCEND		0.06%	N21166 001 Feb 09, 2004 Jan CAHN
GEL, METERED; TOPICAL			
ESTROGEL			
+ ASCEND		0.06%	N21166 002 Feb 09, 2004 Jan CAHN

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL
ESTRASORB

+ ESPRIT PHARMA	0.25%	N21371 001 Oct 09, 2003 Feb CAHN
-----------------	-------	----------------------------------

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL
ENJUVIA

DURAMED	0.3MG	N21443 001 Dec 20, 2004 Mar CMFD
	0.45MG	N21443 002 Dec 20, 2004 Mar CMFD
	0.625MG	N21443 003 May 10, 2004 Mar CMFD
+	1.25MG	N21443 004 May 10, 2004 Mar CMFD

ETHINYLMESTRADIOL; LEVONORGESTREL

TABLET; ORAL
SEASONIQUE

+ DURAMED RES	0.03MG, 0.01MG; 0.15MG, N/A	N21840 001 May 25, 2006 May NEWA
TABLET; ORAL-28		
LEVONORGESTREL AND ETHINYLMESTRADIOL		
AB2 WATSON LABS	0.02MG; 0.1MG	N77681 001 May 31, 2006 May NEWA

ETHINYLMESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
BALZIVA-21

BARR	0.035MG; 0.4MG	N76198 001 Apr 22, 2004 Mar CRLD
TABLET; ORAL-28		
OVCON-35		
AB + WARNER CHILCOTT	0.035MG; 0.4MG	N17716 001 Mar CRLD

ETHINYLMESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
LOESTRIN 24 FE

+ WARNER CHILCOTT	0.02MG; 1MG	N21871 001 Feb 17, 2006 Feb NEWA
-------------------	-------------	----------------------------------

ETODOLAC

CAPSULE; ORAL
ETODOLAC

@ ENDO PHARMS	200MG	N74842 001 Jul 17, 1997 Feb DISC
@	300MG	N74842 002 Jul 17, 1997 Feb DISC
AB + TARO	300MG	N75078 002 Apr 30, 1998 Mar CRLD
LODINE		
@ WYETH PHARMS INC	300MG	N18922 003 Jan 31, 1991 Mar DISC

TABLET; ORAL

ETODOLAC

>A>	AB	ACTAVIS ELIZABETH	400MG	N74819 001 Feb 28, 1997 Jun CAHN
		@ ENDO PHARMS	400MG	N74841 001 Jun 27, 1997 Feb DISC
>D>	AB	PUREPAC PHARM	400MG	N74819 001 Feb 28, 1997 Jun CAHN

ETOPOSIDE

INJECTABLE; INJECTION

>D>		TOPOSAR		
>D>	AP	SICOR PHARMS	20MG/ML	N74166 001 Feb 27, 1995 Jun DISC
>A>		@	20MG/ML	N74166 001 Feb 27, 1995 Jun DISC

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

>A>	AB	ACTAVIS ELIZABETH	20MG	N75650 001 Sep 14, 2001 Jun CAHN
>A>	AB		40MG	N75650 002 Sep 14, 2001 Jun CAHN
>D>	AB	PUREPAC PHARM	20MG	N75650 001 Sep 14, 2001 Jun CAHN
>D>	AB		40MG	N75650 002 Sep 14, 2001 Jun CAHN

FENOFIBRATE

CAPSULE; ORAL

LIPOFEN

CIPHER	50MG	N21612 001 Jan 11, 2006 Jan NEWA
	100MG	N21612 002 Jan 11, 2006 Jan NEWA
+	150MG	N21612 003 Jan 11, 2006 Jan NEWA

TABLET; ORAL

FENOFIBRATE

AB	+	TEVA	160MG	N76433 002 May 13, 2005 Jan CRLD
		TRICOR		
	@ ABBOTT		54MG	N21203 001 Sep 04, 2001 Jan DISC
	@		160MG	N21203 003 Sep 04, 2001 Jan DISC

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE

AP		SANDOZ	EQ 10MG BASE/ML	N77155 001 Feb 15, 2005 Jan CAHN
----	--	--------	-----------------	----------------------------------

FENOPROFEN CALCIUM

TABLET; ORAL

FENOPROFEN CALCIUM

>A>	AB	ACTAVIS ELIZABETH	EQ 600MG BASE	N72274 001 May 02, 1988 Jun CAHN
		@ CLONMEL HLTHCARE	EQ 600MG BASE	N72326 001 Aug 17, 1988 Jan DISC
>D>	AB	PUREPAC PHARM	EQ 600MG BASE	N72274 001 May 02, 1988 Jun CAHN

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ (SUGAR-FREE)

CEPHALON	EQ 0.2MG BASE	N20747 001 Nov 04, 1998 Mar CTNA
+	EQ 0.4MG BASE	N20747 002 Nov 04, 1998 Mar CTNA
	EQ 0.6MG BASE	N20747 003 Nov 04, 1998 Mar CTNA
	EQ 0.8MG BASE	N20747 004 Nov 04, 1998 Mar CTNA
	EQ 1.2MG BASE	N20747 005 Nov 04, 1998 Mar CTNA
	EQ 1.6MG BASE	N20747 006 Nov 04, 1998 Mar CTNA

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	30MG	N76502	001	Apr 11,	2006	Mar	NEWA
AB		60MG	N76502	002	Apr 11,	2006	Mar	NEWA
AB		180MG	N76502	003	Apr 11,	2006	Mar	NEWA

FINASTERIDE

TABLET; ORAL

FINASTERIDE

>A>			N76340	001	Jun 19,	2006	Jun	NEWA
>A>	AB	IVAX PHARMS		5MG				
		PROSCAR						
>D>	+ MERCK		N20180	001	Jun 19,	1992	Jun	CFTG

>A>	AB	+	N20180	001	Jun 19,	1992	Jun	CFTG
-----	----	---	--------	-----	---------	------	-----	------

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB	GLENMARK PHARMA	50MG	N77253	001	Jan 25,	2006	Jan	NEWA
AB		100MG	N77253	002	Jan 25,	2006	Jan	NEWA
AB		150MG	N77253	003	Jan 25,	2006	Jan	NEWA
AB		200MG	N77253	004	Jan 25,	2006	Jan	NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	SANDOZ	0.5MG/5ML (0.1MG/ML)	N77071	001	May 03,	2005	Jan	CAHN
AP		1MG/10ML (0.1MG/ML)	N77071	002	May 03,	2005	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAH HFA

+ FOREST LABS EQ 78UGM BASE/INH

N21247 001 Jan 27, 2006 Jan NEWA

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

>A>	AB1	ACTAVIS MID ATLANTIC	0.05%	N73085	001	Feb 14,	1992	Jun	CAHN
>D>	AB1	ALPHARMA US PHARMS	0.05%	N73085	001	Feb 14,	1992	Jun	CAHN
		FLUOCINONIDE EMULSIFIED	BASE						
>A>	AB2	ACTAVIS MID ATLANTIC	0.05%	N74204	001	Jun 13,	1995	Jun	CAHN
>D>	AB2	ALPHARMA US PHARMS	0.05%	N74204	001	Jun 13,	1995	Jun	CAHN

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

FLUORESCITE

+ ALCON EQ 500MG BASE/5ML (EQ 100MG
BASE/ML)

N21980 001 Mar 28, 2006 May CAHN

+ ALCON RES EQ 500MG BASE/5ML (EQ 100MG
BASE/ML)

N21980 001 Mar 28, 2006 Mar NEWA

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

>D> AP + SICOR PHARMS 50MG/ML

N40023 001 Oct 18, 1991 Jun DISC

INJECTABLE; INJECTION

>D>	ADRUCIL							
>A>	@ SICOR PHARMS	50MG/ML	N40023	001	Oct 18, 1991	Jun	DISC	
AP	+	50MG/ML	N40023	001	Oct 18, 1991	Mar	CRLD	
>D>	AP	+	50MG/ML	N81225	001	Aug 28, 1991	Jun	DISC
>A>	@	50MG/ML	N81225	001	Aug 28, 1991	Jun	DISC	
FLUOROURACIL								
AP	+	AM PHARM PARTNERS	50MG/ML	N40278	001	Sep 30, 1998	Mar	CRLD
AP	+		50MG/ML	N40279	001	Sep 30, 1998	Mar	CRLD
AP	+		50MG/ML	N40291	001	Mar 24, 1999	Mar	CRLD
AP	+		50MG/ML	N40379	001	Nov 15, 2000	Mar	CRLD
	@ BEDFORD		50MG/ML	N89508	001	Jan 26, 1988	Apr	DISC
AP	+		50MG/ML	N89508	001	Jan 26, 1988	Mar	CRLD
AP	+	SICOR PHARMS	50MG/ML	N40333	001	Jan 27, 2000	Mar	CRLD
AP	+		50MG/ML	N40334	001	Feb 25, 2000	Mar	CRLD
AP	+	STERIS	50MG/ML	N87792	001	Oct 13, 1982	Mar	CRLD
	@ WATSON LABS		50MG/ML	N87792	001	Oct 13, 1982	Apr	DISC

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

SARAFEM

WARNER CHILCOTT	EQ 10MG BASE	N21860	001	May 19, 2006	May	NEWA
	EQ 15MG BASE	N21860	002	May 19, 2006	May	NEWA
+	EQ 20MG BASE	N21860	003	May 19, 2006	May	NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

+	PHARM ASSOC	2.5MG/5ML	N40146	001	Aug 21, 1996	Apr	CRLD
@ TEVA PHARMS		2.5MG/5ML	N81310	001	Apr 29, 1993	Apr	DISC
PROLIXIN							
@ APOTHECON		2.5MG/5ML	N12145	003		Apr	DISC

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

@ SCHERING	125MG	N18554	001	Jan 27, 1989	May	DISC		
FLUTAMIDE								
AB	PAR PHARM	125MG	N75298	001	Sep 18, 2001	Apr	CAHN	
AB	+	SANDOZ	125MG	N75818	001	Sep 18, 2001	May	CRLD

FLUTICASONE PROPIONATE

CREAM; TOPICAL

FLUTICASONE PROPIONATE

>A>	AB	G AND W LABS	0.05%	N77055	001	Jun 30, 2006	Jun	NEWA
-----	----	--------------	-------	--------	-----	--------------	-----	------

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB		G AND W LABS	0.005%	N77168	001	Mar 03, 2006	Feb	NEWA
----	--	--------------	--------	--------	-----	--------------	-----	------

SPRAY, METERED; NASAL

FLONASE

AB	+	GLAXOSMITHKLINE	0.05MG/SPRAY	N20121	001	Oct 19, 1994	Feb	CFTG
----	---	-----------------	--------------	--------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

AB		ROXANE	0.05MG/SPRAY	N76504	001	Feb 22, 2006	Feb	NEWA
----	--	--------	--------------	--------	-----	--------------	-----	------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

>A>	AEROSOL, METERED; INHALATION						
>A>	ADVAIR HFA						
>A>	+ GLAXOSMITHKLINE	0.045MG/INH;EQ 0.021MG BASE/INH	N21254 001	Jun 08, 2006	Jun	NEWA	
>A>	+ 0.115MG/INH;EQ 0.021MG BASE/INH	N21254 002	Jun 08, 2006	Jun	NEWA		
>A>	+ 0.23MG/INH;EQ 0.021MG BASE/INH	N21254 003	Jun 08, 2006	Jun	NEWA		

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

>A> AB	ACTAVIS ELIZABETH	25MG	N75901 001	Dec 28, 2000	Jun	CAHN	
>A> AB		50MG	N75901 002	Dec 28, 2000	Jun	CAHN	
>A> AB		100MG	N75901 003	Dec 28, 2000	Jun	CAHN	
AB	CARACO	25MG	N75900 001	Feb 23, 2006	Feb	NEWA	
AB		50MG	N75900 002	Feb 23, 2006	Feb	NEWA	
AB		100MG	N75900 003	Feb 23, 2006	Feb	NEWA	
>D> AB	PUREPAC PHARM	25MG	N75901 001	Dec 28, 2000	Jun	CAHN	
>D> AB		50MG	N75901 002	Dec 28, 2000	Jun	CAHN	
>D> AB		100MG	N75901 003	Dec 28, 2000	Jun	CAHN	

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

>D>	+ ORGANON USA INC	300 IU/0.36ML	N21211 001	Mar 23, 2004	Jun	DISC	
>A>	@	300 IU/0.36ML	N21211 001	Mar 23, 2004	Jun	DISC	

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

AP	HOSPIRA	2.4GM/100ML	N77174 001	May 31, 2005	Feb	CAHN	
----	---------	-------------	------------	--------------	-----	------	--

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>A> AB	TEVA	10MG;12.5MG	N76945 001	Jul 05, 2006	Jun	NEWA	
>A> AB		20MG;12.5MG	N76945 002	Jul 05, 2006	Jun	NEWA	

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

>A> AB	ACTAVIS ELIZABETH	100MG	N75350 001	Sep 12, 2003	Jun	CAHN	
>A> AB		300MG	N75350 002	Sep 12, 2003	Jun	CAHN	
>A> AB		400MG	N75350 003	Sep 12, 2003	Jun	CAHN	
>D> AB	PUREPAC PHARM	100MG	N75350 001	Sep 12, 2003	Jun	CAHN	
>D> AB		300MG	N75350 002	Sep 12, 2003	Jun	CAHN	
>D> AB		400MG	N75350 003	Sep 12, 2003	Jun	CAHN	
AB	SANDOZ	100MG	N75428 001	Jan 24, 2006	Jan	NEWA	
AB		300MG	N75428 002	Jan 24, 2006	Jan	NEWA	
AB		400MG	N75428 003	Jan 24, 2006	Jan	NEWA	

TABLET; ORAL

GABAPENTIN

>A> AB	ACTAVIS ELIZABETH	600MG	N75694 001	Oct 21, 2004	Jun	CAHN	
>A> AB		800MG	N75694 002	Oct 21, 2004	Jun	CAHN	
>D> AB	PUREPAC PHARM	600MG	N75694 001	Oct 21, 2004	Jun	CAHN	

TABLET; ORALGABAPENTIN

>D>	AB	PUREPAC PHARM	800MG	N75694	002	Oct 21,	2004	Jun	CAHN
	AB	SANDOZ	600MG	N76120	001	Jan 27,	2006	Jan	NEWA
>A>	AB		600MG	N76877	001	Jul 06,	2006	Jun	NEWA
	AB		800MG	N76120	002	Jan 27,	2006	Jan	NEWA
>A>	AB		800MG	N76877	002	Jul 06,	2006	Jun	NEWA

GADOVERSETAMIDEINJECTABLE; INJECTIONOPTIMARK

+ MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20937	001	Dec 08,	1999	Jan	CPOT
+	3309MG/10ML (330.9MG/ML)	N20937	002	Dec 08,	1999	Jan	NEWA
+	4963.5MG/15ML (330.9MG/ML)	N20937	003	Dec 08,	1999	Jan	NEWA
+	6618MG/20ML (330.9MG/ML)	N20937	004	Dec 08,	1999	Jan	NEWA
+	16.545GM/50ML (330.9MG/ML)	N20975	001	Dec 08,	1999	Jan	CPOT
OPTIMARK IN PLASTIC CONTAINER							
+ MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20976	001	Dec 08,	1999	Jan	CPOT
+	3309MG/10ML (330.9MG/ML)	N20976	002	Dec 08,	1999	Jan	NEWA
+	4963.5MG/15ML (330.9MG/ML)	N20976	003	Dec 08,	1999	Jan	NEWA
+	6618MG/20ML (330.9MG/ML)	N20976	004	Dec 08,	1999	Jan	NEWA

GALANTAMINE HYDROBROMIDECAPSULE, EXTENDED RELEASE; ORALRAZADYNE ER

+ JANSSEN	EQ 8MG BASE	N21615	001	Apr 01,	2005	May	CMS2
	EQ 16MG BASE	N21615	002	Apr 01,	2005	May	CMS2
	EQ 24MG BASE	N21615	003	Apr 01,	2005	May	CMS2

GANCICLOVIRCAPSULE; ORAL

>D>		CYTOVENE							
>D>	AB	ROCHE PALO	250MG	N20460	001	Dec 22,	1994	Jun	DISC
>A>		@	250MG	N20460	001	Dec 22,	1994	Jun	DISC
>D>	AB	+	500MG	N20460	002	Dec 12,	1997	Jun	DISC
>A>		@	500MG	N20460	002	Dec 12,	1997	Jun	DISC
GANCICLOVIR									
>D>	AB	RANBAXY	250MG	N76457	001	Jun 27,	2003	Jun	CTEC
>A>			250MG	N76457	001	Jun 27,	2003	Jun	CTEC
>D>	AB		500MG	N76457	002	Jun 27,	2003	Jun	CRLD
>A>		+	500MG	N76457	002	Jun 27,	2003	Jun	CRLD

GATIFLOXACININJECTABLE; INJECTIONTEQUIN

@ BRISTOL MYERS SQUIBB	400MG/40ML(10MG/ML)	N21062	004	Dec 17,	1999	May	DISC
TEQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
@ BRISTOL MYERS SQUIBB	200MG/100ML(2MG/ML)	N21062	001	Dec 17,	1999	May	DISC
@	400MG/200ML(2MG/ML)	N21062	002	Dec 17,	1999	May	DISC

>D> SUSPENSION; ORAL

>D> TEQUIN

+ BRISTOL MYERS SQUIBB	200MG/5ML	N21678	001	Aug 27,	2004	Jun	DISC
@	200MG/5ML	N21678	001	Aug 27,	2004	Jun	DISC

TABLET; ORALTEQUIN

@ BRISTOL MYERS SQUIBB	200MG	N21061	001	Dec 17,	1999	May	DISC
------------------------	-------	--------	-----	---------	------	-----	------

TABLET; ORAL

TEQUIN

@ BRISTOL MYERS SQUIBB 400MG

N21061 002 Dec 17, 1999 May DISC

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

GENTACIDIN

>D>	AT	NOVARTIS	EQ 0.3% BASE
>A>		@	EQ 0.3% BASE

N62480	001	Mar 30, 1984	Jun	DISC
N62480	001	Mar 30, 1984	Jun	DISC

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	COBALT	1MG	N77280	001	Feb 03, 2006	Jan	NEWA
AB		2MG	N77280	002	Feb 03, 2006	Jan	NEWA
AB		4MG	N77280	003	Feb 03, 2006	Jan	NEWA
AB	GENPHARM	1MG	N77486	001	Feb 10, 2006	Jan	NEWA
AB		2MG	N77486	002	Feb 10, 2006	Jan	NEWA
AB		4MG	N77486	003	Feb 10, 2006	Jan	NEWA

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

>A>	AB	CARACO	5MG	N77820	001	Jul 11, 2006	Jun	NEWA
>A>	AB		10MG	N77820	002	Jul 11, 2006	Jun	NEWA
		@ ENDO PHARMS	5MG	N74378	001	Nov 28, 1994	Feb	DISC
		@	10MG	N74378	002	Nov 28, 1994	Feb	DISC

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

AB	WATSON LABS	2.5MG	N76467	003	Mar 27, 2006	Mar	NEWA
	GLUCOTROL XL						
AB	PFIZER	2.5MG	N20329	003	Aug 10, 1999	Mar	CFTG

GLYBURIDE

TABLET; ORAL

DIABETA

BX	+	SANOFI AVENTIS US	5MG	N17532	003	May 01, 1984	Feb	CRLD
----	---	-------------------	-----	--------	-----	--------------	-----	------

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	1.25MG;250MG	N76716	001	Jun 28, 2005	Jun	CAHN
>A>	AB		2.5MG;500MG	N76716	002	Jun 28, 2005	Jun	CAHN
>A>	AB		5MG;500MG	N76716	003	Jun 28, 2005	Jun	CAHN
>D>	AB	PUREPAC PHARM	1.25MG;250MG	N76716	001	Jun 28, 2005	Jun	CAHN
>D>	AB		2.5MG;500MG	N76716	002	Jun 28, 2005	Jun	CAHN
>D>	AB		5MG;500MG	N76716	003	Jun 28, 2005	Jun	CAHN

GLCOPYRROLATE

TABLET; ORAL

ROBINUL

>D>	AA	+	FIRST HORIZON	1MG	N12827	001	Jun	CAHN
>A>	AA	+	SCIELE PHARMA INC	1MG	N12827	001	Jun	CAHN
			ROBINUL FORTE					
>D>	AA	+	FIRST HORIZON	2MG	N12827	002	Jun	CAHN

TABLET; ORAL

ROBINUL FORTE

>A> AA + SCIELE PHARMA INC 2MG N12827 002 Jun CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

TENEX

AB DR REDDYS LABS INC EQ 1MG BASE N19032 001 Oct 27, 1986 May CAHN
AB + EQ 2MG BASE N19032 002 Nov 07, 1988 May CAHN
AB @ EQ 3MG BASE N19032 003 Nov 07, 1988 May CAHNHALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB PERRIGO ISRAEL 0.05% N77123 001 Dec 16, 2004 Apr CAHN

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

>A> AB ACTAVIS MID ATLANTIC 0.05% N77109 001 Jun 14, 2005 Jun CAHN

>D> AB ALPHARMA US PHARMS 0.05% N77109 001 Jun 14, 2005 Jun CAHN

AB PERRIGO 0.05% N76872 001 Dec 16, 2004 Mar CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO SANDOZ EQ 50MG BASE/ML N76463 001 Jun 24, 2005 Jan CAHN

AO EQ 100MG BASE/ML N76463 002 Jun 24, 2005 Jan CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP SANDOZ EQ 5MG BASE/ML N76464 001 Sep 29, 2004 Jan CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

APRESOLINE

@ NOVARTIS 10MG N08303 004 Feb DISC

@ 25MG N08303 001 Feb DISC

@ 50MG N08303 002 Feb DISC

@ 100MG N08303 005 Feb DISC

HYDRALAZINE HYDROCHLORIDE

AA + PLIVA 10MG N89097 001 Dec 18, 1985 Feb CRLD

AA + 25MG N88467 001 May 01, 1984 Feb CRLD

AA + 50MG N88468 001 May 01, 1984 Feb CRLD

AA + 100MG N89098 001 Dec 18, 1985 Feb CRLD

@ TG UNITED LABS 10MG N88846 001 Feb 26, 1985 May CAHN

@ 25MG N88847 001 Feb 26, 1985 May CAHN

@ 50MG N88848 001 Feb 26, 1985 May CAHN

@ 100MG N88849 001 Feb 26, 1985 May CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLORTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

@ TG UNITED LABS 25MG;15MG;0.1MG N84897 001 May CAHN

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>A>	AB	ACTAVIS ELIZABETH	25MG	N85054 002	Jun	CAHN
>A>	AB		50MG	N85208 001	Jun	CAHN
>D>	AB	PUREPAC PHARM	25MG	N85054 002	Jun	CAHN
>D>	AB		50MG	N85208 001	Jun	CAHN
	@	TG UNITED LABS	25MG	N85683 001	May	CAHN
	@		50MG	N83965 001	May	CAHN
>A>	AB	WEST WARD	25MG	N84878 002	Jul 12, 2006	JUN NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

>A>	AB	ACTAVIS ELIZABETH	12.5MG;10MG	N76230 001	Jul 01, 2002	Jun	CAHN
>A>	AB		12.5MG;20MG	N76230 002	Jul 01, 2002	Jun	CAHN
>A>	AB		25MG;20MG	N76230 003	Jul 01, 2002	Jun	CAHN
	AB	AUROBINDO	12.5MG;10MG	N77606 001	Mar 14, 2006	Feb	NEWA
	AB		12.5MG;20MG	N77606 002	Mar 14, 2006	Feb	NEWA
	AB		25MG;20MG	N77606 003	Mar 14, 2006	Feb	NEWA
>D>	AB	PUREPAC PHARM	12.5MG;10MG	N76230 001	Jul 01, 2002	Jun	CAHN
>D>	AB		12.5MG;20MG	N76230 002	Jul 01, 2002	Jun	CAHN
>D>	AB		25MG;20MG	N76230 003	Jul 01, 2002	Jun	CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

>D>	AB	MERCK	15MG;250MG	N13402 001	Jun	DISC
>A>	@		15MG;250MG	N13402 001	Jun	DISC
>D>	AB	ALDORIL 25				
>D>	AB	MERCK	25MG;250MG	N13402 002	Jun	DISC
>A>	@		25MG;250MG	N13402 002	Jun	DISC
>D>	AB	ALDORIL D30				
>D>	AB	MERCK	30MG;500MG	N13402 003	Jun	DISC
>A>	@		30MG;500MG	N13402 003	Jun	DISC
>D>	AB	ALDORIL D50				
>D>	AB	+ MERCK	50MG;500MG	N13402 004	Jun	DISC
>A>	@		50MG;500MG	N13402 004	Jun	DISC

METHYLDOPA AND HYDROCHLOROTHIAZIDE

>D>	AB	MYLAN	15MG;250MG	N70264 001	Jan 23, 1986	Jun	CTEC
>A>			15MG;250MG	N70264 001	Jan 23, 1986	Jun	CTEC
>D>	AB		25MG;250MG	N70265 001	Jan 23, 1986	Jun	CRLD
>A>	+		25MG;250MG	N70265 001	Jan 23, 1986	Jun	CRLD
>D>	AB	PAR PHARM	15MG;250MG	N70616 001	Feb 02, 1987	Jun	DISC
>A>	@		15MG;250MG	N70616 001	Feb 02, 1987	Jun	DISC
>D>	AB		25MG;250MG	N70612 001	Feb 02, 1987	Jun	DISC
>A>	@		25MG;250MG	N70612 001	Feb 02, 1987	Jun	DISC
>D>	AB		30MG;500MG	N70613 001	Feb 02, 1987	Jun	DISC
>A>	@		30MG;500MG	N70613 001	Feb 02, 1987	Jun	DISC
>D>	AB		50MG;500MG	N70614 001	Feb 02, 1987	Jun	DISC
>A>	@		50MG;500MG	N70614 001	Feb 02, 1987	Jun	DISC
>D>	AB	SANDOZ	15MG;250MG	N70182 001	Jan 15, 1986	Jun	DISC
>A>	@		15MG;250MG	N70182 001	Jan 15, 1986	Jun	DISC
>D>	AB		25MG;250MG	N70183 001	Jan 15, 1986	Jun	DISC
>A>	@		25MG;250MG	N70183 001	Jan 15, 1986	Jun	DISC

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

>D>	AB	SANDOZ	30MG;500MG	N70543	001	Jan 15, 1986	Jun	DISC
>A>		@	30MG;500MG	N70543	001	Jan 15, 1986	Jun	DISC
>D>	AB		50MG;500MG	N70544	001	Jan 15, 1986	Jun	DISC
>A>		@	50MG;500MG	N70544	001	Jan 15, 1986	Jun	DISC
>D>	AB	WATSON LABS	15MG;250MG	N70958	001	Feb 06, 1989	Jun	DISC
>A>		@	15MG;250MG	N70958	001	Feb 06, 1989	Jun	DISC
>D>	AB		25MG;250MG	N70959	001	Jan 19, 1989	Jun	DISC
>A>		@	25MG;250MG	N70959	001	Jan 19, 1989	Jun	DISC
>D>	AB		30MG;500MG	N71069	001	Jan 19, 1989	Jun	DISC
>A>		@	30MG;500MG	N71069	001	Jan 19, 1989	Jun	DISC
>D>	AB		50MG;500MG	N70960	001	Feb 06, 1989	Jun	DISC
>A>		@	50MG;500MG	N70960	001	Feb 06, 1989	Jun	DISC

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	AB	ACTAVIS ELIZABETH	25MG;40MG	N70851	001	May 15, 1986	Jun	CAHN
>A>	AB		25MG;80MG	N70852	001	May 15, 1986	Jun	CAHN
>D>	AB	PUREPAC PHARM	25MG;40MG	N70851	001	May 15, 1986	Jun	CAHN
>D>	AB		25MG;80MG	N70852	001	May 15, 1986	Jun	CAHN

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

>D>	+ MERCK		25MG;10MG	N18061	001		Jun	DISC
>A>	@		25MG;10MG	N18061	001		Jun	DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

NOVARTIS		12.5MG;320MG	N20818	004	Apr 28, 2006	Apr	NEWA
		25MG;160MG	N20818	003	Jan 17, 2002	Apr	CRLD
+		25MG;320MG	N20818	005	Apr 28, 2006	Apr	NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

>A>	AT	ACTAVIS MID ATLANTIC	1%	N87795	001	May 03, 1983	Jun	CAHN
>A>	AT		2.5%	N89682	001	Mar 10, 1988	Jun	CAHN
>D>	AT	ALPHARMA US PHARMS	1%	N87795	001	May 03, 1983	Jun	CAHN
>D>	AT		2.5%	N89682	001	Mar 10, 1988	Jun	CAHN

OINTMENT; TOPICAL

HYDROCORTISONE

>A>	AT	ACTAVIS MID ATLANTIC	1%	N87796	001	Oct 13, 1982	Jun	CAHN
>D>	AT	ALPHARMA US PHARMS	1%	N87796	001	Oct 13, 1982	Jun	CAHN

POWDER; FOR RX COMPOUNDING

HYDROCORTISONE

>D>	+ PHARMA TEK		100%	N85982	001		Jun	CTNA
-----	--------------	--	------	--------	-----	--	-----	------

>A> HYDRO-RX

>A>	+ X GEN PHARMS		100%	N85982	001		Jun	CTNA
-----	----------------	--	------	--------	-----	--	-----	------

TABLET; ORAL

CORTEF

>D>	BP	PHARMACIA AND UPJOHN	10MG	N08697	001		Jun	CTEC
>A>	@		10MG	N08697	001		Jun	CTEC

TABLET; ORAL

>D>	HYDROCORTONE				
>D> BP	MERCK	10MG	N08506 007	Jun	DISC
>A>	@	10MG	N08506 007	Jun	DISC
>D> BP	+	20MG	N08506 011	Jun	DISC
>A>	@	20MG	N08506 011	Jun	DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

AP	HOSPIRA	EQ 100MG BASE/VIAL	N40666 001	Apr 06, 2006	Mar	NEWA
----	---------	--------------------	------------	--------------	-----	------

HYDROCORTISONE; NEOMYCIN; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	PHARMAFORCE	1%;EQ 3.5MG BASE;10,000 UNITS	N65219 001	May 01, 2006	Apr	NEWA
----	-------------	-------------------------------	------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

>D>	ATARAX					
>D> AA	+	ROERIG	10MG/5ML	N10485 001	Jun	DISC
>A>	@		10MG/5ML	N10485 001	Jun	DISC
HYDROXYZINE HYDROCHLORIDE						
>D> AA	ALPHARMA US PHARMS	10MG/5ML	N86880 001	Jun	CRLD	
>A> AA	+	10MG/5ML	N86880 001	Jun	CRLD	
>D> AA	HI TECH PHARMA	10MG/5ML	N40010 001	Oct 28, 1994	Jun	CRLD
>A> AA	+	10MG/5ML	N40010 001	Oct 28, 1994	Jun	CRLD
>D> AA	MORTON GROVE	10MG/5ML	N87294 001	Apr 12, 1982	Jun	CRLD
>A> AA	+	10MG/5ML	N87294 001	Apr 12, 1982	Jun	CRLD
>D> AA	VINTAGE PHARMS	10MG/5ML	N40391 001	Apr 10, 2002	Jun	CRLD
>A> AA	+	10MG/5ML	N40391 001	Apr 10, 2002	Jun	CRLD

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

BARR EQ 100MG HCL

N88488 001 Jun 15, 1984 Mar CTEC

VISTARIL

@ PFIZER EQ 100MG HCL

N11459 006 Mar DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

+ ROCHE EQ 3MG BASE/3ML

N21858 001 Jan 06, 2006 Jan NEWA

IBUPROFEN

TABLET; ORAL

>D>	IBU					
>D> AB	BASF	400MG	N18197 001	Jun	DISC	
>A>	@	400MG	N18197 001	Jun	DISC	
>D> AB		400MG	N70083 001	Feb 22, 1985	Jun	DISC
>A>	@	400MG	N70083 001	Feb 22, 1985	Jun	DISC
>D> AB		600MG	N70099 001	Mar 29, 1985	Jun	DISC
>A>	@	600MG	N70099 001	Mar 29, 1985	Jun	DISC
>D> AB		800MG	N70745 001	Jul 23, 1986	Jun	DISC
>A>	@	800MG	N70745 001	Jul 23, 1986	Jun	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ FARMACON IL

EQ 20MG BASE/2ML (EQ 10MG
BASE/ML)

N21903 001 Apr 13, 2006 Apr NEWA

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

>A>	AB	ACTAVIS ELIZABETH	1.25MG
>A>	AB		2.5MG
>D>	AB	PUREPAC PHARM	1.25MG
>D>	AB		2.5MG

N74722	001	Jun 17, 1996	Jun	CAHN
N74722	002	Jun 17, 1996	Jun	CAHN
N74722	001	Jun 17, 1996	Jun	CAHN
N74722	002	Jun 17, 1996	Jun	CAHN

INDOMETHACIN

CAPSULE; ORAL

>D>		INDOCIN	
>D>	AB	MERCK	25MG
>A>		@	25MG
>D>	AB	+	50MG
>A>		@	50MG
>D>		INDO-LEMMON	
>D>	AB	TEVA	25MG
>A>		@	25MG
>D>	AB		50MG
>A>		@	50MG
INDOMETHACIN			
>D>	AB	CLONMEL HLTHCARE	25MG
>A>		@	25MG
>D>	AB		50MG
>A>		@	50MG
>D>	AB	IVAX PHARMS	25MG
>A>		@	25MG
>D>	AB		50MG
>A>		@	50MG
>D>	AB	MUTUAL PHARM	25MG
>A>		@	25MG
>D>	AB		50MG
>A>		@	50MG
>D>	AB	MYLAN	25MG
>A>			25MG
>D>	AB		50MG
>A>		@	50MG
>D>	AB	+ PAR PHARM	50MG
>D>	AB	PAR PHARM	25MG
>A>		@	25MG
>D>	AB		50MG
>A>		@	50MG
>D>	AB		50MG
>A>		@	50MG
>D>	AB	PLIVA	25MG
>A>		@	25MG
>D>	AB		50MG
>A>		@	50MG
>D>	AB	SANDOZ	25MG
>A>		@	25MG

CAPSULE; ORALINDOMETHACIN

>D>	AB	SANDOZ	50MG	N70674	001	Apr 29,	1987	Jun	DISC	
>A>		@	50MG	N70674	001	Apr 29,	1987	Jun	DISC	
>D>	AB	TEVA	25MG	N71342	001	Apr 18,	1988	Jun	DISC	
>A>		@	25MG	N71342	001	Apr 18,	1988	Jun	DISC	
>D>	AB		50MG	N71343	001	Apr 18,	1988	Jun	DISC	
>A>		@	50MG	N71343	001	Apr 18,	1988	Jun	DISC	
CAPSULE, EXTENDED RELEASE; ORAL										
INDOCIN SR										
>D>	AB	+	SANDOZ	75MG	N74464	001	May 28,	1998	Jun	CTEC
>A>		+		75MG	N74464	001	May 28,	1998	Jun	CTEC
>D>		INDOMETHACIN								
>D>	AB	INWOOD LABS	75MG	N72410	001	Mar 15,	1989	Jun	DISC	
>A>		@	75MG	N72410	001	Mar 15,	1989	Jun	DISC	
SUPPOSITORY; RECTAL										
INDOMETHACIN										
+ G AND W LABS		50MG	N73314	001	Aug 31,	1992	Apr	CTNA		

INSULIN GLULISINE RECOMBINANTINJECTABLE; SUBCUTANEOUSAPIDRA

+ SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N21629	001	Apr 16,	2004	Mar	CMFD
+	300 UNITS/3ML (100 UNITS/ML)	N21629	002	Dec 20,	2005	Mar	CMFD

INSULIN PURIFIED PORKINJECTABLE; INJECTIONILETIN II

+ LILLY	500 UNITS/ML	N18344	002			Jun	DISC	
>A>	@	500 UNITS/ML	N18344	002			Jun	DISC

INSULIN RECOMBINANT HUMANPOWDER; INHALATIONEXUBERA

PFIZER	1MG/INH	N21868	001	Jan 27,	2006	Jan	NEWA
+	3MG/INH	N21868	002	Jan 27,	2006	Jan	NEWA

IPRATROPIUM BROMIDEAEROSOL, METERED; INHALATIONATROVENT

@ BOEHRINGER INGELHEIM	0.018MG/INH	N19085	001	Dec 29,	1986	May	DISC
------------------------	-------------	--------	-----	---------	------	-----	------

SOLUTION; INHALATIONATROVENT

@ BOEHRINGER INGELHEIM	0.02%	N20228	001	Sep 29,	1993	May	DISC
------------------------	-------	--------	-----	---------	------	-----	------

IPRATROPIUM BROMIDE

AN + DEY	0.02%	N74755	001	Jan 10,	1997	May	CRLD
	0.02%	N75867	001	Jul 22,	2002	May	DISC

ISONIAZIDINJECTABLE; INJECTIONISONIAZID

AP SANDOZ	100MG/ML	N40648	001	Jul 05,	2005	Jan	CAHN
---------------	----------	--------	-----	---------	------	-----	------

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO

AB	DR REDDYS LABS INC	20MG	N19091	001	Dec 30,	1991	May	CAHN
ISOSORBIDE MONONITRATE								
>A>	AB	ACTAVIS ELIZABETH	10MG	N75037	002	Oct 30,	1998	Jun
>A>	AB		20MG	N75037	001	Oct 30,	1998	Jun
>D>	AB	PUREPAC PHARM	10MG	N75037	002	Oct 30,	1998	Jun
>D>	AB		20MG	N75037	001	Oct 30,	1998	Jun
TABLET, EXTENDED RELEASE; ORAL								
ISOSORBIDE MONONITRATE								
>A>	AB	ACTAVIS ELIZABETH	30MG	N75306	001	Dec 31,	1998	Jun
>A>	AB		60MG	N75306	002	Dec 31,	1998	Jun
>D>	AB	PUREPAC PHARM	30MG	N75306	001	Dec 31,	1998	Jun
>D>	AB		60MG	N75306	002	Dec 31,	1998	Jun
AB	WEST WARD		30MG	N76813	002	Mar 30,	2006	Mar

ISOTRETINOIN

CAPSULE; ORAL

CLARAVIS

AB	BARR	30MG	N76135	003	May 11,	2006	May	NEWA
SOTRET								
AB	RANBAXY	30MG	N76503	001	Jun 20,	2003	May	CTEC

ISRADIPINE

CAPSULE; ORAL

DYNACIRC

@ RELIANT PHARMS

2.5MG

N19546 001 Dec 20, 1990 May DISC

ISRADIPINE

>D>	AB	ABRIKA PHARMS	5MG	N77317	002	Jan 05,	2006	Jun	CRLD
>A>	AB	+	5MG	N77317	002	Jan 05,	2006	Jun	CRLD
	AB		5MG	N77317	002	Jan 05,	2006	Apr	CTEC
	AB	AMIDE PHARM	2.5MG	N77169	001	Apr 24,	2006	Apr	NEWA
	AB		5MG	N77169	002	Apr 24,	2006	Apr	NEWA

IVERMECTIN

TABLET; ORAL

STROMECTOL

>D>		MERCK	3MG	N50742	002	Oct 08,	1998	Jun	CRLD
>A>		+	3MG	N50742	002	Oct 08,	1998	Jun	CRLD
>D>		+	6MG	N50742	001	Nov 22,	1996	Jun	DISC
>A>		@	6MG	N50742	001	Nov 22,	1996	Jun	DISC

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	SANDOZ	15MG/ML	N76271	001	Oct 06,	2004	Jan	CAHN
AP		30MG/ML	N76271	002	Oct 06,	2004	Jan	CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

KETOTIFEN FUMARATE

AT	APOTEX	EQ 0.025% BASE	N77354	001	May 09,	2006	Apr	NEWA
----	--------	----------------	--------	-----	---------	------	-----	------

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

AT + NOVARTIS EQ 0.025% BASE N21066 001 Jul 02, 1999 Apr CFTG

LAMOTRIGINE

TABLET, CHEWABLE; ORAL

LAMICTAL CD

>D>	GLAXOSMITHKLINE	5MG	N20764 001 Aug 24, 1998 Jun CFTG
>A> AB		5MG	N20764 001 Aug 24, 1998 Jun CFTG
>D>	+	25MG	N20764 002 Aug 24, 1998 Jun CFTG
>A> AB	+	25MG	N20764 002 Aug 24, 1998 Jun CFTG
>A>	LAMOTRIGINE		
>A> AB	TEVA	5MG	N76420 001 Jun 21, 2006 Jun NEWA
>A> AB		25MG	N76420 002 Jun 21, 2006 Jun NEWA

LANSOPRAZOLE; NAPROXENCAPSULE, DELAYED REL PELLETS, TABLET; ORAL
PREVACID NAPRAPAC 250 (COPACKAGED)

TAP PHARM 15MG,N/A;N/A,250MG

N21507 002 Nov 14, 2003 Feb CTNA

PREVACID NAPRAPAC 375 (COPACKAGED)

TAP PHARM 15MG,N/A;N/A,375MG

N21507 003 Nov 14, 2003 Feb CTNA

PREVACID NAPRAPAC 500 (COPACKAGED)

+ TAP PHARM 15MG,N/A;N/A,500MG

N21507 004 Nov 14, 2003 Feb CTNA

LEVETIRACETAM

TABLET; ORAL

KEPPRA

UCB INC 750MG

N21035 003 Nov 30, 1999 Mar CRLD

+ 1GM

N21035 004 Jan 06, 2006 Mar NEWA

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

@ ALCON EQ 0.5% BASE

N21114 001 Feb 23, 2000 Feb CAHN

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

@ NOVARTIS EQ 0.05% BASE

N20219 001 Nov 10, 1993 May DISC

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

ANESTACON

AT + POLYMEDICA 2%

N80429 001 Jan CDFR

LIDOCAINE; TETRACAIN

>A> CREAM; TOPICAL

>A> LIDOCAINE AND TETRACAIN

>A> + ZARS 7%;7%

N21717 001 Jun 29, 2006 Jun NEWA

PATCH; TOPICAL

SYNERA

+ ENDO PHARMS 70MG;70MG

N21623 001 Jun 23, 2005 Feb CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

>A>	AB	ACTAVIS ELIZABETH	2.5MG	N76180	001	Jul 01,	2002	Jun	CAHN
>A>	AB		5MG	N76180	002	Jul 01,	2002	Jun	CAHN
>A>	AB		10MG	N76180	003	Jul 01,	2002	Jun	CAHN
>A>	AB		20MG	N76164	001	Jul 01,	2002	Jun	CAHN
>A>	AB		30MG	N76164	002	Jul 01,	2002	Jun	CAHN
>A>	AB		40MG	N76164	003	Jul 01,	2002	Jun	CAHN
	AB	AUROBINDO	2.5MG	N77622	001	Feb 22,	2006	Feb	NEWA
	AB		5MG	N77622	002	Feb 22,	2006	Feb	NEWA
	AB		10MG	N77622	003	Feb 22,	2006	Feb	NEWA
	AB		20MG	N77622	004	Feb 22,	2006	Feb	NEWA
	AB		30MG	N77622	005	Feb 22,	2006	Feb	NEWA
	AB		40MG	N77622	006	Feb 22,	2006	Feb	NEWA
>D>	AB	PUREPAC PHARM	2.5MG	N76180	001	Jul 01,	2002	Jun	CAHN
>D>	AB		5MG	N76180	002	Jul 01,	2002	Jun	CAHN
>D>	AB		10MG	N76180	003	Jul 01,	2002	Jun	CAHN
>D>	AB		20MG	N76164	001	Jul 01,	2002	Jun	CAHN
>D>	AB		30MG	N76164	002	Jul 01,	2002	Jun	CAHN
>D>	AB		40MG	N76164	003	Jul 01,	2002	Jun	CAHN
		PRINIVIL							
>D>	AB	MERCK	2.5MG	N19558	006	Jan 28,	1994	Jun	DISC
>A>		@	2.5MG	N19558	006	Jan 28,	1994	Jun	DISC

LORAZEPAM

TABLET; ORAL

LORAZEPAM

>A>	AB	ACTAVIS ELIZABETH	0.5MG	N71403	001	Apr 21,	1987	Jun	CAHN
>A>	AB		1MG	N71404	001	Apr 21,	1987	Jun	CAHN
>A>	AB		2MG	N71141	001	Apr 21,	1987	Jun	CAHN
	AB	MYLAN	0.5MG	N77657	001	Mar 16,	2006	Mar	NEWA
	AB		1MG	N77657	002	Mar 16,	2006	Mar	NEWA
	AB		2MG	N77657	003	Mar 16,	2006	Mar	NEWA
>D>	AB	PUREPAC PHARM	0.5MG	N71403	001	Apr 21,	1987	Jun	CAHN
>D>	AB		1MG	N71404	001	Apr 21,	1987	Jun	CAHN
>D>	AB		2MG	N71141	001	Apr 21,	1987	Jun	CAHN
	AB	VINTAGE PHARMS	0.5MG	N77754	001	May 10,	2006	Apr	NEWA
	AB		1MG	N77754	002	May 10,	2006	Apr	NEWA
	AB		2MG	N77754	003	May 10,	2006	Apr	NEWA

LOVASTATIN

TABLET; ORAL

LOVASTATIN

>A>	AB	ACTAVIS ELIZABETH	10MG	N75828	001	Dec 17,	2001	Jun	CAHN
>A>	AB		20MG	N75828	002	Dec 17,	2001	Jun	CAHN
>A>	AB		40MG	N75828	003	Dec 17,	2001	Jun	CAHN
	AB	MUTUAL PHARM	10MG	N77520	001	Apr 14,	2006	Apr	NEWA
	AB		20MG	N77520	002	Apr 14,	2006	Apr	NEWA
	AB		40MG	N77520	003	Apr 14,	2006	Apr	NEWA
>D>	AB	PUREPAC PHARM	10MG	N75828	001	Dec 17,	2001	Jun	CAHN
>D>	AB		20MG	N75828	002	Dec 17,	2001	Jun	CAHN
>D>	AB		40MG	N75828	003	Dec 17,	2001	Jun	CAHN

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL
 ADVICOR
 + KOS LIFE 20MG;750MG N21249 002 Dec 17, 2001 Feb CMFD

LUBIPROSTONE

CAPSULE; ORAL
 AMITIZA
 + SUCAMPO PHARMS 24UGM N21908 001 Jan 31, 2006 Jan NEWA

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET, CHEWABLE; ORAL
 ZEGERID
 SANTARUS 700MG;20MG;600MG N21850 001 Mar 24, 2006 Mar NEWA
 + 700MG;40MG;600MG N21850 002 Mar 24, 2006 Mar NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; SUBCUTANEOUS
 DEPO-SUBQ PROVERA 104
 + PHARMACIA AND UPJOHN 104MG/0.65ML N21583 001 Dec 17, 2004 Jan CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL
 MEGESTROL ACETATE
 AB APOTEX 40MG/ML N77404 001 Feb 16, 2006 Jan NEWA

MEPROBAMATE

TABLET; ORAL
 MEPROBAMATE
 @ ROXANE 600MG N84332 001 Jan DISC
 @ SANDOZ 200MG N14547 002 Jan DISC
 @ 400MG N14547 001 Jan DISC
 @ 400MG N80655 001 Jan DISC
 @ SCHERER LABS 400MG N83343 001 Jan DISC
 @ TABLICAPS 400MG N83494 001 Jan DISC
 AA + WATSON LABS 200MG N83304 001 Jan CRLD
 @ 200MG N85720 001 Jan DISC
 + 400MG N83308 001 Jan CRLD
 @ 400MG N85721 001 Jan DISC
 MILTOWN
 @ MEDPOINTE PHARM HLC 200MG N09698 004 Jan DISC
 @ 400MG N09698 002 Jan DISC
 TRANMEP
 @ SOLVAY 400MG N16249 001 Jan DISC

MESALAMINE

ENEMA; RECTAL
 ROWASA
 AB + ALAVEN PHARM 4GM/60ML N19618 001 Dec 24, 1987 Apr CAHN
 SUPPOSITORY; RECTAL
 CANASA
 @ AXCAN SCANDIPHARM 500MG N21252 001 Jan 05, 2001 May DISC

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

>D>		ARAMINE						
>D>	AP	+ MERCK	EQ 10MG BASE/ML	N09509	002	Dec 22, 1987	Jun	DISC
>A>		@	EQ 10MG BASE/ML	N09509	002	Dec 22, 1987	Jun	DISC
		METARAMINOL BITARTRATE						
>D>	AP	ABRAXIS PHARM	EQ 10MG BASE/ML	N80722	001		Jun	CRLD
>A>		+	EQ 10MG BASE/ML	N80722	001		Jun	CRLD

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	500MG	N76033	001	Jan 24, 2002	Jun	CAHN
>A>	AB		850MG	N76033	002	Jan 24, 2002	Jun	CAHN
>A>	AB		1GM	N76033	003	Jan 24, 2002	Jun	CAHN
	AB	INTERPHARM	500MG	N77880	001	Jun 05, 2006	May	NEWA
	AB		850MG	N77880	002	Jun 05, 2006	May	NEWA
	AB		1GM	N77880	003	Jun 05, 2006	May	NEWA
>D>	AB	PUREPAC PHARM	500MG	N76033	001	Jan 24, 2002	Jun	CAHN
>D>	AB		850MG	N76033	002	Jan 24, 2002	Jun	CAHN
>D>	AB		1GM	N76033	003	Jan 24, 2002	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

BX	DEPOMED INC	500MG	N21748	001	Jun 03, 2005	Jan	CAHN
BX		1GM	N21748	002	Jun 03, 2005	Jan	CAHN

METFORMIN HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	500MG	N76450	001	Oct 01, 2004	Jun	CAHN
>A>	AB		750MG	N76878	001	Apr 13, 2005	Jun	CAHN
>D>	AB	PUREPAC PHARM	500MG	N76450	001	Oct 01, 2004	Jun	CAHN
>D>	AB		750MG	N76878	001	Apr 13, 2005	Jun	CAHN
	AB	SUN PHARM IND (IN)	500MG	N77336	001	Feb 09, 2006	Jan	NEWA
	AB		750MG	N77336	002	Feb 09, 2006	Jan	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

+>	CEDAR PHARMS	20MG	N40547	004	Feb 18, 2005	May	CRLD
	TAPAZOLE						
AB	JONES PHARMA	5MG	N40320	001	Mar 31, 2000	May	CTNA
AB		10MG	N40320	002	Mar 31, 2000	May	CTNA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE

>D>		@ ABRAXIS PHARM	EQ 25MG BASE/ML	N40263	001	Feb 26, 1999	Jun	CMFD
>A>	AP	+	EQ 50MG BASE/2ML (25MG/ML)	N40263	001	Feb 26, 1999	Jun	CMFD
>A>	AP		EQ 250MG BASE/10ML (25MG/ML)	N40263	002	Feb 26, 1999	Jun	NEWA
		METHOTREXATE PRESERVATIVE FREE						
	+	BEDFORD	EQ 1GM BASE/VIAL	N40632	001	Aug 12, 2005	Apr	CAIN
	+	MAYNE PHARMA USA	EQ 1GM BASE/40ML (25 MG/ML)	N11719	012	Apr 13, 2005	Apr	CPOT
		METHOTREXATE SODIUM						
AP	+	BEDFORD	EQ 50MG BASE/2ML (25MG/ML)	N89340	001	Sep 16, 1986	Apr	CPOT
	+		EQ 100MG BASE/4ML (25 MG/ML)	N89341	001	Sep 16, 1986	Apr	CTEC
	+		EQ 200MG BASE/8ML (25 MG/ML)	N89342	001	Sep 16, 1986	Apr	CTEC
	+		EQ 250MG BASE/10ML (25 MG/ML)	N89343	001	Sep 16, 1986	Apr	CTEC

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

+ SHIRE	10MG/9HR (1.1MG/HR)
+	15MG/9HR (1.6MG/HR)
+	20MG/9HR (2.2MG/HR)
+	30MG/9HR (3.3MG/HR)

N21514 001	Apr 06, 2006	Apr	NEWA
N21514 002	Apr 06, 2006	Apr	NEWA
N21514 003	Apr 06, 2006	Apr	NEWA
N21514 004	Apr 06, 2006	Apr	NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

BX UCB INC	40MG	N21259 004	Feb 19, 2006	Feb	NEWA
	50MG	N21259 005	Feb 19, 2006	Feb	NEWA
+	60MG	N21259 006	Feb 19, 2006	Feb	NEWA

RITALIN LA

BX + NOVARTIS	40MG	N21284 003	Jun 05, 2002	Feb	CTEC
---------------	------	------------	--------------	-----	------

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A> AB ACTAVIS ELIZABETH	5MG	N40321 001	Feb 05, 2002	Jun	CAHN
>A> AB	10MG	N40321 002	Feb 05, 2002	Jun	CAHN
>A> AB	20MG	N40321 003	Feb 05, 2002	Jun	CAHN
>D> AB PUREPAC PHARM	5MG	N40321 001	Feb 05, 2002	Jun	CAHN
>D> AB	10MG	N40321 002	Feb 05, 2002	Jun	CAHN
>D> AB	20MG	N40321 003	Feb 05, 2002	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A> AB ACTAVIS ELIZABETH	20MG	N75450 001	Dec 21, 2001	Jun	CAHN
>D> AB PUREPAC PHARM	20MG	N75450 001	Dec 21, 2001	Jun	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>A> AB ACTAVIS ELIZABETH	EQ 10MG BASE	N70581 001	Oct 17, 1985	Jun	CAHN
AB MUTUAL PHARM	EQ 5MG BASE	N71536 002	Jan 16, 1997	Apr	CMFD
AB	EQ 10MG BASE	N71536 001	Apr 28, 1993	Apr	CMFD
>D> AB PUREPAC PHARM	EQ 10MG BASE	N70581 001	Oct 17, 1985	Jun	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

REGLAN ODT

@ SCHWARZ PHARMA EQ 5MG BASE

@ EQ 10MG BASE

N21793 001	Jun 10, 2005	May	DISC
N21793 002	Jun 10, 2005	May	DISC

METRONIDAZOLE

GEL; TOPICAL

METROGEL

AB + GALDERMA LABS LP	0.75%	N19737 001	Nov 22, 1988	May	CFTG
-----------------------	-------	------------	--------------	-----	------

METRONIDAZOLE

AB ALTANA	0.75%	N77018 001	Jun 06, 2006	May	NEWA
-----------	-------	------------	--------------	-----	------

>A> AB QLT USA	0.75%	N77547 001	Jul 13, 2006	Jun	NEWA
----------------	-------	------------	--------------	-----	------

LOTION; TOPICAL

METROLOTION

AB + GALDERMA LABS LP	0.75%	N20901 001	Nov 24, 1998	May	CFTG
-----------------------	-------	------------	--------------	-----	------

METRONIDAZOLE

AB ALTANA	0.75%	N77197 001	May 24, 2006	May	NEWA
-----------	-------	------------	--------------	-----	------

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

>A> ASTELLAS 100MG/VIAL N21506 003 Jun 27, 2006 Jun NEWA

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

>A> AB ACTAVIS MID ATLANTIC 200MG N73508 001 Nov 19, 1993 Jun CAHN

>D> AB ALPHARMA US PHARMS 200MG N73508 001 Nov 19, 1993 Jun CAHN

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+ BARRIER

0.25%;81.35%;15%

N21026 001 Feb 16, 2006 Feb NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP + HOSPIRA EQ 5MG BASE/ML N75293 002 Jun 20, 2000 Mar CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB TRIAX PHARMS EQ 50MG BASE N50649 001 May 31, 1990 Feb CAHN
@ EQ 75MG BASE N50649 003 Feb 12, 2001 Feb CAHN

AB + EQ 100MG BASE N50649 002 May 31, 1990 Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

MEDICIS

EQ 45MG BASE

N50808 001 May 08, 2006 May NEWA

EQ 90MG BASE

N50808 002 May 08, 2006 May NEWA

+ EQ 135MG BASE

N50808 003 May 08, 2006 May NEWA

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

>A> AB ACTAVIS ELIZABETH 15MG N76308 001 Jun 20, 2003 Jun CAHN

>A> AB 30MG N76308 002 Jun 20, 2003 Jun CAHN

>A> AB 45MG N76308 003 Jun 20, 2003 Jun CAHN

>D> AB PUREPAC PHARM 15MG N76308 001 Jun 20, 2003 Jun CAHN

>D> AB 30MG N76308 002 Jun 20, 2003 Jun CAHN

>D> AB 45MG N76308 003 Jun 20, 2003 Jun CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB AUROBINDO PHARMA LTD 45MG N77376 004 Feb 28, 2006 Feb NEWA

AB BARR 45MG N76307 003 Feb 28, 2006 Feb NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE

AP AM PHARM EQ 20MG BASE/10ML (2MG/ML) N77496 001 Apr 11, 2006 Mar NEWA

AP EQ 25MG BASE/12.5ML (2MG/ML) N77496 002 Apr 11, 2006 Mar NEWA

AP EQ 30MG BASE/15ML (2MG/ML) N77496 003 Apr 11, 2006 Mar NEWA

AP BEDFORD EQ 20MG BASE/10ML (2MG/ML) N76611 001 Apr 11, 2006 Mar NEWA

INJECTABLE; INJECTION

MITOXANTRONE

AP	BEDFORD	EQ 25MG BASE/12.5ML (2MG/ML)	N76611 002 Apr 11, 2006 Mar NEWA
AP		EQ 30MG BASE/15ML (2MG/ML)	N76611 003 Apr 11, 2006 Mar NEWA
AP	MAYNE PHARMA USA	EQ 20MG BASE/10ML (2MG/ML)	N76871 001 Apr 11, 2006 Mar NEWA
AP		EQ 25MG BASE/12.5ML (2MG/ML)	N76871 002 Apr 11, 2006 Mar NEWA
AP		EQ 30MG BASE/15ML (2MG/ML)	N76871 003 Apr 11, 2006 Mar NEWA
AP	SICOR PHARMS	EQ 20MG BASE/10ML (2MG/ML)	N77356 001 Apr 11, 2006 Mar NEWA
AP		EQ 25MG BASE/12.5ML (2MG/ML)	N77356 002 Apr 11, 2006 Mar NEWA
AP		EQ 30MG BASE/15ML (2MG/ML)	N77356 003 Apr 11, 2006 Mar NEWA
	NOVANTRONE		
AP	+ SERONO INC	EQ 20MG BASE/10ML(2MG/ML)	N19297 001 Dec 23, 1987 Mar CFTG
AP	+	EQ 25MG BASE/12.5ML (2MG/ML)	N19297 002 Dec 23, 1987 Mar CFTG
AP	+	EQ 30MG BASE/15ML (2MG/ML)	N19297 003 Dec 23, 1987 Mar CFTG

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

AB	G AND W LABS	0.1%	N77447 001 May 22, 2006 May NEWA
	LOTION; TOPICAL		
	MOMETASONE FUROATE		
AB	PERRIGO	0.1%	N77180 001 Apr 06, 2005 Mar CAHN
AB	TARO	0.1%	N76788 001 Mar 15, 2006 Feb NEWA
	OINTMENT; TOPICAL		
	MOMETASONE FUROATE		
>A>	AB G AND W LABS	0.1%	N77401 001 Jun 20, 2006 Jun NEWA

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

HOSPIRA 5MG/ML

N19916 002 Mar 30, 2006 Mar NEWA

NABILONE

CAPSULE; ORAL

CESAMET

+ VALEANT 1MG

N18677 001 Dec 26, 1985 May CMFD

NABUMETONE

TABLET; ORAL

NABUMETONE

>D>	AB COPLEY PHARM	750MG	N75179 001 Jun 06, 2000 Jun DISC
>A>	@	750MG	N75179 001 Jun 06, 2000 Jun DISC
AB	PAR PHARM	500MG	N76009 001 Jan 24, 2003 Apr CAHN
AB		750MG	N76009 002 Jan 24, 2003 Apr CAHN

NADOLOL

TABLET; ORAL

CORGARD

>D>	AB APOTHECON	20MG	N18063 005 Oct 28, 1986 Jun CAHN
>D>	AB	40MG	N18063 001 Jun CAHN
>D>	AB	80MG	N18063 002 Jun CAHN
>D>	AB	120MG	N18063 003 Jun CAHN
>D>	AB +	160MG	N18063 004 Jun CAHN
>A>	AB KING PHARMS	20MG	N18063 005 Oct 28, 1986 Jun CAHN
>A>	AB	40MG	N18063 001 Jun CAHN

TABLET; ORAL

CORGARD

>A>	AB	KING PHARMS	80MG	N18063 002	Jun	CAHN
>A>	AB		120MG	N18063 003	Jun	CAHN
>A>	AB	+	160MG	N18063 004	Jun	CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP	+	SANDOZ	EQ 1GM BASE/VIAL	N62527 002	Aug 02,	1984	Apr	CRLD
AP	+		EQ 1GM BASE/VIAL	N62732 001	Dec 23,	1986	Apr	CRLD
AP	+		EQ 2GM BASE/VIAL	N62527 003	Aug 02,	1984	Apr	CRLD
AP	+		EQ 2GM BASE/VIAL	N62732 002	Dec 23,	1986	Apr	CRLD
AP	+		EQ 10GM BASE/VIAL	N62527 004	Aug 02,	1984	Apr	CRLD

NALTREXONEFOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
VIVITROL

+ ALKERMES	380MG/VIAL	N21897 001	Apr 13,	2006	Apr	NEWA
------------	------------	------------	---------	------	-----	------

NAPROXENTABLET, DELAYED RELEASE; ORAL
NAPROXEN

>A>	AB	ACTAVIS ELIZABETH	375MG	N74936 001	Feb 24,	1998	Jun	CAHN
>A>	AB		500MG	N74936 002	Feb 24,	1998	Jun	CAHN
>D>	AB	PUREPAC PHARM	375MG	N74936 001	Feb 24,	1998	Jun	CAHN
>D>	AB		500MG	N74936 002	Feb 24,	1998	Jun	CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

>A>		NEOMYCIN AND POLYMYXIN B SULFATE						
>A>	AT	X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N65106 001	Jan 31,	2006	Jun	CTNA
>A>	AT		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML	N65108 001	Jan 31,	2006	Jun	CTNA
>D>		NEOSPORIN AND POLYMYXIN B SULFATE						
>D>	AT	X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N65106 001	Jan 31,	2006	Jun	CTNA
	AT		EQ 40MG BASE/ML;200,000 UNITS/ML	N65106 001	Jan 31,	2006	Jan	NEWA
>D>	AT		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N65108 001	Jan 31,	2006	Jun	CTNA
	AT		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N65108 001	Jan 31,	2006	Jan	NEWA
		NEOSPORIN G.U. IRRIGANT						
AT	+	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707 001			Jan	CTEC
AT	+		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N60707 002			Jan	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

AB		BARR	20MG	N74439 001	Dec 10,	1996	Apr	CAHN
AB			30MG	N74439 002	Dec 10,	1996	Apr	CAHN

INJECTABLE; INJECTION

CARDENE

+ PDL BIOPHARMA INC	2.5MG/ML	N19734 001	Jan 30,	1992	Jan	CAHN
---------------------	----------	------------	---------	------	-----	------

NIFEDIPINE

CAPSULE; ORAL
NIFEDIPINE

>A>	AB	ACTAVIS ELIZABETH	10MG	N72579 001 Jan 08, 1991 Jun CAHN
>A>	AB		20MG	N72556 001 Sep 20, 1990 Jun CAHN
>D>	AB	PUREPAC PHARM	10MG	N72579 001 Jan 08, 1991 Jun CAHN
>D>	AB		20MG	N72556 001 Sep 20, 1990 Jun CAHN
TABLET, EXTENDED RELEASE; ORAL				
AFEDITAB CR				
AB1		WATSON LABS	30MG	N75128 001 Mar 10, 2000 Jan CAHN
AB1			60MG	N75659 001 Oct 26, 2001 Jan CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
SULAR

>D>	+	FIRST HORIZON	10MG	N20356 001 Feb 02, 1995 Jun CAHN
>D>			20MG	N20356 002 Feb 02, 1995 Jun CAHN
>D>	+		30MG	N20356 003 Feb 02, 1995 Jun CAHN
>D>	+		40MG	N20356 004 Feb 02, 1995 Jun CAHN
>A>	+	SCIELE PHARMA INC	10MG	N20356 001 Feb 02, 1995 Jun CAHN
>A>			20MG	N20356 002 Feb 02, 1995 Jun CAHN
>A>	+		30MG	N20356 003 Feb 02, 1995 Jun CAHN
>A>	+		40MG	N20356 004 Feb 02, 1995 Jun CAHN

NITROGLYCERIN

AEROSOL; SUBLINGUAL
NITROLINGUAL

>D>	@	POHL BOSKAMP	0.4MG/SPRAY	N18705 001 Oct 31, 1985 Jun CAHN
>A>	@		0.4MG/SPRAY	N18705 001 Oct 31, 1985 Jun CAHN
SPRAY, METERED; SUBLINGUAL				
NITROLINGUAL PUMPSPRAY				
>D>	+	POHL BOSKAMP	0.4MG/SPRAY	N18705 002 Jan 10, 1997 Jun CAHN
>A>	+		0.4MG/SPRAY	N18705 002 Jan 10, 1997 Jun CAHN

NOREpinephrine Bitartrate

INJECTABLE; INJECTION
NOREPINEPHRINE BITARTRATE

AP	METRICS PHARM	EQ 1MG BASE/ML	N40522 001 Sep 30, 2004 May CAHN
----	---------------	----------------	----------------------------------

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL
NORTRIPTYLINE HYDROCHLORIDE

>A>	AA	TARO	EQ 10MG BASE/5ML	N77965 001 Jun 20, 2006 Jun NEWA
-----	----	------	------------------	----------------------------------

NYSTATIN

CREAM; TOPICAL
NYSTATIN

>A>	AT	ACTAVIS MID ATLANTIC	100,000 UNITS/GM	N62949 001 Jun 13, 1988 Jun CAHN
>D>	AT	ALPHARMA US PHARMS	100,000 UNITS/GM	N62949 001 Jun 13, 1988 Jun CAHN
		@ TARO	100,000 UNITS/GM	N62457 001 Jul 28, 1983 May DISC
	AT	VINTAGE	100,000 UNITS/GM	N65315 001 May 31, 2006 May NEWA
OINTMENT; TOPICAL				
NYSTATIN				
>A>	AT	ACTAVIS MID ATLANTIC	100,000 UNITS/GM	N62840 001 Nov 13, 1987 Jun CAHN

OINTMENT; TOPICAL

NYSTATIN

>D>	AT	ALPHARMA US PHARMS	100,000 UNITS/GM	N62840 001 Nov 13, 1987 Jun CAHN
SUSPENSION; ORAL				
NYSTATIN				
AA	TARO	100,000 UNITS/ML	N62876 001 Feb 29, 1988 May CMFD	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

>A>	AT	ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	N62367 001 May 28, 1985 Jun CAHN
>D>	AT	ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	N62367 001 May 28, 1985 Jun CAHN
OINTMENT; TOPICAL				
MYKACET				
>A>	AT	ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	N62733 001 Mar 09, 1987 Jun CAHN
>D>	AT	ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	N62733 001 Mar 09, 1987 Jun CAHN

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP	AM PHARM	EQ 0.2MG BASE/ML	N77450 001 Feb 10, 2006 Jan NEWA
AP		EQ 1MG BASE/ML	N77450 002 Feb 10, 2006 Jan NEWA
OCTREOTIDE ACETATE (PRESERVATIVE FREE)			
AP	AM PHARM	EQ 0.05MG BASE/ML	N77457 001 Feb 10, 2006 Jan NEWA
AP		EQ 0.1MG BASE/ML	N77457 002 Feb 10, 2006 Jan NEWA
AP		EQ 0.5MG BASE/ML	N77457 003 Feb 10, 2006 Jan NEWA

OFLOXACIN

TABLET; ORAL

OFLOXACIN

AB	DR REDDYS LABS LTD	200MG	N77098 001 Feb 10, 2006 Jan NEWA
AB		300MG	N77098 002 Feb 10, 2006 Jan NEWA
AB		400MG	N77098 003 Feb 10, 2006 Jan NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

ZEGERID

SANTARUS 20MG;1.1GM

+ 40MG;1.1GM

FOR SUSPENSION; ORAL

ZEGERID

SANTARUS 20MG/PACKET;1.68GM/PACKET

+ 40MG/PACKET;1.68GM/PACKET

N21849 001 Feb 27, 2006 Feb NEWA

N21849 002 Feb 27, 2006 Feb NEWA

N21636 001 Jun 15, 2004 Feb CAIN

N21706 001 Dec 21, 2004 Feb CAIN

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

AP	AKORN	30MG/ML	N40484 001 May 24, 2006 May NEWA
----	-------	---------	----------------------------------

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

>D>	+	SANOFI AVENTIS US	50MG/VIAL	N21492 001 Aug 09, 2002 Jun DISC
>A>	@		50MG/VIAL	N21492 001 Aug 09, 2002 Jun DISC
>D>	+		100MG/VIAL	N21492 002 Aug 09, 2002 Jun DISC

INJECTABLE; IV (INFUSION)

ELOXATIN

>A> @ SANOFI AVENTIS US 100MG/VIAL N21492 002 Aug 09, 2002 Jun DISC

OXAPROZIN

TABLET; ORAL

OXAPROZIN

>A> AB ACTAVIS ELIZABETH 600MG N75843 001 Oct 03, 2001 Jun CAHN
>D> AB PUREPAC PHARM 600MG N75843 001 Oct 03, 2001 Jun CAHNOXAZEPAM

CAPSULE; ORAL

OXAZEPAM

>A> AB ACTAVIS ELIZABETH 10MG N72251 001 Apr 14, 1988 Jun CAHN
>A> AB 15MG N72252 001 Apr 14, 1988 Jun CAHN
>A> AB 30MG N72253 001 Apr 14, 1988 Jun CAHN
>D> AB PUREPAC PHARM 10MG N72251 001 Apr 14, 1988 Jun CAHN
>D> AB 15MG N72252 001 Apr 14, 1988 Jun CAHN
>D> AB 30MG N72253 001 Apr 14, 1988 Jun CAHNOXYMETHOLONE

TABLET; ORAL

ANADROL-50

+ ALAVEN PHARM 50MG N16848 001 Apr CAHN

OXYMORPHONE HYDROCHLORIDE>A> TABLET; ORAL
>A> OPANA
>A> ENDO PHARMS 5MG N21611 001 Jun 22, 2006 Jun NEWA
>A> + 10MG N21611 002 Jun 22, 2006 Jun NEWA
>A> TABLET, EXTENDED RELEASE; ORAL
>A> OPANA ER
>A> ENDO PHARMS 5MG N21610 001 Jun 01, 2006 Jun NEWA
>A> 10MG N21610 002 Jun 01, 2006 Jun NEWA
>A> 20MG N21610 003 Jun 01, 2006 Jun NEWA
>A> + 40MG N21610 004 Jun 01, 2006 Jun NEWAPACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

+ ABRAXIS BIOSCIENCE 100MG/VIAL N21660 001 Jan 07, 2005 Apr CAHN

PAROXETINE MESYLATE

TABLET; ORAL

PEXEVA

JDS PHARMS EQ 10MG BASE N21299 001 Jul 03, 2003 Apr CAHN
EQ 20MG BASE N21299 002 Jul 03, 2003 Apr CAHN
EQ 30MG BASE N21299 003 Jul 03, 2003 Apr CAHN
+ EQ 40MG BASE N21299 004 Jul 03, 2003 Apr CAHNPEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+ OSI EYETECH EQ 0.3MG ACID/0.09ML N21756 001 Dec 17, 2004 May CAHN

PENICILLAMINE

CAPSULE; ORAL				
CUPRIMINE				
>D>	MERCK	125MG	N19853 002	Jun DISC
>A>	@	125MG	N19853 002	Jun DISC

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL				
PENICILLIN V POTASSIUM				
AA	AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61529 001	Jan CAHN
AA		EQ 250MG BASE/5ML	N61529 002	Jan CAHN
TABLET; ORAL				
PENICILLIN V POTASSIUM				
@ AM ANTIBIOTICS	EQ 250MG BASE	N61528 001	Jan CAHN	
@	EQ 500MG BASE	N61528 002	Jan CAHN	

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL				
PENTOXIFYLLINE				
>A> AB	ACTAVIS ELIZABETH	400MG	N74878 001 Jul 09, 1997	Jun CAHN
>D> AB	PUREPAC PHARM	400MG	N74878 001 Jul 09, 1997	Jun CAHN

PERGOLIDE MESYLATE

TABLET; ORAL				
PERGOLIDE MESYLATE				
AB	PAR PHARM	EQ 0.05MG BASE	N76061 001 Nov 27, 2002	Apr CAHN
AB		EQ 0.25MG BASE	N76061 002 Nov 27, 2002	Apr CAHN
AB		EQ 1MG BASE	N76061 003 Nov 27, 2002	Apr CAHN
PERMAX				
AB	VALEANT	EQ 0.05MG BASE	N19385 001 Dec 30, 1988	Jan CRLD
AB	+	EQ 0.25MG BASE	N19385 002 Dec 30, 1988	Jan CRLD

PERMETHRIN

CREAM; TOPICAL				
PERMETHRIN				
>A> AB	ACTAVIS MID ATLANTIC	5%	N74806 001 Jan 23, 1998	Jun CAHN
>D> AB	ALPHARMA US PHARMS	5%	N74806 001 Jan 23, 1998	Jun CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL				
CAM-METRAZINE				
@ TG UNITED LABS	35MG	N83922 001	May CAHN	
@	35MG	N85318 001	May CAHN	
@	35MG	N85320 001	May CAHN	
@	35MG	N85321 001	May CAHN	
PHENDIMETRAZINE TARTRATE				
@ TG UNITED LABS	35MG	N85761 001	May CAHN	
@	35MG	N85941 001 Jun 27, 1983	May CAHN	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL				
PHENTERMINE HYDROCHLORIDE				
@ TG UNITED LABS	18.75MG	N88576 001 May 23, 1984	May CAHN	
@	30MG	N85417 001	May CAHN	

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

@	TG UNITED LABS	30MG	N86732	002	May	CAHN
@		30MG	N87215	001	May	CAHN
@		37.5MG	N87915	001	Dec 22,	1983 May CAHN
@		37.5MG	N87918	001	Dec 22,	1983 May CAHN
@		37.5MG	N87930	001	Oct 14,	1983 May CAHN
@		37.5MG	N88610	001	Jun 04,	1984 May CAHN
@		37.5MG	N88611	001	Jun 04,	1984 May CAHN
@		37.5MG	N88625	001	Aug 23,	1984 May CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

>A>	AA	ACTAVIS ELIZABETH	37.5MG	N40276	001	Nov 25,	1998 Jun CAHN
>D>	AA	PUREPAC PHARM	37.5MG	N40276	001	Nov 25,	1998 Jun CAHN
		@ TG UNITED LABS	8MG	N83923	001		May CAHN
		@	8MG	N85319	001		May CAHN
		@	37.5MG	N87805	001	Dec 06,	1982 May CAHN
		@	37.5MG	N88596	001	Apr 04,	1984 May CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC PLAIN

+ +	ALPHARMA US PHARMS	5MG/5ML; 6.25MG/5ML	N88761	001	Nov 08,	1984 Jan CTEC
	PROMETHAZINE VC PLAIN					
	@ MORTON GROVE	5MG/5ML; 6.25MG/5ML	N88897	001	Jan 04,	1985 Jan DISC

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

@	MERCK	1MG/0.5ML	N12223	002	Feb	DISC
@		10MG/ML	N12223	001	Feb	DISC
	VITAMIN K1					
BP	+ HOSPIRA	1MG/0.5ML	N87954	001	Jul 25,	1983 Feb CRLD
	+	10MG/ML	N87955	001	Jul 25,	1983 Feb CRLD

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB	IMPAKX LABS	5MG	N77248	001	Mar 31,	2006 Mar NEWA
AB		7.5MG	N77248	002	Mar 31,	2006 Mar NEWA
	SALAGEN					
AB	+ MGI PHARMA INC	7.5MG	N20237	002	Apr 18,	2003 Mar CFTG

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

AA	COASTAL PHARMS	17GM/SCOOPFUL	N77893	001	May 26,	2006 May NEWA
AA	KALI LABS	17GM/SCOOPFUL	N77736	001	May 26,	2006 May NEWA
AA	TEVA PHARMS	17GM/SCOOPFUL	N77445	001	May 04,	2006 Apr NEWA

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

>D>	+ BAXTER HLTHCARE	14.9MG/ML	N19904	001	Dec 26,	1989 Jun CTEC
>A>	AP +	14.9MG/ML	N19904	001	Dec 26,	1989 Jun CTEC

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

>D>	+	BAXTER HLTHCARE	746MG/100ML	N19904 005	Dec 17, 1990	Jun	CTEC
>A>	AP	+	746MG/100ML	N19904 005	Dec 17, 1990	Jun	CTEC

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

>D>	+	BAXTER HLTHCARE	1.49GM/100ML	N19904 006	Dec 17, 1990	Jun	CTEC
>A>	AP	+	1.49GM/100ML	N19904 006	Dec 17, 1990	Jun	CTEC

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

AB	UPSHER SMITH	8MEQ	N19123 001	Apr 17, 1986	Jan	CRLD
----	--------------	------	------------	--------------	-----	------

POTASSIUM CHLORIDE

AB	+	COPLEY PHARM	8MEQ	N70618 001	Sep 09, 1987	Jan	CRLD
----	---	--------------	------	------------	--------------	-----	------

POTASSIUM CITRATETABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

AB	COREPHARMA	5MEQ	N77440 001	Jun 09, 2006	May	NEWA
----	------------	------	------------	--------------	-----	------

AB		10MEQ	N77440 002	Jun 09, 2006	May	NEWA
----	--	-------	------------	--------------	-----	------

UROCIT-K

AB	MISSION PHARMA	5MEQ	N19071 001	Aug 30, 1985	May	CFTG
----	----------------	------	------------	--------------	-----	------

AB	+	10MEQ	N19071 002	Aug 31, 1992	May	CFTG
----	---	-------	------------	--------------	-----	------

PRAVASTATIN SODIUMTABLET; ORAL

PRAVACHOL

AB	BRISTOL MYERS SQUIBB	10MG	N19898 002	Oct 31, 1991	Apr	CFTG
----	----------------------	------	------------	--------------	-----	------

AB		20MG	N19898 003	Oct 31, 1991	Apr	CFTG
----	--	------	------------	--------------	-----	------

AB		40MG	N19898 004	Mar 22, 1993	Apr	CFTG
----	--	------	------------	--------------	-----	------

PRAVASTATIN SODIUM

AB	TEVA	10MG	N76056 001	Apr 24, 2006	Apr	NEWA
----	------	------	------------	--------------	-----	------

AB		20MG	N76056 002	Apr 24, 2006	Apr	NEWA
----	--	------	------------	--------------	-----	------

AB		40MG	N76056 003	Apr 24, 2006	Apr	NEWA
----	--	------	------------	--------------	-----	------

PRAZOSIN HYDROCHLORIDECAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

@ CLONMEL HLTHCARE	EQ 1MG BASE	N72705 001	May 16, 1989	Jan	DISC
--------------------	-------------	------------	--------------	-----	------

@	EQ 5MG BASE	N72707 001	May 16, 1989	Jan	DISC
---	-------------	------------	--------------	-----	------

PREDNISOLONE ACETATEINJECTABLE; INJECTION

PREDNISOLONE ACETATE

@ STERIS	25MG/ML	N83398 001	Mar	DISC
----------	---------	------------	-----	------

@	50MG/ML	N83764 001	Mar	DISC
---	---------	------------	-----	------

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED

AB	ALCON	1%	N17469 001	May	CTNA
----	-------	----	------------	-----	------

PREDNISOLONE SODIUM PHOSPHATETABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

>A>	BIOMARIN PHARM	EQ 10MG BASE	N21959 001	Jun 01, 2006	Jun	NEWA
-----	----------------	--------------	------------	--------------	-----	------

>A>		EQ 15MG BASE	N21959 002	Jun 01, 2006	Jun	NEWA
-----	--	--------------	------------	--------------	-----	------

>A>	+	EQ 30MG BASE	N21959 003	Jun 01, 2006	Jun	NEWA
-----	---	--------------	------------	--------------	-----	------

PROCHLORPERAZINE

SUPPOSITORY; RECTAL
 COMPAZINE
 @ GLAXOSMITHKLINE 2.5MG N11127 003 May DISC
 @ 5MG N11127 001 May DISC

PROCHLORPERAZINE EDISYLATE

SYRUP; ORAL
 COMPAZINE
 @ GLAXOSMITHKLINE EQ 5MG BASE/5ML N11188 001 May DISC

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
 COMPAZINE
 @ GLAXOSMITHKLINE EQ 10MG BASE N21019 001 Oct 06, 1999 May DISC

PROGESTERONE

GEL; VAGINAL
 CRINONE
 COLUMBIA LABS 4% N20701 001 Jul 31, 1997 May CAHN
 + 8% N20701 002 Jul 31, 1997 May CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL
 PHENERGAN
 @ WYETH PHARMS INC 12.5MG N10926 002 Mar DISC
 @ 25MG N10926 001 Mar DISC
 PROMETHAZINE HYDROCHLORIDE
 AB + G AND W LABS 25MG N40428 001 Feb 05, 2002 Mar CRLD
 PROMETHEGAN
 + G AND W LABS 50MG N87165 001 Aug 14, 1987 Jan CRLD
 SYRUP; ORAL
 PROMETHAZINE HYDROCHLORIDE
 AA VINTAGE 6.25MG/5ML N40643 001 Apr 26, 2006 Apr NEWA

PROPOFOL

INJECTABLE; INJECTION
 PROPOFOL
 AB HOSPIRA 10MG/ML N77908 001 Mar 17, 2006 Mar NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
 PROPOXYPHENE HYDROCHLORIDE
 AA PAR PHARM 65MG N80269 001 Mar CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
 PROPRANOLOL HYDROCHLORIDE
 AP SANDOZ 1MG/ML N76400 001 Feb 26, 2003 Jan CAHN

PROPYLTHIOURACIL

TABLET; ORAL
 PROPYLTHIOURACIL
 >A> BD ACTAVIS ELIZABETH 50MG N80172 001 Jun CAHN

TABLET; ORAL

PROPYLTHIOURACIL

>D> BD PUREPAC PHARM 50MG N80172 001 Jun CAHN

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

REGONOL

AP SANDOZ 5MG/ML N17398 001 Jan CAHN

QUAZEPAM

TABLET; ORAL

DORAL

@ QUESTCOR PHARMS

7.5MG

N18708 003 Feb 26, 1987 May CAHN

+ 15MG N18708 001 Dec 27, 1985 May CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL

>A> AB LUPIN EQ 5MG BASE N77690 001 Jun 20, 2006 Jun NEWA

>A> AB EQ 10MG BASE N77690 002 Jun 20, 2006 Jun NEWA

>A> AB EQ 20MG BASE N77690 003 Jun 20, 2006 Jun NEWA

>A> AB EQ 40MG BASE N77690 004 Jun 20, 2006 Jun NEWA

QUINAPRIL HYDROCHLORIDE

AB TORPHARM EQ 5MG BASE N76240 001 Jan 26, 2006 Jan NEWA

AB EQ 10MG BASE N76240 002 Jan 26, 2006 Jan NEWA

AB EQ 20MG BASE N76240 003 Jan 26, 2006 Jan NEWA

AB EQ 40MG BASE N76240 004 Jan 26, 2006 Jan NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

BX + MUTUAL PHARM 324MG N89338 001 Feb 11, 1987 Jan CTEC

BX WATSON LABS 324MG N87810 001 Sep 29, 1982 Jan CMFD

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

@ CLONMEL HLTHCARE 200MG N87011 001 Jan DISC

@ LANNETT 200MG N83743 001 Jan DISC

@ MUTUAL PHARM 100MG N81029 001 Apr 14, 1989 Jan DISC

@ PHARM FORM 200MG N83808 001 Jan DISC

@ SANDOZ 200MG N84631 001 Jan DISC

@ 200MG N84914 001 Jan DISC

AB 200MG N88072 002 Jan NEWA

@ 300MG N89839 001 Sep 29, 1988 Jan DISC

@ WATSON LABS 200MG N83288 001 Jan DISC

@ 200MG N85140 002 Jan DISC

RANITIDINE

INJECTABLE; INJECTION

RANITIDINE

AP BEDFORD EQ 25MG BASE/ML N77458 001 Feb 16, 2006 Feb NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL
 RANEXA
 + CV THERAP 500MG N21526 002 Jan 27, 2006 Jan NEWA

RASAGILINE MESYLATE

TABLET; ORAL
 AZILECT
 TEVA EQ 0.5MG BASE N21641 001 May 16, 2006 May NEWA
 + EQ 1MG BASE N21641 002 May 16, 2006 May NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL
 RISPERDAL
 JANSSEN PHARMA 3MG N21444 004 Dec 23, 2004 Mar CMFD
 4MG N21444 005 Dec 23, 2004 Mar CMFD

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS
 SECREFLO
 + CHIRHOCLIN 16UGM/VIAL N21136 001 Apr 04, 2002 May CTNA

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL
 EMSAM
 SOMERSET 6MG/24HR N21336 001 Feb 27, 2006 Mar CAIN
 9MG/24HR N21336 002 Feb 27, 2006 Mar CAIN
 + 12MG/24HR N21336 003 Feb 27, 2006 Mar CAIN

SELEGILINE HYDROCHLORIDE

FILM, EXTENDED RELEASE; TRANSDERMAL
 EMSAM
 SOMERSET 6MG/24HR N21336 001 Feb 27, 2006 Feb NEWA
 9MG/24HR N21336 002 Feb 27, 2006 Feb NEWA
 + 12MG/24HR N21336 003 Feb 27, 2006 Feb NEWA

>A> TABLET, ORALLY DISINTEGRATING; ORAL
 >A> ZELAPAR
 >A> + VALEANT PHARM INTL 1.25MG N21479 001 Jun 14, 2006 Jun NEWA

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL
 >A> SERTRALINE HYDROCHLORIDE
 >A> AB ROXANE EQ 20MG BASE/ML N76934 001 Jun 30, 2006 Jun NEWA
 ZOLOFT
 >D> + PFIZER EQ 20MG BASE/ML N20990 001 Dec 07, 1999 Jun CFTG
 >A> AB + EQ 20MG BASE/ML N20990 001 Dec 07, 1999 Jun CFTG
 TABLET; ORAL
 >A> SERTRALINE HYDROCHLORIDE
 >A> AB IVAX PHARMS EQ 25MG BASE N75719 003 Jun 30, 2006 Jun NEWA
 >A> AB EQ 50MG BASE N75719 001 Jun 30, 2006 Jun NEWA
 >A> AB EQ 100MG BASE N75719 002 Jun 30, 2006 Jun NEWA
 ZOLOFT
 >D> PFIZER EQ 25MG BASE N19839 005 Mar 06, 1996 Jun CFTG
 >A> AB EQ 25MG BASE N19839 005 Mar 06, 1996 Jun CFTG

TABLET; ORAL

ZOLOFT

>D>	PFIZER	EQ 50MG BASE	N19839 001 Dec 30, 1991 Jun CFTG
>A>	AB	EQ 50MG BASE	N19839 001 Dec 30, 1991 Jun CFTG
>D>	+	EQ 100MG BASE	N19839 002 Dec 30, 1991 Jun CFTG
>A>	AB	EQ 100MG BASE	N19839 002 Dec 30, 1991 Jun CFTG

SIMVASTATIN

TABLET; ORAL

>A>	SIMVASTATIN		
>A>	AB	IVAX PHARMS	5MG N76052 001 Jun 23, 2006 Jun NEWA
>A>	AB		10MG N76052 002 Jun 23, 2006 Jun NEWA
>A>	AB		20MG N76052 003 Jun 23, 2006 Jun NEWA
>A>	AB		40MG N76052 004 Jun 23, 2006 Jun NEWA
>A>	AB	RANBAXY	80MG N76285 005 Jun 23, 2006 Jun NEWA
ZOCOR			
>D>	MERCK		5MG N19766 001 Dec 23, 1991 Jun CFTG
>A>	AB		5MG N19766 001 Dec 23, 1991 Jun CFTG
>D>			10MG N19766 002 Dec 23, 1991 Jun CFTG
>A>	AB		10MG N19766 002 Dec 23, 1991 Jun CFTG
>D>			20MG N19766 003 Dec 23, 1991 Jun CFTG
>A>	AB		20MG N19766 003 Dec 23, 1991 Jun CFTG
>D>			40MG N19766 004 Dec 23, 1991 Jun CFTG
>A>	AB		40MG N19766 004 Dec 23, 1991 Jun CFTG
>D>	+		80MG N19766 005 Jul 10, 1998 Jun CFTG
>A>	AB	+	80MG N19766 005 Jul 10, 1998 Jun CFTG

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	B BRAUN	900MG/100ML N17464 001 May CRLD
AP	+		900MG/100ML N19635 002 Mar 09, 1988 May CRLD
AP	+	BAXTER HLTHCARE	900MG/100ML N16677 001 May CRLD
AP	+		900MG/100ML N20178 001 Dec 07, 1992 May CRLD
AP	+	HOSPIRA	900MG/100ML N16366 001 May CRLD
AP	+		900MG/100ML N19465 001 Jul 15, 1985 May CRLD
AP	+		900MG/100ML N19480 001 Sep 17, 1985 May CRLD

SODIUM IODIDE, I-131

>A>	CAPSULE; ORAL		
>A>	SODIUM IODIDE I 131		
>A>	DRAXIMAGE		100mCi N21305 004 Nov 18, 2004 Jun NEWA

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

OSMOPREP

+ SALIX PHARMS	0.398GM;1.102GM	N21892 001 Mar 16, 2006 Mar NEWA
----------------	-----------------	----------------------------------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL N20280 006 Aug 24, 1995 May CTEC
GENOTROPIN PRESERVATIVE FREE			
BX		PHARMACIA AND UPJOHN	1.5MG/VIAL N20280 004 Aug 24, 1995 May CTEC

INJECTABLE; INJECTION

OMNITROPE

BX	SANDOZ	1.5MG/VIAL	N21426 002 May 30, 2006 May NEWA
BX		5.8MG/VIAL	N21426 001 May 30, 2006 May NEWA

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

>A>	AB	ACTAVIS ELIZABETH	25MG	N40353 003 Mar 15, 2006 Jun CAHN
>A>	AB		50MG	N40353 001 Jul 29, 1999 Jun CAHN
>A>	AB		100MG	N40353 002 Jul 29, 1999 Jun CAHN
>D>	AB	PUREPAC PHARM	25MG	N40353 003 Mar 15, 2006 Jun CAHN
	AB		25MG	N40353 003 Mar 15, 2006 Feb NEWA
>D>	AB		50MG	N40353 001 Jul 29, 1999 Jun CAHN
>D>	AB		100MG	N40353 002 Jul 29, 1999 Jun CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

AP	+	SANDOZ	20MG/ML	N08453 002 Jan CAHN
	@		50MG/ML	N08453 003 Jan CAHN
	@		500MG/VIAL	N08453 001 Jan CAHN
	@		1GM/VIAL	N08453 004 Jan CAHN
>D>		SUCCINYLCHOLINE CHLORIDE		
>D>	AP	ORGANON USA INC	20MG/ML	N80997 001 Jun DISC
>A>		@	20MG/ML	N80997 001 Jun DISC

SULCONAZOLE NITRATE

SOLUTION; TOPICAL

EXELDERM

>D>		@ WESTWOOD SQUIBB	1%	N18738 001 Aug 30, 1985 Jun CMFD
>A>	+		1%	N18738 001 Aug 30, 1985 Jun CMFD

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM

AT	ALCON	30%	N89068 001 May 05, 1987 Apr CAHN
----	-------	-----	----------------------------------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

BACTRIM PEDIATRIC

AB	MUTUAL PHARM	200MG/5ML;40MG/5ML	N17560 002 Apr CMFD
----	--------------	--------------------	---------------------

SULINDAC

TABLET; ORAL

CLINORIL

>D>	AB	MERCK	150MG	N17911 001 Jun DISC
>A>		@	150MG	N17911 001 Jun DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX

+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (12MG/ML)	N20080 001 Dec 28, 1992 Feb CDFR
	IMITREX STATDOSE		
+	GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (8MG/ML)	N20080 002 Feb 01, 2006 Feb NEWA

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE

+ GLAXOSMITHKLINE

EQ 6MG BASE/0.5ML (12MG/ML)

N20080 003 Dec 23, 1996 Feb NEWA

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

>D>	PFIZER	12.5MG	N21938 001 Jan 26, 2006 Jun CPOT
>A>		EQ 12.5MG BASE	N21938 001 Jan 26, 2006 Jun CPOT
		12.5MG	N21938 001 Jan 26, 2006 Jan NEWA
>D>		25MG	N21938 002 Jan 26, 2006 Jun CPOT
>A>		EQ 25MG BASE	N21938 002 Jan 26, 2006 Jun CPOT
		25MG	N21938 002 Jan 26, 2006 Jan NEWA
>D>	+	50MG	N21938 003 Jan 26, 2006 Jun CPOT
>A>	+	EQ 50MG BASE	N21938 003 Jan 26, 2006 Jun CPOT
	+	50MG	N21938 003 Jan 26, 2006 Jan NEWA

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

>A>	+ SAVIENT PHARMA	EQ 10MG BASE/5ML	N21807 001 Oct 29, 2005 Jun CAHN
>D>	+ SAVIENT PHARMS	EQ 10MG BASE/5ML	N21807 001 Oct 29, 2005 Jun CAHN

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

@ CIS BIO INTL SA

N/A

N20887 001 Sep 14, 1998 May DISC

N/A

N20887 001 Sep 14, 1998 Apr CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

@ CIS BIO INTL SA

N/A

N21012 001 Aug 03, 1999 May DISC

+

N/A

N21012 001 Aug 03, 1999 Apr CAHN

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW 30ML

@ GE HEALTHCARE

N/A

N20372 002 Jul 07, 2005 May DISC

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

>A>	AB ACTAVIS ELIZABETH	15MG	N71638 001 Aug 07, 1987 Jun CAHN
>A>	AB	30MG	N71620 001 Aug 07, 1987 Jun CAHN
>D>	AB PUREPAC PHARM	15MG	N71638 001 Aug 07, 1987 Jun CAHN
>D>	AB	30MG	N71620 001 Aug 07, 1987 Jun CAHN

TERCONAZOLE

SUPPOSITORY; VAGINAL

TERAZOL 3

AB + ORTHO MCNEIL PHARM

80MG

N19641 001 May 24, 1988 Mar CFTG

TERCONAZOLE

>A>	AB ALTANA	80MG	N76850 001 Jul 12, 2006 Jun NEWA
	AB PERRIGO NEW YORK	80MG	N77149 001 Mar 17, 2006 Mar NEWA

TESTOSTERONE

GEL; TRANSDERMAL ANDROGEL						
AB + UNIMED PHARMS	1%	N21015	001	Feb 28, 2000	Jan	CTEC
TESTOSTERONE						
AB WATSON LABS	1%	N76737	001	Jan 27, 2006	Jan	NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION DELATESTRYL						
AO + INDEVUS PHARMS	200MG/ML	N09165	003		Jan	CAHN
@	200MG/ML	N09165	001		Jan	CAHN
TESTOSTERONE ETHANATE						
AO PADDOCK	200MG/ML	N40575	001	Jun 14, 2006	May	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL ACHROMYCIN V						
@ RADIUS PHARMS	250MG	N50278	003		May	CAHN
@	500MG	N50278	001		May	CAHN
@ SCIREG INTL INC	250MG	N50278	003		Apr	CAHN
@	500MG	N50278	001		Apr	CAHN

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION THALLOUS CHLORIDE TL 201						
AP TRACE RADIOCHEMICALS	1mCi/ML	N75569	001	Nov 21, 2001	Feb	CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL THEOPHYLLINE						
AB NOSTRUM	400MG	N40595	001	Apr 21, 2006	Apr	NEWA
AB	600MG	N40560	002	Apr 21, 2006	Apr	NEWA
>D> T-PHYL						
>D> BC PURDUE FREDERICK	200MG	N88253	001	Aug 17, 1983	Jun	DISC
>A> @	200MG	N88253	001	Aug 17, 1983	Jun	DISC
UNIPHYL						
AB + PURDUE FREDERICK	400MG	N87571	001	Sep 01, 1982	Apr	CTEC
AB +	600MG	N40086	001	Apr 15, 1996	Apr	CTEC

THIABENDAZOLE

>D> SUSPENSION; ORAL MINTEZOL						
>D> + MERCK	500MG/5ML	N16097	001		Jun	DISC
>A> @	500MG/5ML	N16097	001		Jun	DISC

TICARCILLIN DISODIUM

INJECTABLE; INJECTION TICAR						
@ GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N50497	001		May	DISC
@	EQ 3GM BASE/VIAL	N50497	002		May	DISC
@	EQ 20GM BASE/VIAL	N50497	004		May	DISC
@	EQ 30GM BASE/VIAL	N50497	005	Apr 04, 1984	May	DISC

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	250MG	N75253 001 Aug 20, 1999 Jun CAHN
>D>	AB	PUREPAC PHARM	250MG	N75253 001 Aug 20, 1999 Jun CAHN

TIMOLOL MALEATE

TABLET; ORAL

>D>		BLOCADREN		
>D>	AB	MERCK	5MG	N18017 001 Jun DISC
>A>		@	5MG	N18017 001 Jun DISC
>D>	AB		10MG	N18017 002 Jun DISC
>A>		@	10MG	N18017 002 Jun DISC
>D>	AB	+	20MG	N18017 004 Jun DISC
>A>		@	20MG	N18017 004 Jun DISC
		TIMOLOL MALEATE		
>D>	AB	MYLAN	20MG	N72668 001 Jun 08, 1990 Jun CRLD
>A>	AB	+	20MG	N72668 001 Jun 08, 1990 Jun CRLD

TINIDAZOLE

TABLET; ORAL

TINDAMAX

		MISSION PHARMA	250MG	N21618 001 May 17, 2004 Jan CAHN
	+		500MG	N21618 002 May 17, 2004 Jan CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	EQ 2MG BASE	N76283 001 Jul 12, 2002 Jun CAHN
>A>	AB		EQ 4MG BASE	N76283 002 Jul 12, 2002 Jun CAHN
>D>	AB	PUREPAC PHARM	EQ 2MG BASE	N76283 001 Jul 12, 2002 Jun CAHN
>D>	AB		EQ 4MG BASE	N76283 002 Jul 12, 2002 Jun CAHN

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

>A>	AB	ACTAVIS ELIZABETH	EQ 400MG BASE	N73308 001 Jan 24, 1992 Jun CAHN
>D>	AB	PUREPAC PHARM	EQ 400MG BASE	N73308 001 Jan 24, 1992 Jun CAHN

TABLET; ORAL

TOLMETIN SODIUM

>A>	AB	ACTAVIS ELIZABETH	EQ 600MG BASE	N73527 001 Jun 30, 1992 Jun CAHN
>D>	AB	PUREPAC PHARM	EQ 600MG BASE	N73527 001 Jun 30, 1992 Jun CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	50MG	N75960 001 Jun 19, 2002 Jun CAHN
		@ IVAX PHARMS	50MG	N75963 001 Jul 03, 2002 Jan DISC
>D>	AB	PUREPAC PHARM	50MG	N75960 001 Jun 19, 2002 Jun CAHN

TRANLYLCYPROMINE SULFATE

TABLET; ORAL

PARNATE

>D>		+	GLAXOSMITHKLINE	EQ 10MG BASE	N12342 003 Aug 16, 1985 Jun CFTG
-----	--	---	-----------------	--------------	----------------------------------

TABLET; ORAL

PARNATE

>A>	AB	+	GLAXOSMITHKLINE	EQ 10MG BASE	N12342 003 Aug 16, 1985 Jun CFTG
>A>			TRANLYLCYPROMINE SULFATE		
>A>	AB		KALI LABS	EQ 10MG BASE	N40640 001 Jun 29, 2006 Jun NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

>A>	AB		ACTAVIS ELIZABETH	50MG	N71636 001 Apr 18, 1988 Jun CAHN
>A>	AB			100MG	N71514 001 Apr 18, 1988 Jun CAHN
>D>	AB		PUREPAC PHARM	50MG	N71636 001 Apr 18, 1988 Jun CAHN
>D>	AB			100MG	N71514 001 Apr 18, 1988 Jun CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT		ACTAVIS MID ATLANTIC	0.1%	N87798 001 Jun 04, 1982 Jun CAHN
>D>	AT		ALPHARMA US PHARMS	0.1%	N87798 001 Jun 04, 1982 Jun CAHN
	AT		VINTAGE	0.025%	N40671 001 Jun 09, 2006 May NEWA
	AT			0.1%	N40671 002 Jun 09, 2006 May NEWA

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT		ACTAVIS MID ATLANTIC	0.1%	N87799 001 Jun 07, 1982 Jun CAHN
>D>	AT		ALPHARMA US PHARMS	0.1%	N87799 001 Jun 07, 1982 Jun CAHN

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

@	SANDOZ	25MG/ML	N11685 003	Jan CAHN
@		40MG/ML	N12802 001	Jan CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+	SANDOZ	5MG/ML	N16466 001	Jan CAHN
+		20MG/ML	N16466 002	Jan CAHN

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLORMETHIAZIDE

@	TG UNITED LABS	4MG	N85568 001	May CAHN
---	----------------	-----	------------	----------

TRIFLUOPERAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

STELAZINE

@	GLAXOSMITHKLINE	EQ 2MG BASE/ML	N11552 005	May DISC
---	-----------------	----------------	------------	----------

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

@	NOVARTIS	50MG	N05914 002	Jan DISC
---	----------	------	------------	----------

TROLEANDOMYCIN

CAPSULE; ORAL
 TAO
 @ PFIZER EQ 250MG BASE N50336 002 Mar DISC

>D> UNOPROSTONE ISOPROPYL

>D> SOLUTION/DROPS; OPHTHALMIC
 >D> RESCULA
 >D> + R TECH UENO LTD 0.15% N21214 001 Aug 03, 2000 Jun DISC
 >A> @ 0.15% N21214 001 Aug 03, 2000 Jun DISC
 + 0.15% N21214 001 Aug 03, 2000 Feb CAHN

>D> UREA

>D> INJECTABLE; INJECTION
 >D> UREAPHIL
 >D> + HOSPIRA 40GM/VIAL N12154 001 Jun DISC
 >A> @ 40GM/VIAL N12154 001 Jun DISC

UROKINASE

INJECTABLE; INJECTION
 ABBOKINASE
 @ IMARX THERAP 5,000 IU/VIAL N21846 003 Apr CAHN
 @ 9,000 IU/VIAL N21846 002 Apr CAHN
 + 250,000 IU/VIAL N21846 001 Apr CAHN

VARENICLINE TARTRATE

TABLET; ORAL
 CHANTIX
 PFIZER EQ 0.5MG BASE N21928 001 May 10, 2006 May NEWA
 + EQ 1MG BASE N21928 002 May 10, 2006 May NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION
 VECURONIUM BROMIDE
 AP + BEDFORD 20MG/VIAL N75549 002 Jun 13, 2000 Jan CRLD

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL
 VERAPAMIL HYDROCHLORIDE
 >A> AB ACTAVIS ELIZABETH 80MG N71019 001 Sep 24, 1986 Jun CAHN
 >A> AB 120MG N70468 001 Sep 24, 1986 Jun CAHN
 >D> AB PUREPAC PHARM 80MG N71019 001 Sep 24, 1986 Jun CAHN
 >D> AB 120MG N70468 001 Sep 24, 1986 Jun CAHN

WARFARIN SODIUM

TABLET; ORAL
 WARFARIN SODIUM
 >A> AB PLIVA 1MG N40616 009 Jul 05, 2006 Jun NEWA
 >A> AB 2MG N40616 001 Jul 05, 2006 Jun NEWA
 >A> AB 2.5MG N40616 002 Jul 05, 2006 Jun NEWA
 >A> AB 3MG N40616 003 Jul 05, 2006 Jun NEWA
 >A> AB 4MG N40616 004 Jul 05, 2006 Jun NEWA
 >A> AB 5MG N40616 005 Jul 05, 2006 Jun NEWA
 >A> AB 6MG N40616 006 Jul 05, 2006 Jun NEWA

TABLET; ORAL

WARFARIN SODIUM

>A>	AB	PLIVA	7.5MG	N40616	007	Jul 05,	2006	Jun	NEWA
>A>	AB		10MG	N40616	008	Jul 05,	2006	Jun	NEWA
AB	ZYDUS PHARMS USA		1MG	N40663	001	May 30,	2006	May	NEWA
AB			2MG	N40663	002	May 30,	2006	May	NEWA
AB			2.5MG	N40663	003	May 30,	2006	May	NEWA
AB			3MG	N40663	004	May 30,	2006	May	NEWA
AB			4MG	N40663	005	May 30,	2006	May	NEWA
AB			5MG	N40663	006	May 30,	2006	May	NEWA
AB			6MG	N40663	007	May 30,	2006	May	NEWA
AB			7.5MG	N40663	008	May 30,	2006	May	NEWA
AB			10MG	N40663	009	May 30,	2006	May	NEWA

ZIDOVUDINE

CAPSULE; ORAL

RETROVIR

AB	+	GLAXOSMITHKLINE	100MG	N19655	001	Mar 19,	1987	Mar	CFTG
AB		ZIDOVUDINE		N78128	001	Mar 27,	2006	Mar	NEWA

ZIPRASIDONE HYDROCHLORIDE

SUSPENSION; ORAL

GEODON

+	PFIZER INC		EQ 10MG BASE/ML	N21483	001	Mar 29,	2006	Mar	NEWA
---	------------	--	-----------------	--------	-----	---------	------	-----	------

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB	GLENMARK PHARMS		25MG	N77651	001	Jan 30,	2006	Jan	NEWA
AB			50MG	N77651	002	Jan 30,	2006	Jan	NEWA
AB			100MG	N77651	003	Jan 30,	2006	Jan	NEWA
AB	INVAGEN PHARMS		25MG	N77869	001	May 31,	2006	May	NEWA
AB			50MG	N77869	002	May 31,	2006	May	NEWA
AB			100MG	N77869	003	May 31,	2006	May	NEWA
AB	SUN PHARM IND (IN)		25MG	N77634	001	Mar 17,	2006	Mar	NEWA
AB			50MG	N77634	002	Mar 17,	2006	Mar	NEWA
AB			100MG	N77634	003	Mar 17,	2006	Mar	NEWA
AB	WATSON LABS		25MG	N77650	001	Apr 20,	2006	Apr	NEWA
AB			50MG	N77650	002	Apr 20,	2006	Apr	NEWA
AB			100MG	N77650	003	Apr 20,	2006	Apr	NEWA

OTC DRUG PRODUCT LIST - 26TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLMENT 6 - June 2006

2-1

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACETAMINOPHEN

>A>	ACTAVIS MID ATLANTIC	120MG	N18337 003	Sep 12, 1983	Jun	CAHN	
>A>		325MG	N18337 002		Jun	CAHN	
>A>	+	650MG	N18337 001		Jun	CAHN	
>D>	ALPHARMA US PHARMS	120MG	N18337 003	Sep 12, 1983	Jun	CAHN	
>D>		325MG	N18337 002		Jun	CAHN	
>D>	+	650MG	N18337 001		Jun	CAHN	
	INFANTS' FEVERALL						
>A>	ACTAVIS MID ATLANTIC	80MG	N18337 004	Aug 26, 1992	Jun	CAHN	
>D>	ALPHARMA US PHARMS	80MG	N18337 004	Aug 26, 1992	Jun	CAHN	
	TYLENOL						
>A>	@ MCNEIL CONS	120MG	N17756 002		Jun	CAHN	
>A>	@	650MG	N17756 001		Jun	CAHN	
>D>	@ MCNEIL CONS SPECLT	120MG	N17756 002		Jun	CAHN	
>D>	@	650MG	N17756 001		Jun	CAHN	
	TABLET, EXTENDED RELEASE; ORAL						
	TYLENOL (CAPLET)						
>A>	+	MCNEIL CONS	650MG	N19872 001	Jun 08, 1994	Jun	CAHN
>D>	+	MCNEIL CONS SPECLT	650MG	N19872 001	Jun 08, 1994	Jun	CAHN
	TYLENOL (GELTAB)						
>A>	+	MCNEIL CONS	650MG	N19872 002	Jan 11, 2001	Jun	CAHN
>D>	+	MCNEIL CONS SPECLT	650MG	N19872 002	Jan 11, 2001	Jun	CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP WITH TINT

+ MEDI FLEX INC 2%;70% (10.5ML)

N20832 005 Apr 03, 2006 Apr NEWA

CLOTRIMAZOLE

CREAM; VAGINAL

CLOTRIMAZOLE

>A>	ACTAVIS MID ATLANTIC	1%	N74165 001	Jul 16, 1993	Jun	CAHN
>D>	ALPHARMA US PHARMS	1%	N74165 001	Jul 16, 1993	Jun	CAHN

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ALPHARMA US PHARMS 5.2MG/SPRAY

N74800 001 Jul 26, 2001 Jan CPOT

+ BAUSCH AND LOMB 5.2MG/SPRAY

N75702 001 Jul 03, 2001 Jan CRLD

NASALCROM

@ PHARMACIA UPJOHN 5.2MG/SPRAY

N20463 001 Jan 03, 1997 Jan DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

ADAMS RESP THERAP 30MG;600MG

N21620 002 Apr 29, 2004 May CAHN

+ 60MG;1.2GM

N21620 001 Apr 29, 2004 May CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
DELSYM

>A>	+ ADAMS RESP THERAP	EQ 30MG HBR/5ML	N18658 001 Oct 08, 1982 Jun CAHN
>D>	+ UCB INC	EQ 30MG HBR/5ML	N18658 001 Oct 08, 1982 Jun CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL
MUCINEX
ADAMS RESP THERAP 600MG
+ 1.2GM

N21282 001 Jul 12, 2002 May CAHN
N21282 002 Dec 18, 2002 May CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
MUCINEX D
ADAMS RESP THERAP 600MG;60MG
+ 1.2GM;120MG

N21585 001 Jun 22, 2004 May CAHN
N21585 002 Jun 22, 2004 May CAHN

IBUPROFEN

SUSPENSION/DROPS; ORAL
CHILDREN'S MOTRIN

>D>	+ MCNEIL	40MG/ML	N20603 001 Jun 10, 1996 Jun CAHN
>A>	+ MCNEIL CONS	40MG/ML	N20603 001 Jun 10, 1996 Jun CAHN

TABLET, CHEWABLE; ORAL
CHILDREN'S MOTRIN

>D>	MCNEIL	50MG	N20601 001 Nov 15, 1996 Jun CAHN
>A>	MCNEIL CONS	50MG	N20601 001 Nov 15, 1996 Jun CAHN

JUNIOR STRENGTH MOTRIN

>D>	+ MCNEIL	100MG	N20601 003 Nov 15, 1996 Jun CAHN
>A>	+ MCNEIL CONS	100MG	N20601 003 Nov 15, 1996 Jun CAHN

TABLET; ORAL
JUNIOR STRENGTH MOTRIN

>D>	MCNEIL	100MG	N20602 001 Jun 10, 1996 Jun CAHN
>A>	MCNEIL CONS	100MG	N20602 001 Jun 10, 1996 Jun CAHN

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL
CHILDREN'S MOTRIN COLD
>A> + MCNEIL CONS 100MG/5ML;15MG/5ML
>D> + MCNEIL CONS SPECLT 100MG/5ML;15MG/5ML

N21128 001 Aug 01, 2000 Jun CAHN
N21128 001 Aug 01, 2000 Jun CAHN

TABLET; ORAL
SINE-AID IB

>A>	MCNEIL CONS	200MG;30MG	N19899 001 Dec 31, 1992 Jun CAHN
>D>	MCNEIL CONS SPECLT	200MG;30MG	N19899 001 Dec 31, 1992 Jun CAHN

INSULIN PURIFIED PORK

>D>	INJECTABLE; INJECTION REGULAR ILETIN II (PORK)		
>D>	+ LILLY	100 UNITS/ML	N18344 001 Jun DISC
>A>	@	100 UNITS/ML	N18344 001 Jun DISC

INSULIN SUSP ISOPHANE BEEF/PORK

>D>	INJECTABLE; INJECTION NPH ILETIN I (BEEF-PORK)		
>D>	+ LILLY	100 UNITS/ML	N17936 002 Jun DISC

>D> INJECTABLE; INJECTION
 >D> NPH ILETIN I (BEEF-PORK)
 >A> @ LILLY 100 UNITS/ML N17936 002 Jun DISC

>D> INSULIN SUSP ISOPHANE PURIFIED PORK
 >D> INJECTABLE; INJECTION
 >D> NPH ILETIN II (PORK)
 >D> + LILLY 100 UNITS/ML N18345 001 Jun DISC
 >A> @ 100 UNITS/ML N18345 001 Jun DISC

>D> INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN
 >D> INJECTABLE; INJECTION
 >D> HUMULIN U
 >D> + LILLY 100 UNITS/ML N19571 002 Jun 10, 1987 Jun DISC
 >A> @ 100 UNITS/ML N19571 002 Jun 10, 1987 Jun DISC

>D> INSULIN ZINC SUSP PURIFIED PORK
 >D> INJECTABLE; INJECTION
 >D> LENTE ILETIN II (PORK)
 >D> + LILLY 100 UNITS/ML N18347 001 Jun DISC
 >A> @ 100 UNITS/ML N18347 001 Jun DISC

KETOCONAZOLE
 SHAMPOO; TOPICAL
 NIZORAL A-D
 >A> + MCNEIL CONS 1% N20310 001 Oct 10, 1997 Jun CAHN
 >D> + MCNEIL CONS SPECLT 1% N20310 001 Oct 10, 1997 Jun CAHN

KETOPROFEN
 TABLET; ORAL
 ACTRON
 @ BAYER 12.5MG N20499 001 Oct 06, 1995 Feb DISC
 ORUDIS KT
 @ WYETH CONS 12.5MG N20429 001 Oct 06, 1995 Feb DISC

LOPERAMIDE HYDROCHLORIDE
 SOLUTION; ORAL
 IMODIUM A-D
 >D> + MCNEIL 1MG/5ML N19487 001 Mar 01, 1988 Jun CAHN
 >A> + MCNEIL CONS 1MG/5ML N19487 001 Mar 01, 1988 Jun CAHN
 SUSPENSION; ORAL
 IMODIUM A-D
 >D> + MCNEIL 1MG/7.5ML N19487 002 Jul 08, 2004 Jun CAHN
 + 1MG/7.5ML N19487 002 Jul 08, 2004 Mar CDFR
 >A> + MCNEIL CONS 1MG/7.5ML N19487 002 Jul 08, 2004 Jun CAHN
 TABLET; ORAL
 IMODIUM A-D
 >D> + MCNEIL 2MG N19860 001 Nov 22, 1989 Jun CAHN
 >A> + MCNEIL CONS 2MG N19860 001 Nov 22, 1989 Jun CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE
 TABLET; ORAL
 IMODIUM ADVANCED
 >A> + MCNEIL CONS 2MG;125MG N21140 001 Nov 30, 2000 Jun CAHN
 >D> + MCNEIL CONS SPECLT 2MG;125MG N21140 001 Nov 30, 2000 Jun CAHN

LORATADINE

SYRUP; ORAL LORATADINE >A> SILARK	1MG/ML	N77421 001 Jun 29, 2006 Jun NEWA
TABLET; ORAL LORATADINE >A> APOTEX	10MG	N76471 001 Feb 14, 2006 Jan NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL M-ZOLE 3 COMBINATION PACK		
>D>	ALPHARMA US PHARMS 2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>D>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>D>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>D>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>D>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>D>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>D>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>D>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
M-ZOLE 7 DUAL PACK		
>A>	ACTAVIS MID ATLANTIC 2%,100MG	N74586 001 Jul 17, 1997 Jun CAHN
>D>	ALPHARMA US PHARMS 2%,100MG	N74586 001 Jul 17, 1997 Jun CAHN
CREAM; SUPPOSITORY; TOPICAL, VAGINAL M-ZOLE 3 COMBINATION PACK		
>A>	ACTAVIS MID ATLANTIC 2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>A>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>A>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>A>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>A>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>A>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>A>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
>A>	2%,200MG	N74926 001 Apr 16, 1999 Jun CAHN
CREAM; VAGINAL MICONAZOLE 7		
>A>	ACTAVIS MID ATLANTIC 2%	N74164 001 Mar 29, 1996 Jun CAHN
>D>	ALPHARMA US PHARMS 2%	N74164 001 Mar 29, 1996 Jun CAHN
SUPPOSITORY; VAGINAL MICONAZOLE NITRATE		
>A>	ACTAVIS MID ATLANTIC 100MG	N73507 001 Nov 19, 1993 Jun CAHN
>D>	ALPHARMA US PHARMS 100MG	N73507 001 Nov 19, 1993 Jun CAHN

MINOXIDIL

AEROSOL, FOAM; TOPICAL MEN'S ROGAINE + PHARMACIA AND UPJOHN 5%	N21812 001 Jan 20, 2006 Jan NEWA
--	----------------------------------

NAPROXEN SODIUM

CAPSULE; ORAL NAPROXEN SODIUM + BANNER PHARMACAPS EQ 200MG BASE	N21920 001 Feb 17, 2006 Feb NEWA
---	----------------------------------

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL NICORETTE GLAXOSMITHKLINE EQ 2MG BASE	N18612 004 Sep 25, 2000 Mar CRLD
--	----------------------------------

GUM, CHEWING; BUCCAL

NICORETTE

GLAXOSMITHKLINE	EQ 2MG BASE	N18612 003 Dec 23, 1998 Mar CRLD
	EQ 4MG BASE	N20066 003 Dec 23, 1998 Mar CRLD
	EQ 4MG BASE	N20066 004 Sep 25, 2000 Mar CRLD

NICORETTE (MINT)

GLAXOSMITHKLINE	EQ 2MG BASE	N18612 003 Dec 23, 1998 Apr CTNA
	EQ 4MG BASE	N20066 003 Dec 23, 1998 Apr CTNA

NICOTINE POLACRILEX

PERRIGO	EQ 2MG BASE	N76776 001 Sep 16, 2004 Apr CTNA
	EQ 2MG BASE	N76777 001 Sep 16, 2004 Apr CTNA
	EQ 4MG BASE	N76778 001 Sep 16, 2004 Apr CTNA
	EQ 4MG BASE	N76779 001 Sep 16, 2004 Apr CTNA
WATSON LABS	EQ 2MG BASE	N76569 001 Jul 29, 2004 Apr CTNA
	EQ 4MG BASE	N76568 002 Jul 29, 2004 Apr CTNA

TROCHE/LOZENGE; ORAL

NICOTINE POLACRILEX

PERRIGO R AND D	EQ 2MG BASE	N77007 001 Jan 31, 2006 Jan NEWA
	EQ 4MG BASE	N77007 002 Jan 31, 2006 Jan NEWA

PERMETHRIN

LOTION; TOPICAL

PERMETHRIN

>A>	ACTAVIS MID ATLANTIC	1%	N75014 001 Mar 28, 2000 Jun CAHN
>D>	ALPHARMA US PHARMS	1%	N75014 001 Mar 28, 2000 Jun CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

WOCKHARDT	EQ 75MG BASE	N76760 001 Feb 24, 2006 Feb NEWA
-----------	--------------	----------------------------------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2006

NO JUNE 2006 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2006 ADDITIONS

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>							
021652 001	5034394	Dec	18, 2011	DS	DP	D-40	Aug 02, 2007
	5034394*PED	Jun	18, 2012				
	5047407	Nov	17, 2009	DS	DP	U-257	
	5047407*PED	May	17, 2010				
	5089500	Jun	26, 2009			U-257	
	5089500*PED	Dec	26, 2009				
	5905082	May	18, 2016	DS	DP		
	5905082*PED	Nov	18, 2016				
	6294540	May	14, 2018	DS	DP	U-257	
	6294540*PED	Nov	14, 2018				
<u>ALBUTEROL SULFATE - PROAIR HFA</u>							
021457 001						I-235	Feb 03, 2009
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>							
020983 001	6131566	Apr	14, 2015	DP	U-716		
	6131566	Apr	14, 2015	DP	U-589		
	6532955	Apr	14, 2015	DP	U-716		
	6532955	Apr	14, 2015	DP	U-590		
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>							
021762 001						NC	Apr 07, 2008
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>							
021287 001	4661491	May	27, 2007			U-706	
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>							
020364 006						NS	Apr 11, 2009
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>							
020364 007						NS	Apr 11, 2009
<u>ANIDULAFUNGIN - ERAXIS</u>							
021632 001	5965525	Oct	12, 2016	DS	DP	U-540	
	6384013	Mar	19, 2012	DS			
	6743777	Mar	19, 2012	DP	U-540		
	6960564	Apr	12, 2021	DP	U-540		
<u>APREPITANT - EMEND</u>							
021549 001	5145684	Jan	25, 2011			DP	
<u>APREPITANT - EMEND</u>							
021549 002	5145684	Jan	25, 2011			DP	
<u>APREPITANT - EMEND</u>							
021549 003							
						>A> I-498	Jun 30, 2009
						>A> NS	Jun 30, 2009
						>A> NCE	Mar 26, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 001						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 002						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 003						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 004						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 005						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 006						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021713 001	6977257	Apr	24, 2022	DS	DP	I-488	Mar 01, 2008
<u>ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE - SEPTOCAIN</u>							
022010 001						NP	Mar 30, 2009
<u>AZELASTINE HYDROCHLORIDE - ASTELIN</u>							
020114 001						D-102	Feb 17, 2009

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES			EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX							
021852 001	4866048	Dec 29, 2007	DS	DP	U-88	NC	Jan 09, 2009
	4866048	Dec 29, 2007	DS	DP	U-193		
	5763426	Jun 09, 2015	DS	DP			
	6753013	Jan 27, 2020	DP	DP	U-88		
	6753013	Jan 27, 2020	DP	DP	U-193		
BETAXOLOL HYDROCHLORIDE - BETOPTIC S							
019845 001	>A> 4911920	Mar 27, 2007					
	>A> 4911920*PED	Sep 27, 2007					
BIVALIRUDIN - ANGIOMAX							
020873 001						I-486	Nov 30, 2008
BORTEZOMIB - VELCADE							
021602 001						ODE	Mar 25, 2012
BRIMONIDINE TARTRATE - ALPHAGAN P							
021770 001	5424078	Jun 13, 2012	DP				
	5424078*PED	Dec 13, 2012	DP				
	6562873	Jul 10, 2021	DP				
	6562873*PED	Jan 10, 2022	DP				
	6627210	Jul 18, 2021	DP				
	6627210*PED	Jan 18, 2022	DP				
	6641834	Jul 28, 2021	DP				
	6641834*PED	Jan 28, 2022	DP				
	6673337	Jul 26, 2021	DP				
	6673337*PED	Jan 26, 2022	DP				
BRINZOLAMIDE - AZOPT							
020816 001	>A> 5240923	Aug 31, 2010			U-224		
	>A> 5240923*PED	Mar 01, 2011					
	>A> 5378703	Apr 01, 2012			U-224		
	>A> 5378703*PED	Oct 01, 2012					
	>A> 5461081	Oct 24, 2012			U-225		
	>A> 5461081*PED	Apr 24, 2013					
BROMFENAC SODIUM - XIBROM							
021664 001						I-485	Jan 27, 2009
BUDESONIDE - PULMICORT RESPULES							
020929 001	6899099	Dec 23, 2018			U-645		
	6899099*PED	Jun 23, 2019					
BUDESONIDE - PULMICORT RESPULES							
020929 002	6899099	Dec 23, 2018			U-645		
	6899099*PED	Jun 23, 2019					
BUDESONIDE - RHINOCORT							
020746 001	6986904	Apr 29, 2017	DP	DP	U-699		
BUDESONIDE - RHINOCORT							
020746 002	6986904	Apr 29, 2017	DP	DP	U-699		
BUPROPION HYDROCHLORIDE - WELLBUTRIN XL							
021515 001						>A> I-497	Jun 12, 2009
BUPROPION HYDROCHLORIDE - WELLBUTRIN XL							
021515 002						>A> I-497	Jun 12, 2009
CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)							
021823 001						M-52	Jan 24, 2009
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100							
021485 002	4963590	Nov 27, 2007	DP	DP	U-219		
	5112861	May 12, 2009			U-219		
	5135950	Oct 31, 2010	DS	DP	U-219		
	6500867	Jun 29, 2020	DP	DP	U-219		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>				>A> NCE	Jun 28, 2011
021986 001					
<u>DASATINIB - SPRYCEL</u>				>A> NCE	Jun 28, 2011
021986 002					
<u>DASATINIB - SPRYCEL</u>				>A> NCE	Jun 28, 2011
021986 003					
<u>DECITABINE - DACOGEN</u>				NCE	May 02, 2011
021790 001					
<u>DEFERASIROX - EXJADE</u>					
021882 001	>A> 6465504	Jun 24, 2017	DS DP		
	>A> 6596750	Jun 24, 2017	DS	U-735	
<u>DEFERASIROX - EXJADE</u>					
021882 002	>A> 6465504	Jun 24, 2017	DS DP		
<u>DEFERASIROX - EXJADE</u>					
021882 003	>A> 6465504	Jun 24, 2017	DS DP		
<u>DESFLURANE - SUPRANE</u>					
020118 001	5617906	Apr 08, 2014	DP		
<u>DESLORATADINE - CLARINEX</u>					
021165 001	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-427	
	4659716*PED	Oct 01, 2007		U-427	
<u>DESLORATADINE - CLARINEX</u>					
021300 001	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-611	
	4659716*PED	Oct 01, 2007			
<u>DESLORATADINE - CLARINEX</u>					
021312 001	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-427	
	4659716*PED	Oct 01, 2007		U-427	
	>A> 5178878	Jan 12, 2010	DP		
	5607697	Jun 07, 2015	DP		
<u>DESLORATADINE - CLARINEX</u>					
021312 002	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-427	
	4659716*PED	Oct 01, 2007	DP		
	>A> 5178878	Jan 12, 2010	DP		
	5607697	Jun 07, 2015	DP		
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 24 HOUR</u>					
021605 001	4659716	Mar 31, 2007	DP	U-726	
	4659716	Mar 31, 2007	DP	U-644	
	4659716*PED	Oct 01, 2007	DP		
	6979463	Mar 28, 2022	DP		
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>					
021313 001	4659716	Mar 31, 2007	DP	U-707	NCE
	4659716*PED	Oct 01, 2007	DP		NC
	6100274	Jul 07, 2019	DP		PED
	6100274*PED	Jan 07, 2020	DP		
	6709676	Feb 18, 2021	DP	U-707	
<u>DESMOPRESSIN ACETATE - DDAVP</u>					
019955 001	7022340	Apr 30, 2023	DP		
<u>DESMOPRESSIN ACETATE - DDAVP</u>					
019955 002	7022340	Apr 30, 2023	DP		
<u>DOCETAXEL - TAXOTERE</u>					
020449 001	5750561	Jul 03, 2012	DP	I-490	Mar 22, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>					
021720 001	4895841	Nov 25, 2010	DS DP	U-713	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
021720 002	4895841	Nov	25, 2010	DS DP	U-713	
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
021676 001	5569652	Oct	29, 2013		U-1	
	5798338	Jul	10, 2015	DP		
	6787531	Aug	31, 2020	DP		
	6933395	Aug	11, 2017	DP		
	6958326	Dec	20, 2021	DP		
	RE37564	Jun	30, 2014	DP		
	RE37838	Jun	30, 2014	DP		
	RE38253	Jun	30, 2014	DP		
<u>EFAVIRENZ - SUSTIVA</u>						
020972 001	5519021	May	21, 2013	DS DP		
	5663169	Sep	02, 2014		U-257	
	5811423	Aug	07, 2012	DS DP	U-256	
	6238695	Apr	06, 2019	DP		
<u>EFAVIRENZ - SUSTIVA</u>						
020972 002	5519021	May	21, 2013	DS DP		
	5663169	Sep	02, 2014		U-257	
	5811423	Aug	07, 2012	DS DP	U-256	
	6238695	Apr	06, 2019	DP		
<u>EFAVIRENZ - SUSTIVA</u>						
020972 003	5519021	May	21, 2013	DS DP		
	5663169	Sep	02, 2014		U-257	
	5811423	Aug	07, 2012	DS DP	U-256	
	6238695	Apr	06, 2019	DP		
<u>EFAVIRENZ - SUSTIVA</u>						
021360 002	5519021	May	21, 2013	DS DP		
<u>EMTRICITABINE - EMTRIVA</u>						
021500 001	5210085	May	11, 2010		NCE	
	5210085*PED	Nov	11, 2010		PED	
	5814639	Sep	29, 2015			
	5814639*PED	Mar	29, 2016			
	5914331	Sep	29, 2015			
	5914331*PED	Mar	29, 2016			
	6642245	Nov	04, 2020		U-541	
	6642245*PED	May	04, 2021			
	6703396	Mar	09, 2021	DS DP		
	6703396*PED	Sep	09, 2021			
<u>EMTRICITABINE - EMTRIVA</u>						
021896 001	5210085	May	11, 2010		U-257	
	5210085*PED	Nov	11, 2010			
	5814639	Sep	29, 2015	DS DP		
	5814639*PED	Mar	29, 2016			
	5914331	Sep	29, 2015	DS		
	5914331*PED	Mar	29, 2016			
	6642245	Nov	04, 2020		U-257	
	6642245*PED	May	04, 2021			
	6703396	Mar	09, 2021	DS DP		
	6703396*PED	Sep	09, 2021			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
021752 001	5210085	May 11, 2010		U-248	NCE	Jul 02, 2008
	5210085	May 11, 2010		U-541	PED	Jan 02, 2009
	5210085*PED	Nov 11, 2010				
	5814639	Sep 29, 2015	DS	DP		
	5814639*PED	Mar 29, 2016				
	5914331	Sep 29, 2015	DS	DP	U-248	
	5914331*PED	Mar 29, 2016				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS	DP		
	6703396*PED	Sep 09, 2021				
<u>ENTACAPONE - COMTAN</u>						
020796 001	4963590	Nov 27, 2007	DP	U-219		
	5112861	May 12, 2009		U-219		
	5135950	Oct 31, 2010	DS	DP	U-219	
	6599530	Sep 14, 2018	DP	U-219		
<u>EPLERENONE - INSPRA</u>						
021437 001	4559332	Apr 09, 2007	DS	DP	U-537	
<u>EPLERENONE - INSPRA</u>						
021437 002	4559332	Apr 09, 2007	DS	DP	U-537	
<u>EPLERENONE - INSPRA</u>						
021437 003	4559332	Apr 09, 2007	DS	DP	U-537	
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021153 001	4738974	Apr 19, 2007	DS	DP	U-635	I-484
	4738974	Apr 19, 2007	DS	DP	U-373	NPP
	4738974*PED	Oct 19, 2007			U-373	
	4786505	Apr 20, 2007	DP	U-373		
	4786505	Apr 20, 2007	DP	U-729		
	4853230	Apr 20, 2007	DP	U-729		
	4853230	Apr 20, 2007	DP	U-373		
	5690960	Nov 25, 2014	DP	U-729		
	5690960	Nov 25, 2014	DP	U-373		
	5714504	Feb 03, 2015	DP	U-729		
	5714504	Feb 03, 2015	DP	U-373		
	5877192	May 27, 2014	DP	U-373		
	5877192	May 27, 2014	DP	U-729		
	5900424	May 04, 2016	DS	U-729		
	5900424	May 04, 2016	DS	U-373		
	6369085	May 25, 2018	DS	DP	U-729	
	6428810	Nov 03, 2019	DP	U-469		
	6428810	Nov 03, 2019	DP	U-729		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>							
021153 002	4738974	Apr 19, 2007	DS	DP	U-635	I-484	Nov 24, 2007
	4738974	Apr 19, 2007	DS	DP	U-373	NPP	Apr 28, 2009
	4738974*PED	Oct 19, 2007			U-373		
	4786505	Apr 20, 2007		DP	U-373		
	4786505	Apr 20, 2007		DP	U-729		
	4853230	Apr 20, 2007		DP	U-729		
	4853230	Apr 20, 2007		DP	U-373		
	5690960	Nov 25, 2014		DP	U-729		
	5690960	Nov 25, 2014		DP	U-373		
	5714504	Feb 03, 2015		DP	U-729		
	5714504	Feb 03, 2015		DP	U-373		
	5877192	May 27, 2014		DP	U-373		
	5877192	May 27, 2014		DP	U-729		
	5900424	May 04, 2016	DS		U-729		
	5900424	May 04, 2016	DS		U-373		
	6369085	May 25, 2018	DS	DP	U-729		
	6428810	Nov 03, 2019		DP	U-469		
	6428810	Nov 03, 2019		DP	U-729		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>							
021840 001						NP	May 25, 2009
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>							
021180 001	5876746	Nov 20, 2015		DP	U-514		
<u>ETHINYL ESTRADIOL; NORETHINDRONE - OVCON-35</u>							
021490 001	6667050	Apr 06, 2019		DP	U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE</u>							
021871 001	5552394	Jul 22, 2014		U-1		NP	Feb 17, 2009
<u>EXEMESTANE - AROMASIN</u>							
020753 001						I-495	Oct 05, 2008
<u>EZETIMIBE - ZETIA</u>							
021445 001	7030106	Jan 25, 2022		DP		I-493	May 23, 2009
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>							
021695 001						>A> M-47	Oct 21, 2008
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>							
021695 003						>A> M-47	Oct 21, 2008
<u>FENOFIBRATE - FENOFIBRATE</u>							
076433 001						PC	May 22, 2006
<u>FENOFIBRATE - FENOFIBRATE</u>							
076433 002						PC	May 22, 2006
<u>FENOFIBRATE - LIPOFEN</u>							
021612 001	5545628	Jan 10, 2015			U-701		
<u>FENOFIBRATE - LIPOFEN</u>							
021612 002	5545628	Jan 10, 2015			U-701		
<u>FENOFIBRATE - LIPOFEN</u>							
021612 003	5545628	Jan 10, 2015			U-701		
<u>FENOFIBRATE - TRICOR</u>							
021656 001	7037529	Jan 09, 2018		DP			
	7041319	Jan 09, 2018		DP			
<u>FENOFIBRATE - TRICOR</u>							
021656 002	7037529	Jan 09, 2018		DP			
	7041319	Jan 09, 2018		DP			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL HYDROCHLORIDE - IONSYS					
021338 001	>A> 5232438	Oct 03, 2008	DP	U-736	NDF
	>A> 5445606	Dec 11, 2011	DP		
	>A> 5697896	Dec 16, 2014	DP		
	>A> 5843014	Dec 01, 2015	DP		
	>A> 6169920	Jan 02, 2018	DP		
	>A> 6171294	Jun 05, 2015		U-736	
	>A> 6181963	Nov 02, 2019	DP		
	>A> 6195582	Jan 28, 2019	DP	U-736	
	>A> 6216033	Jun 05, 2015	DP		
	>A> 6317626	Jun 02, 2012	DP		
	>A> 6425892	Jun 05, 2015		U-736	
	>A> 6842640	Jun 02, 2015	DP		
	>A> 6881208	Apr 19, 2022		U-736	
	>A> 6975902	Apr 01, 2024	DP		
	>A> 7018370	Jun 05, 2015		U-736	
	>A> 7027859	Sep 26, 2014	DP		
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR					
021704 001	RE39069	May 29, 2018	DP		
FINASTERIDE - FINASTERIDE					
076340 001				>A> PC	Dec 16, 2006
FLUNISOLIDE - AEROSPIN HFA					
021247 001				NP	Jan 27, 2009
FLUOCINOLONE ACETONIDE - RETISERT					
021737 001	6217895	Mar 22, 2019	DP	U-708	
	6548078	Mar 22, 2019	DP	U-708	
FLUOCINONIDE - VANOS					
021758 001				I-487	Mar 02, 2009
FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY					
021235 001	RE39030	May 29, 2017	DP	U-397	
	RE39030	May 29, 2017	DP	U-396	
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 001	5658549	Sep 19, 2014	DP	U-710	NPP
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 002	5658549	Sep 19, 2014	DP	U-710	NPP
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 003	5658549	Sep 19, 2014	DP	U-710	NPP
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50					
021077 001	4992474	Feb 12, 2008		U-211	
	4992474*PED	Aug 12, 2008		U-211	
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008		U-211	
	5225445*PED	Aug 12, 2008		U-211	
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50					
021077 002	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50					
021077 003	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA					
021254 001				>A> NP	Jun 08, 2009
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA					
021254 002				>A> NP	Jun 08, 2009
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA					
021254 003				>A> NP	Jun 08, 2009
FROVATRIPTAN SUCCINATE - FROVA					
021006 001	5464864	Nov 07, 2015	U-436		
FULVESTRANT - FASLODEX					
021344 001	4659516	Oct 01, 2006			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER					
021615 001				NDF	Apr 01, 2008
GALANTAMINE HYDROBROMIDE - RAZADYNE ER					
021615 002				NDF	Apr 01, 2008
GALANTAMINE HYDROBROMIDE - RAZADYNE ER					
021615 003				NDF	Apr 01, 2008
GLIMEPIRIDE - AMARYL					
020496 001				M-54 PED	Nov 28, 2008 May 28, 2009
GLIMEPIRIDE - AMARYL					
020496 002				M-54 PED	Nov 28, 2008 May 28, 2009
GLIMEPIRIDE - AMARYL					
020496 003				M-54 PED	Nov 28, 2008 May 28, 2009
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL					
021700 001	5002953	Sep 17, 2011	DS DP U-690		
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP U-690		
	5741803*PED	Oct 21, 2015			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL					
021700 002	5002953	Sep 17, 2011	DS DP U-690		
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP U-690		
	5741803*PED	Oct 21, 2015			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>							
021700 003	5002953	Sep	17, 2011	DS	DP	U-690	
	5002953*PED	Mar	17, 2012				
	5741803	Apr	21, 2015	DS	DP	U-690	
	5741803*PED	Oct	21, 2015				
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>							
021859 001						NCE	Dec 02, 2010
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>							
020818 004						NS	Apr 28, 2009
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>							
020818 005						NS	Apr 28, 2009
<u>IBANDRONATE SODIUM - BONIVA</u>							
021455 001	4927814	Jul	09, 2007	DS	DP	U-642	
	6143326	Apr	21, 2017			U-642	
<u>IBANDRONATE SODIUM - BONIVA</u>							
021858 001	4927814	Jul	09, 2007	DS	DP	U-700	
						NDF	Jan 06, 2009
						NCE	May 16, 2008
<u>IBUPROFEN LYSINE - NEOPROFEN</u>							
021903 001						NE	Apr 13, 2009
						ODE	Apr 13, 2013
<u>IMATINIB MESYLATE - GLEEVEC</u>							
021335 001	5521184	Jan	04, 2015			I-392	May 20, 2006
	5521184*PED	Jul	04, 2015			I-376	Dec 20, 2005
	6894051	May	23, 2019	DS	DP	U-649	
	6894051*PED	Nov	23, 2019			NCE	May 10, 2006
						ODE	Feb 01, 2009
						ODE	May 10, 2008
						PED	Aug 01, 2009
						PED	Nov 10, 2008
						PED	Nov 20, 2006
						PED	Nov 10, 2006
						PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>							
021335 002	5521184	Jan	04, 2015			I-392	May 20, 2006
	5521184*PED	Jul	04, 2015			I-376	Dec 20, 2005
	6894051	May	23, 2019	DS	DP	U-649	
	6894051*PED	Nov	23, 2019			NCE	May 10, 2006
						ODE	Feb 01, 2009
						ODE	May 10, 2008
						PED	Aug 01, 2009
						PED	Nov 10, 2008
						PED	Nov 20, 2006
						PED	Nov 10, 2006
						PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>							
021588 001	5521184	Jan	04, 2015			I-392	May 20, 2006
	5521184*PED	Jul	04, 2015			I-376	Dec 20, 2005
	6894051	May	23, 2019	DS	DP	U-649	
	6894051*PED	Nov	23, 2019			NCE	May 10, 2006
						ODE	Feb 01, 2009
						ODE	May 10, 2008
						PED	Aug 01, 2009
						PED	Nov 10, 2008
						PED	Nov 20, 2006
						PED	Nov 10, 2006
						PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>							
021588 002	5521184	Jan	04, 2015			I-392	May 20, 2006
	5521184*PED	Jul	04, 2015			I-376	Dec 20, 2005
	6894051	May	23, 2019	DS	DP	U-649	
	6894051*PED	Nov	23, 2019			NCE	May 10, 2006
						ODE	Feb 01, 2009
						ODE	May 10, 2008
						PED	Aug 01, 2009
						PED	Nov 10, 2008
						PED	Nov 20, 2006
						PED	Nov 10, 2006
						PED	Jun 20, 2006

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
021536 001					I-489	Oct 19, 2008
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
021868 001	5740794	Apr	21, 2015	DP	NP	Jan 27, 2009
	5997848	Mar	07, 2014		U-704	
	6051256	Mar	07, 2014	DP		
	6257233	May	14, 2019		U-704	
	6423344	Mar	07, 2014	DP		
	6543448	Sep	21, 2014	DP		
	6546929	May	14, 2019		U-704	
	6582728	Jun	24, 2020	DP		
	6592904	Mar	07, 2014	DP		
	6685967	Sep	11, 2018	DP		
	6737045	Mar	07, 2014		U-704	
	RE37872	Feb	12, 2010	DP		
	RE38385	Feb	12, 2010	DP		
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
021868 002	5740794	Apr	21, 2015	DP	NP	Jan 27, 2009
	5997848	Mar	07, 2014		U-704	
	6051256	Mar	07, 2014	DP		
	6257233	May	14, 2019		U-704	
	6423344	Mar	07, 2014	DP		
	6543448	Sep	21, 2014	DP		
	6546929	May	14, 2019		U-704	
	6582728	Jun	24, 2020	DP		
	6592904	Mar	07, 2014	DP		
	6685967	Sep	11, 2018	DP		
	6737045	Mar	07, 2014		U-704	
	RE37872	Feb	12, 2010	DP		
	RE38385	Feb	12, 2010	DP		
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
021527 001	6983743	May	26, 2020	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
020406 001	6749864	Feb	13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
020406 002	6749864	Feb	13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
021281 001	6749864	Feb	13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
021281 002	6749864	Feb	13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
021428 001	6749864	Feb	13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
021428 002	6749864	Feb	13, 2007	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 003	5968976	Mar	19, 2016	DP	U-613	
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 004	5968976	Mar	19, 2016	DP	U-613	
<u>LENALIDOMIDE - REVLIMID</u>						
021880 001	5635517	Jul	24, 2016	DS	ODE	Dec 27, 2012
	6045501	Aug	28, 2018		U-694	
	6315720	Oct	23, 2020		U-694	
	6555554	Jul	24, 2016	DP		
	6561976	Aug	28, 2018		U-694	
	6561977	Oct	23, 2020		U-694	
	6755784	Oct	23, 2020		U-694	
	6908432	Aug	28, 2018		U-694	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
021880 002	5635517	Jul 24, 2016	DS		ODE	Dec 27, 2012
	6045501	Aug 28, 2018		U-694		
	6315720	Oct 23, 2020		U-694		
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018		U-694		
	6561977	Oct 23, 2020		U-694		
	6755784	Oct 23, 2020		U-694		
	6908432	Aug 28, 2018		U-694		
<u>LEVETIRACETAM - KEPPTRA</u>						
021035 004	>A> 4943639	Jul 14, 2008	DS		NPP	Jun 21, 2008
<u>LEVOBETAXOLOL HYDROCHLORIDE - BETAXON</u>						
021114 001	>A> 4911920	Mar 27, 2007		U-369		
	>A> 4911920*PED	Sep 27, 2007				
	>A> 5540918	Jul 30, 2013				
	>A> 5540918*PED	Jan 30, 2014				
<u>LIDOCAINE; TETRACAIN - SYNERA</u>						
021623 001					NC	Jun 23, 2008
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
021906 001	5541206	Jul 30, 2013	DS	DP	U-688	
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014		U-688		
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014	DS	DP		
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014		U-688		
	5674882*PED	Apr 07, 2015				
	5846987	Dec 29, 2012		U-688		
	5846987*PED	Jun 29, 2013				
	5886036	Dec 29, 2012	DP			
	5886036*PED	Jun 29, 2013				
	6037157	Jun 26, 2016		U-688		
	6037157*PED	Dec 26, 2016				
	6703403	Jun 26, 2016		U-688		
	6703403*PED	Dec 26, 2016				
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
021249 001	7011848	Sep 20, 2013		U-712		
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
021249 002	7011848	Sep 20, 2013		U-712		
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
021249 003	7011848	Sep 20, 2013		U-712		
<u>LUBIPROSTONE - AMITIZA</u>						
021908 001	5284858	Feb 08, 2011	DS	DP		
	5317032	May 31, 2011	DS	DP	U-717	
	6414016	Sep 05, 2020	DS	DP	U-717	
	6583174	Oct 16, 2020	DS	DP		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
021850 001	6489346	Jul 16, 2016	DS	DP	U-623	
	6489346	Jul 16, 2016	DS	DP	U-588	
	6645988	Jul 16, 2016	DS	DP	U-623	
	6645988	Jul 16, 2016	DS	DP	U-588	
	6699885	Jul 16, 2016		U-623		
	6699885	Jul 16, 2016		U-588		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID							
021850 002	6489346	Jul 16, 2016	DS	DP	U-623		
	6489346	Jul 16, 2016	DS	DP	U-588		
	6645988	Jul 16, 2016	DS	DP	U-623		
	6645988	Jul 16, 2016	DS	DP	U-588		
	6699885	Jul 16, 2016			U-623		
	6699885	Jul 16, 2016			U-588		
MECASERMIN RINFABATE RECOMBINANT - IPLEX							
021884 001	5200509	Apr 06, 2010	DS				
	5681818	Oct 28, 2014			U-697		
MELOXICAM - MOBIC							
020938 001						ODE PED	Aug 11, 2012 Feb 11, 2013
MELOXICAM - MOBIC							
020938 002						ODE PED	Aug 11, 2012 Feb 11, 2013
MELOXICAM - MOBIC							
021530 001						I-469 ODE PED PED	Aug 11, 2008 Aug 11, 2012 Feb 11, 2013 Feb 11, 2009
MEQUINOL; TRETINOIN - SOLAGE							
020922 001	5194247	Dec 10, 2013		DP	U-294		
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
021410 001	5002953	Sep 17, 2011	DS	DP	U-690	I-494	May 19, 2009
	5002953	Sep 17, 2011	DS	DP	U-734		
	5002953	Sep 17, 2011	DS	DP	U-691		
	5002953	Sep 17, 2011	DS	DP	U-493		
>A> 5741803	Apr 21, 2015	DS	DP	U-734			
>A> 5741803	Apr 21, 2015	DS	DP	U-493			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
021410 002	5002953	Sep 17, 2011	DS	DP	U-690	I-494	May 19, 2009
	5002953	Sep 17, 2011	DS	DP	U-734		
	5002953	Sep 17, 2011	DS	DP	U-691		
	5002953	Sep 17, 2011	DS	DP	U-493		
>A> 5741803	Apr 21, 2015	DS	DP	U-734			
>A> 5741803	Apr 21, 2015	DS	DP	U-493			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
021410 003	5002953	Sep 17, 2011	DS	DP	U-691	I-494	May 19, 2009
	5002953	Sep 17, 2011	DS	DP	U-734		
	5002953	Sep 17, 2011	DS	DP	U-690		
	5002953	Sep 17, 2011	DS	DP	U-493		
>A> 5741803	Apr 21, 2015	DS	DP	U-734			
>A> 5741803	Apr 21, 2015	DS	DP	U-493			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
021410 004	5002953	Sep 17, 2011	DS	DP	U-691	I-494	May 19, 2009
	5002953	Sep 17, 2011	DS	DP	U-734		
	5002953	Sep 17, 2011	DS	DP	U-690		
	5002953	Sep 17, 2011	DS	DP	U-493		
>A> 5741803	Apr 21, 2015	DS	DP	U-734			
>A> 5741803	Apr 21, 2015	DS	DP	U-493			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>							
021410 005	5002953	Sep	17, 2011	DS	DP	U-690	I-494
	5002953	Sep	17, 2011	DS	DP	U-734	
	5002953	Sep	17, 2011	DS	DP	U-691	
	5002953	Sep	17, 2011	DS	DP	U-493	
	>A> 5741803	Apr	21, 2015	DS	DP	U-734	
	>A> 5741803	Apr	21, 2015	DS	DP	U-493	
	>A> 5741803*PED	Oct	21, 2015				
<u>METHYLPHENIDATE - DAYTRANA</u>							
021514 001	5958446	Dec	12, 2012	DP		NDF	Apr 06, 2009
	6210705	Sep	30, 2018	DP	U-727		
	6348211	Sep	30, 2018	DP	U-727		
<u>METHYLPHENIDATE - DAYTRANA</u>							
021514 002	5958446	Dec	12, 2012	DP		NDF	Apr 06, 2009
	6210705	Sep	30, 2018	DP	U-727		
	6348211	Sep	30, 2018	DP	U-727		
<u>METHYLPHENIDATE - DAYTRANA</u>							
021514 003	5958446	Dec	12, 2012	DP		NDF	Apr 06, 2009
	6210705	Sep	30, 2018	DP	U-727		
	6348211	Sep	30, 2018	DP	U-727		
<u>METHYLPHENIDATE - DAYTRANA</u>							
021514 004	5958446	Dec	12, 2012	DP		NDF	Apr 06, 2009
	6210705	Sep	30, 2018	DP	U-727		
	6348211	Sep	30, 2018	DP	U-727		
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>							
021026 001	4911932	Mar	27, 2007	DP	U-718	NP	Feb 16, 2009
<u>MINOXIDIL - MEN'S ROGAINE</u>							
021812 001	6946120	Apr	20, 2019	DP	U-702	NDF	Jan 20, 2009
<u>MODAFINIL - PROVIGIL</u>							
020717 001	4927855	May	22, 2007		U-255	I-449	Jan 23, 2007
	4927855*PED	Nov	22, 2007			ODE	Dec 24, 2005
	RE37516	Oct	06, 2014		U-255	PED	Jul 23, 2007
	RE37516*PED	Apr	06, 2015			PED	Jun 24, 2006
<u>MODAFINIL - PROVIGIL</u>							
020717 002	4927855	May	22, 2007	U-255		I-449	Jan 23, 2007
	4927855*PED	Nov	22, 2007			ODE	Dec 24, 2005
	RE37516	Oct	06, 2014	U-255		PED	Jul 23, 2007
	RE37516*PED	Apr	06, 2015			PED	Jun 24, 2006
<u>MORPHINE SULFATE - KDIAN</u>							
020616 004	5378474	Mar	23, 2010				
<u>MORPHINE SULFATE - KDIAN</u>							
020616 005	5202128	Apr	13, 2010				
	5378474	Mar	23, 2010				
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>							
021085 001	4990517	Dec	08, 2011	DS	DP	U-298	
	6610327	Oct	29, 2019	DP		U-298	
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>							
021277 001	4990517	Dec	08, 2011	DS	DP	U-298	
	6548079	Jul	25, 2020	DP		U-298	
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>							
021598 001	4990517	Dec	08, 2011	DS	DP	U-709	
	4990517*PED	Jun	08, 2012				

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALTREXONE - VIVITROL</u>					
021897 001	5792477	May 02, 2017	DP	NDF	Apr 13, 2009
	5916598	May 02, 2017	DP		
	6110503	May 02, 2017	DP		
	6194006	Dec 30, 2018	DP		
	6264987	May 19, 2020	DP		
	6331317	Nov 12, 2019	DP		
	6379703	Dec 30, 2018	DP		
	6379704	May 19, 2020	DP		
	6395304	Nov 12, 2019	DP		
	6403114	May 02, 2017	DP		
	6495164	May 25, 2020	DP		
	6495166	Nov 12, 2019	DP		
	6534092	May 19, 2020	DP		
	6537586	Nov 12, 2019	DP		
	6596316	Dec 30, 2018	DP		
	6667061	May 25, 2020	DP		
	6713090	Nov 12, 2019	DP		
	6939033	Nov 12, 2019	DP		
<u>NELARABINE - ARRANON</u>					
021877 001	5747472	Feb 20, 2013	U-696		
	5747472	Feb 20, 2013	U-695		
	5747472	Feb 20, 2013	U-689		
	5821236	Feb 20, 2013	U-695		
<u>NIACIN - NIASPAN</u>					
020381 001	7011848	Sep 20, 2013	U-712		
<u>NIACIN - NIASPAN</u>					
020381 002	7011848	Sep 20, 2013	U-712		
<u>NIACIN - NIASPAN</u>					
020381 003	7011848	Sep 20, 2013	U-712		
<u>NIACIN - NIASPAN</u>					
020381 004	7011848	Sep 20, 2013	U-712		
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>					
020381 005	7011848	Sep 20, 2013	U-712		
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>					
077007 001			PC		Aug 21, 2006
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>					
077007 002			PC		Aug 21, 2006
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 001	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 002	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 003	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 004	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 005	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
021008 001	5538739	Jul	23, 2013	DP	M-55	May 10, 2009
	5538739*PED	Jan	23, 2014		ODE	Nov 25, 2005
	5639480	Jun	17, 2014	DP	PED	Nov 10, 2009
	5639480*PED	Dec	17, 2014		PED	May 25, 2006
	5688530	Nov	18, 2014	U-268		
	5688530*PED	May	18, 2015			
	5922338	Jul	13, 2016	DP		
	5922338*PED	Jan	13, 2017			
	5922682	Jul	13, 2016	DP		
	5922682*PED	Jan	13, 2017			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
021008 002	5538739	Jul	23, 2013		M-55	May 10, 2009
	5538739*PED	Jan	23, 2014		ODE	Nov 25, 2005
	5639480	Jun	17, 2014	DP	PED	Nov 10, 2009
	5639480*PED	Dec	17, 2014		PED	May 25, 2006
	5688530	Nov	18, 2014	U-268		
	5688530*PED	May	18, 2015			
	5922338	Jul	13, 2016	DP		
	5922338*PED	Jan	13, 2017			
	5922682	Jul	13, 2016	DP		
	5922682*PED	Jan	13, 2017			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
021008 003	5538739	Jul	23, 2013		M-55	May 25, 2009
	5538739*PED	Jan	23, 2014		ODE	Nov 25, 2005
	5639480	Jun	17, 2014	DP	PED	Nov 25, 2009
	5639480*PED	Dec	17, 2014		PED	May 25, 2006
	5688530	Nov	18, 2014	U-268		
	5688530*PED	May	18, 2015			
	5922338	Jul	13, 2016	DP		
	5922338*PED	Jan	13, 2017			
	5922682	Jul	13, 2016	DP		
	5922682*PED	Jan	13, 2017			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
021849 001	6489346	Jul	16, 2016	DS	DP	U-588
	6645988	Jul	16, 2016	DS	DP	
	6699885	Jul	16, 2016		U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
021849 002	6489346	Jul	16, 2016	DS	DP	U-623
	6489346	Jul	16, 2016	DS	DP	U-588
	6645988	Jul	16, 2016	DS	DP	
	6699885	Jul	16, 2016		U-623	
	6699885	Jul	16, 2016		U-588	
<u>OXALIPLATIN - ELOXATIN</u>						
021492 001	>A> 5338874	Apr	07, 2013	DS		
	5420319	Aug	09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>						
021492 002	>A> 5338874	Apr	07, 2013	DS		
	5420319	Aug	09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>						
021759 001	5420319	Aug	08, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>						
021759 002	5420319	Aug	08, 2016	DS		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
021014 001	7037525	Feb	12, 2018		U-724	
<u>OXCARBAZEPINE - TRILEPTAL</u>						
021014 002	7037525	Feb	12, 2018		U-724	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXCARBAZEPINE - TRILEPTAL</u>		Feb 12, 2018		U-724		
021014 003	7037525					
<u>OXCARBAZEPINE - TRILEPTAL</u>		Feb 12, 2018		U-724		
021285 001	7037525					
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
021611 001				>A> NDF		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>				>A> NDF		
021611 002				>A> NDF		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>				>A> NDF		
021610 001				>A> NDF		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>				>A> NDF		
021610 002				>A> NDF		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>				>A> NDF		
021610 003				>A> NDF		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>				>A> NDF		
021610 004				>A> NDF		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
020667 001	4843086	Jun	27, 2006	U-231		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
020667 002	4843086	Jun	27, 2006	U-231		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>				U-231		
020667 003	4843086	Jun	27, 2006	U-231		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>				U-231		
020667 004	4843086	Jun	27, 2006	U-231		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>				U-231		
020667 005	4843086	Jun	27, 2006	U-231		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>				U-231		
020667 006	4843086	Jun	27, 2006	U-231		
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>						
076056 001				PC		
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>				PC		
076056 002				PC		
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>				PC		
076056 003				PC		
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 006	4879288	Sep	26, 2011	DS	DP	U-550
<u>QUETIAPINE FUMARATE - SEROQUEL</u>				U-550		
020639 007	4879288	Sep	26, 2011	DS	DP	U-550
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
020815 001	RE38968	Jul	28, 2012	U-662		
	RE38968	Jul	28, 2012	U-657		
	RE39049	Jul	28, 2012	U-662		
	RE39049	Jul	28, 2012	U-657		
	RE39050	Mar	02, 2014	U-662		
	RE39050	Mar	02, 2014	U-657		
<u>RAMIPRIL - ALTACE</u>						
019901 001	5061722	Oct	19, 2008			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RANOLAZINE - RANEXA</u>					
021526 002	4567264	May 18, 2007	DS	NCE	Jan 27, 2011
	6303607	May 27, 2019		U-705	
	6369062	May 27, 2019	DP		
	6479496	May 27, 2019		U-705	
	6503911	May 27, 2019	DP		
	6525057	May 27, 2019		U-705	
	6562826	May 27, 2019		U-705	
	6617328	May 27, 2019	DP		
	6620814	May 27, 2019		U-705	
	6852724	May 27, 2019		U-705	
	6864258	May 27, 2019		U-705	
<u>RASAGILINE MESYLATE - AZILECT</u>					
021641 001	>A> 5387612	Feb 07, 2012		U-219	NCE
	>A> 5453446	Feb 07, 2012		U-219	May 16, 2011
	5457133	Feb 07, 2012	DS	DP	
	>A> 5532415	Jul 02, 2013	DS		
	>A> 5786390	Feb 07, 2012		DP	
	6126968	Sep 18, 2016		DP	
<u>RASAGILINE MESYLATE - AZILECT</u>					
021641 002	>A> 5387612	Feb 07, 2012		U-219	NCE
	>A> 5453446	Feb 07, 2012		U-219	May 16, 2011
	5457133	Feb 07, 2012	DS	DP	
	>A> 5532415	Jul 02, 2013	DS		
	>A> 5786390	Feb 07, 2012		DP	
	6126968	Sep 18, 2016		DP	
<u>RIFAXIMIN - XIFAXAN</u>					
021361 001	7045620	May 22, 2024	DS		
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 001				M-52	Jan 24, 2009
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 002				M-52	Jan 24, 2009
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 003				M-52	Jan 24, 2009
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 003	4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 004	4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 005	4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 006	4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
021025 001	4948807	Aug 14, 2012	DS	U-322	
<u>ROCURONIUM BROMIDE - ZEMURON</u>					
020214 003	4894369	Apr 13, 2008			
<u>SALMETEROL XINAFOATE - SEREVENT</u>					
020236 001	4992474	Feb 12, 2008			
	4992474*PED	Aug 12, 2008			
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008		U-182	
	5225445*PED	Aug 12, 2008			

PREScription AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>SALMETEROL XINAFOATE - SEREVENT</u>								
020692 001	4992474	Feb	12, 2008					
	4992474*PED	Aug	12, 2008					
	5126375	Feb	12, 2008					
	5126375*PED	Aug	12, 2008					
	5225445	Feb	12, 2008		U-211			
	5225445*PED	Aug	12, 2008					
<u>SELEGILINE - EMSAM</u>								
021336 001	RE34579	Aug	18, 2007	DS	DP	U-711	NDF	Feb 27, 2009
<u>SELEGILINE - EMSAM</u>								
021336 002	RE34579	Aug	18, 2007	DS	DP	U-711	NDF	Feb 27, 2009
<u>SELEGILINE - EMSAM</u>								
021336 003	RE34579	Aug	18, 2007	DS	DP	U-711	NDF	Feb 27, 2009
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>								
021179 001	7014846	Aug	11, 2013		DP	U-246		
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>								
021179 002	7014846	Aug	11, 2013		DP	U-246		
<u>SIMVASTATIN - SIMVASTATIN</u>								
076052 001						>A> PC		Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>								
076052 002						>A> PC		Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>								
076052 003						>A> PC		Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>								
076052 004						>A> PC		Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>								
076285 005						>A> PC		Dec 20, 2006
<u>SIMVASTATIN - ZOCOR</u>								
019766 001	RE36481 ***	Jul	10, 2007		U-300			
	RE36481*PED	Jan	10, 2008		U-300			
	RE36520 ***	May	26, 2009		U-300			
	RE36520*PED	Nov	26, 2009		U-300			
<u>SIMVASTATIN - ZOCOR</u>								
019766 002	RE36481 ***	Jul	10, 2007		U-300			
	RE36481*PED	Jan	10, 2008		U-300			
	RE36520 ***	May	26, 2009		U-300			
	RE36520*PED	Nov	26, 2009		U-300			
<u>SIMVASTATIN - ZOCOR</u>								
019766 003	RE36481 ***	Jul	10, 2007		U-300			
	RE36481*PED	Jan	10, 2008		U-300			
	RE36520 ***	May	26, 2009		U-300			
	RE36520*PED	Nov	26, 2009		U-300			
<u>SIMVASTATIN - ZOCOR</u>								
019766 004	RE36481 ***	Jul	10, 2007		U-300			
	RE36481*PED	Jan	10, 2008		U-300			
	RE36520 ***	May	26, 2009		U-300			
	RE36520*PED	Nov	26, 2009		U-300			
<u>SIMVASTATIN - ZOCOR</u>								
019766 005	RE36481 ***	Jul	10, 2007		U-300			
	RE36481*PED	Jan	10, 2008		U-300			
	RE36520 ***	May	26, 2009		U-300			
	RE36520*PED	Nov	26, 2009		U-300			
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>								
021892 001	5616346	May	18, 2013	DP	U-715	NP		Mar 16, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN</u>								
020280 006	4968299	Jun	28, 2008	DP		I-496		Apr 27, 2009

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - GENOTROPIN</u>					
020280 007	4968299	Jun 28, 2008	DP	I-496	Apr 27, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 001	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 002	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 003	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 004				I-496	Apr 27, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 005	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 008	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 009	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 010	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 011	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 012	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 013	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - OMNITROPE</u>					
021426 001				NP	May 30, 2009
<u>SOMATROPIN RECOMBINANT - OMNITROPE</u>					
021426 002				NP	May 30, 2009
<u>SORAFENIB TOSYLATE - NEXAVAR</u>					
021923 001				ODE	Dec 20, 2012
<u>SUMATRIPTAN SUCCINATE - IMITREX STATDOSE</u>					
020080 003	>A> 4816470	Dec 28, 2006		U-72	
	>A> 4816470*PED	Jun 28, 2007			
	>A> 5037845	Aug 06, 2008		U-72	
	>A> 5037845*PED	Feb 06, 2009			
<u>SUNITINIB MALATE - SUTENT</u>					
021938 001	6573293	Feb 15, 2021	DS	DP	U-703
					NCE
					Jan 26, 2011
<u>SUNITINIB MALATE - SUTENT</u>					
021938 002	6573293	Feb 15, 2021	DS	DP	U-703
					NCE
					Jan 26, 2011
<u>SUNITINIB MALATE - SUTENT</u>					
021938 003	6573293	Feb 15, 2021	DS	DP	U-703
					NCE
					Jan 26, 2011
<u>TACROLIMUS - PROGRAF</u>					
050708 001					ODE
					Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050708 002					ODE
					Mar 29, 2013

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - PROGRAF</u>					
050708 003				ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050709 001				ODE	Mar 29, 2013
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>					
021318 001	6977077	Aug 19, 2019	U-597		
<u>THALIDOMIDE - THALOMID</u>					
020785 001	5629327	Mar 01, 2013	U-731		
	6045501	Aug 28, 2018	U-731		
	6045501	Aug 28, 2018	U-371		
	6235756	Mar 01, 2013	U-731		
	6315720	Oct 23, 2020	U-442		
	6315720	Oct 23, 2020	U-731		
	6561976	Aug 28, 2018	U-731		
	6561976	Aug 28, 2018	U-371		
	6561977	Oct 23, 2020	U-371		
	6561977	Oct 23, 2020	U-731		
	6755784	Sep 23, 2020	U-731		
	6755784	Sep 23, 2020	U-371		
	6869399	Oct 23, 2020	U-371		
	6869399	Oct 23, 2020	U-732		
	6869399	Oct 23, 2020	U-733		
	6869399	Oct 23, 2020	U-731		
	6908432	Aug 28, 2018	U-371		
	6908432	Aug 28, 2018	U-731		
<u>THALIDOMIDE - THALOMID</u>					
020785 002	5629327	Mar 01, 2013	U-731		
	6045501	Aug 28, 2018	U-731		
	6045501	Aug 28, 2018	U-371		
	6235756	Mar 01, 2013	U-731		
	6315720	Oct 23, 2020	U-442		
	6315720	Oct 23, 2020	U-731		
	6561976	Aug 28, 2018	U-731		
	6561976	Aug 28, 2018	U-371		
	6561977	Oct 23, 2020	U-371		
	6561977	Oct 23, 2020	U-731		
	6755784	Sep 23, 2020	U-731		
	6755784	Sep 23, 2020	U-371		
	6869399	Oct 23, 2020	U-371		
	6869399	Oct 23, 2020	U-732		
	6869399	Oct 23, 2020	U-731		
	6908432	Aug 28, 2018	U-371		
	6908432	Aug 28, 2018	U-731		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
020785 003	5629327	Mar 01, 2013		U-731		
	6045501	Aug 28, 2018		U-731		
	6045501	Aug 28, 2018		U-371		
	6235756	Mar 01, 2013		U-731		
	6315720	Oct 23, 2020		U-442		
	6315720	Oct 23, 2020		U-731		
	6561976	Aug 28, 2018		U-731		
	6561976	Aug 28, 2018		U-371		
	6561977	Oct 23, 2020		U-371		
	6561977	Oct 23, 2020		U-731		
	6755784	Sep 23, 2020		U-731		
	6755784	Sep 23, 2020		U-371		
	6869399	Oct 23, 2020		U-371		
	6869399	Oct 23, 2020		U-732		
	6869399	Oct 23, 2020		U-733		
	6869399	Oct 23, 2020		U-731		
	6908432	Aug 28, 2018		U-371		
	6908432	Aug 28, 2018		U-731		
<u>THYROTROPIN ALFA - THYROGEN</u>						
020898 001					M-53	Jan 23, 2009
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
021395 001	RE38912	Oct 11, 2021		DP		
<u>TOPIRAMATE - TOPAMAX</u>						
020505 001	7018983	Oct 13, 2015		U-723		
<u>TOPIRAMATE - TOPAMAX</u>						
020505 002	7018983	Oct 13, 2015		U-723		
<u>TOPIRAMATE - TOPAMAX</u>						
020505 003	7018983	Oct 13, 2015		U-723		
<u>TOPIRAMATE - TOPAMAX</u>						
020505 004	7018983	Oct 13, 2015		U-723		
<u>TOPIRAMATE - TOPAMAX</u>						
020505 005	7018983	Oct 13, 2015		U-723		
<u>TOPIRAMATE - TOPAMAX</u>						
020505 006	7018983	Oct 13, 2015		U-723		
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
020844 001	7018983	Oct 13, 2015		U-723		
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
020844 002	7018983	Oct 13, 2015		U-723		
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
020844 003	7018983	Oct 13, 2015		U-723		
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
021272 001	5153222	Oct 06, 2014		U-455		
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
021272 002	5153222	Oct 06, 2014		U-455		
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
021272 003	5153222	Oct 06, 2014		U-455		
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
021272 004	5153222	Oct 06, 2014		U-455		
<u>VARENICLINE TARTRATE - CHANTIX</u>						
021928 001	>A> 6410550	Nov 13, 2018	DS	DP	U-56	
	>A> 6890927	May 06, 2022	DS	DP	U-56	
<u>VARENICLINE TARTRATE - CHANTIX</u>						
021928 002	>A> 6410550	Nov 13, 2018	DS	DP	U-56	
	>A> 6890927	May 06, 2022	DS	DP	U-56	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZANAMIVIR - RELENZA							
021036 001	5648379	Jul	15, 2014		U-722	I-491	Mar 29, 2009
	5648379	Jul	15, 2014		U-721		
	5648379	Jul	15, 2014		U-274		
	6294572	Dec	15, 2014	DS DP			
ZIPRASIDONE HYDROCHLORIDE - GEODON							
020825 001	4831031	Mar	02, 2012	DS DP	U-720	I-492	Aug 19, 2007
ZIPRASIDONE HYDROCHLORIDE - GEODON							
020825 002	4831031	Mar	02, 2012	DS DP	U-720	I-492	Aug 19, 2007
ZIPRASIDONE HYDROCHLORIDE - GEODON							
020825 003	4831031	Mar	02, 2012	DS DP	U-720	I-492	Aug 19, 2007
ZIPRASIDONE HYDROCHLORIDE - GEODON							
020825 004	4831031	Mar	02, 2012	DS DP	U-720	I-492	Aug 19, 2007
ZIPRASIDONE HYDROCHLORIDE - GEODON							
021483 001	4831031	Mar	02, 2012	DS DP	U-720	I-492	Aug 19, 2007
	5312925	Sep	01, 2012	DS DP	U-720		
	6150366	May	27, 2019	DP	U-719		
	6245766	Dec	18, 2018		U-601		
ZIPRASIDONE MESYLATE - GEODON							
020919 001	4831031	Mar	02, 2012	DS DP	U-720		
ZOLEDRONIC ACID - ZOMETA							
021223 001	4939130	Sep	02, 2012	DS DP	U-53		
ZOLEDRONIC ACID - ZOMETA							
021223 002	4939130	Sep	02, 2012	DS DP	U-53		

Footnotes:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
 DS = Drug Substance claim
 DP = Drug Product claim
 U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.
5. *** U.S. Patent Nos. RE 36481 and RE 36520 are being relisted for Zocor (NDA 19-766) pursuant to the decision and related order in Ranbaxy Labs. v. Leavitt, No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents will remain listed in Approved Drug Products with Therapeutic Equivalence Evaluations until any applicable periods of exclusivity pursuant to section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act have been triggered and run, unless the agency's appeal of the decision to the U.S. Court of Appeals for the District of Columbia is decided in the agency's favor before the exclusivity periods have expired. While the patents remain listed, any new or pending ANDA referencing Zocor must contain patent certifications to these patents. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/patternsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>